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ABSTRACT.  
 
The process of blood flow in the leg, against gravity and towards the heart is instigated 
by compression of the veins in the foot. Contraction of the calf muscles results in an 
ejection volume (EV) of blood towards the heart, completing the process. 
Research studies have shown an association between flight travel and deep vein 
thrombosis (DVT). Stasis of blood flow can lead to the development of thrombus 
formation. Deep Vein Thrombosis occurs in situations where people are immobile for 
long periods of time, whether this is a result of ill health or travel on land or in the air. 
This alteration in venous haemodynamics may contribute to the development of DVT.  
A novel prototype design of an in-flight exercise device to stimulate blood flow in the 
seated position was designed and developed. It consisted of a foot pedal attached to a 
base by a hinge mechanism and a spring. Four test set-ups, 1 to 4, of differing resistance 
were evaluated. Calf muscle pump function was assessed by the technique of Air 
Plethysmogrpahy (APG) in ten healthy volunteers. Ejection Volume Fractions (EVF) and 
Residual Volume Fractions (RVF) were determined in the standing position (control) and 
compared to those achieved in the seated position, by compression of the four pedals. The 
normal EVF is greater than or equal to 60%. It is the volume of blood ejected towards the 
heart when a participant stood on their tip-toes for five seconds. The normal residual 
volume (RV), the amount of blood remaining in the veins after exercise, is less than or 
equal to 35% and is an ideal indicator toward the prevention of venous stasis.  Two 
devices (test set-up 2 and 3) achieved comparable EVF and RVF values to those achieved 
by the tiptoe control manoeuvre. As Test set-up 3 was more user friendly, its spring 
parameters were used in the subsequent device designs, namely demonstrator A (DA) and 
demonstrator B (DB). These prototypes were more streamlined versions designed with 
the shape of a foot in mind. They had differing dimensions meaning the springs would be 
positioned differently in relation to the foot.  
An assessment was conducted to determine if a significant difference existed between the 
two. DA produced more efficient results and so was used in the follow up study, 
conducted in Beaumont Hospital, Dublin. The aim of which was to determine if any of 
the in-flight exercises (advocated by airlines) conducted in the seated position were 
efficient at creating venous return. This study consisted of two parts. Volunteers first 
conducted the standard APG assessment, followed by walking, DA and three foot 
exercises in the seated position. The second part of the study was conducted in the same 
sequence however participants wore Mediven® Travel Compression Stockings. DA in 
the seated position was effective at creating venous return however the in-flight exercises 
did not achieve the required EVF of greater than 60 percent.  
The concept of the Tromped was integrated into an aircraft footrest. An assessment was 
conducted with 18 volunteers, six obese, six healthy individuals and with six women 
taking the contraceptive pill. The four footrest prototypes were compared to tiptoe 
(control) in the standing position and DA used in an aircraft seat.  This seat had an incline 
of approximately 40mm from the front to the rear of the cushion and differed from 
previous assessments which were conducted in situ on a level examination couch. Neither 
of these footrests achieved the required EVF or RVF values. DA was only efficient in the 
obese group. Further research is recommended, particularly in redesigning the 
ergonomics of an aircraft seat to specifically enhance venous return in the seated position.   
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GLOSSARY OF TERMS. 
Activated Protein C - destroys Fva and FVIIIa. It is activated by thrombin when it is 
bound to thrombomodulin. 
Acute – of an illness, coming rapidly to a crisis (rapid onset of pain). 
Air Plethysmography – a technique used to determine relative volume changes in the 
lower limbs in response to postural alterations and muscular exercise 
Anatomy is the study of body structure and the relationships among body parts,  
Anterior – at or nearer the front.  
Antithrombin is any substance that inhibits or prevents the effects of thrombin in such a 
way that the blood does not coagulate. A deficiency of antithrombin results in 
recurrent thrombosis  
Antithrombin III (AT III) is a protein which stimulates the removal of blood clots in 
the blood system. Conditions that may have an association with a low value of At 
III include liver disease and disseminated intravascular coagulation (DIC).  
Arteriole(s) - the smallest arteries and site of variable resistance in the circulatory 
system. 
Artery(ies) - blood vessels that carry blood away from the heart. 
Asymptomatic – displaying no signs or symptoms  
Atria – each of the two upper cavities of the heart 
Blood pressure – is the force or pressure which the blood exerts on the walls of the 
artery in which it is contained. 
Bones – are organs, they make up the skeleton in vertebrates. 
Bone – in a different context is the hard whitish tissue from which bones are made 
Bronchi – major air passageways of the lungs which spread out from the trachea 
(windpipe).  
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Capillaries – fine branching blood vessels which form a network between the arteries 
and the veins. 
Cephalad – in the direction towards the heart 
Chronic – a long duration or frequent recurrence. 
Demonstrator A – the first prototype device of the Tromped assessed by Air 
Plethysmography 
Demonstrator B – the second prototype device of the Tromped assessed by Air 
Plethysmography 
Diastole – widening of the chambers of the heart between two contractions when the 
chambers fill with blood 
Dorsi flexion – moving the distal foot up  
Dyspnea – difficulty breathing. 
Degrees of freedom – this phrase is used to describe the number of values in the final 
calculation of a statistic that are free to vary. 
Diaphragm – the flat dome shaped muscle below the lungs that controls breathing. 
Endothelium (Endothelial Cells) - are involved in both the pathology of venous 
thrombosis and they contain antithrombotic substances to aid their dissolution 
ECM (extracellular matrix) – non-living chemical substances located between 
connective tissue cells 
Evertor  - turns a limb outward 
Factor – general name given to signal molecules when first found. 
Factor I, Fibrinogen – a soluble plasma protein  
Factor II, Prothrombin –  a protein which is synthesised by the liver  
Factor III, Tissue Thromboplastin initiates the extrinsic pathway by reacting with 
Factor VII and calcium to form factor VIIa 
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Factor IV, Calcium is an element taken in through the diet that is essential for a variety 
of bodily functions such as neurotransmission, muscle contraction and proper heart 
functions as well as clotting of the blood  
Factor V, Proaccelerin - has the ability to function as both a procoagulant and an 
anticoagulant. It is synthesised in the liver. FV circulates in free form in plasma and 
is present in α-granules of platelets. FV platelets account for approximately 25 
percent of the total amount of FV in the blood and are secreted due to platelet 
activation during coagulation.  
Factor Va is a labile plasma glycoprotein which accelerates the conversion of 
prothrombin to thrombin in blood coagulation (Bergquist et al., 1994), by forming a 
complex with Fxa, phospholipids and calcium. Activated coagulation factor V (Fva) 
is a necessary cofactor to activated factor X (Fxa). 
Factor VI has the same function as activated Factor V 
Factor VII is a stable plasma protein which is affected by tissue thromboplastin to form 
factor VIIa in the extrinsic pathway of blood coagulation. Factor VII is a vitamin K 
dependent clotting factor. The clotting activity of Factor VII is reduced by warfarin  
Factor VIIa catalyses the activation of factor X to factor Xa 
Factor VIII, Antihemophilic factor. A congenital deficiency in the amount of Factor 
VIII resulting in classic haemophilia (more prone to bleeding)  
Factor IX, Christmas Factor, it is a plasma thromboplastin component, a stable blood 
coagulation factor acting in the intrinsic pathway. Its activated form Xa, forms a 
complex with FVIII and calcium on platelet Factor 3 to Fx and Fxa. It is 
antihemophilic factor B.  
Factor X, Stuart Power Factor, is a stable glycoprotein blood coagulation factor that 
can be activated to factor Xa by both intrinsic and extrinsic pathways. A deficiency 
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of Factor X, known as Stuart –Prower factor deficiency may lead to a systemic 
coagulation disorder. 
Factor Xa is an activated form of factor X, which catalyses the conversion of 
prothrombin to thrombin. 
Factor XI, Plasmin thromboplastin antecedent – plasma protein synthesized in the 
liver 
Factor XII, Hageman Factor – plasma protein required for intrinsic stage 1 
Factor XIII, Fibrin-stabilising factor - Activation of FXIII by thrombin. 
Fascia – is a connective tissue which covers the body by forming a sheet of tissue under 
the skin it also surrounds muscles and muscle groups 
Fibrin is an insoluble protein formed from fibrinogen by the proteolytic (spitting of 
proteins by hydrolysis of the peptide bonds with formation of smaller polypeptides) 
action of thrombin during normal clotting of the blood. Fibrin forms the essential 
portion of the blood. 
Fibrinolysis – solubilisation of fibrin in blood clots 
Fibrosis – this occurs when fibrous tissue is formed for healing purposes if there is loss 
of tissue or the cells destroyed do not regenerate e.g. following chronic 
inflammation  
Heart – the hollow muscular organ in the chest that pumps the blood around the body. 
Haemoglobin – oxygen carrying pigment of red blood cells 
Hemoptysis – coughing up of blood from the respiratory tract 
Hemostasis – process of keeping blood within the blood vessels by repairing breaks 
without compromising the fluidity of blood. 
Hypoxia – insufficient oxygen reaching the tissues of the body 
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Incidence – the frequency with which cases are identified. Incidence is commonly 
measured in new cases per 1,000 (or 100,000) of population at risk per year.  
Intermittent claudication - presents with pain during walking due to arterial 
insufficiency which is produced during the walking process.  
Interstitial – found in or relating to small spaces within something. 
Lateral – relating to the side or sides 
Lung – each of the pair of organs within the ribcage of humans and most vertebrates, into 
which air is drawn in breathing. 
Medial – situated in the middle (midline). 
Mediastinum – region between the pleural sacs. 
Morbidity – relating to or indicating disease 
Mortality of a disease - the probability that death will be the end result 
Muscle – the tissue of an animal body which has the ability to contract, in response to a 
stimulus. 
Nitric Oxide (NO) is produced within EC, it inhibites the adhesion and aggregation of 
platelets  
Oedema – the accumulation of fluid in the interstitial place. 
Onset – the time of appearance of the first symptoms of a condition, prior to seeking 
diagnosis. 
Pathology is the study of the functional and structural changes that occur in cells and 
tissues as a result of direct damage by or reaction to a wide variety of events. 
Pericardium – the membrane enclosing the heart 
Perforating Veins - The function of a perforating vein is to form a connection between 
the superficial and deep systems  
Peripheral resistance - resistance to blood flow created by (primarily) the arterioles. 
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Peurperium is a period of about 6 weeks following childbirth when the reproductive 
organs are returning to their normal state  
Physiology is the study of the body‟s function and how it works. 
Placebo is used as a control substance when conducting pharmacological studies to 
determine the efficiency of a new or potential product. 
Plantar flexion – moving the distal foot down (e.g. rising the heel off the ground and 
placing weight on the ball of the foot) 
Plasma – A cellular fluid in which blood cells are suspended. 
Plasmin – it is an enzyme that breaks down fibrin, and is derived from the breakdown of 
circulating plasminogen 
Platelets bind to damaged endothelium cells and subendothelium cells, to aid thrombosis 
development. 
Posterior – at or nearer the rear. 
Prophylaxis – intended to prevent disease 
Protein C is a vitamin K dependent protein in plasma that inhibits the formation of a clot 
Protein C deficiency results in thrombotic disease and excess platelets with recurrent 
thrombophlebitis (inflammation of the vein that occurs when a clot forms) 
Protein S inhibits blood clotting by serving as a cofactor for activated Protein C  
Protein S deficiency is a disorder which leads to decreased levels of plasma protein S 
associated with the onset of venous thrombosis and PE.  
Pulmonary – An adjective meaning “to do with the lungs”  
Resolution - signs of inflammation 
Respiratory System  - supplies oxygen to cells and releases carbon dioxide 
Saphenofemoral junction – junction where the saphenous (superficial vein) drains into 
the deep system (femoral vein) 
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Sequelae - conditions resulting from a disease or injury 
Systole – contraction of the chambers of the heart to drive blood into the Aorta and 
Pulmonary Artery. 
Thorax – the part of the body between the neck and the abdomen 
Thrombin – a plasma protein that converts fibrinogen into fibrin . It is produced from 
prothrombin by the action of the extrinsic system (tissue factor and Phospholipids) 
or by the intrinsic system (contact of blood with a foreign surface).  
Thrombomodulin is produced within EC and is a natural anticoagulant. 
Thrombophilia - a hereditary or acquired predisposition to develop blood clots 
Thromboplastin is a plasma substance that converts prothrombin to thrombin 
Tissue Factor (TF) or tissue thromboplastin is released from endothelial cells, tissue 
cells, platelets and monocytes, TF activates Factor IX. 
Tissue Factor Pathway Inhibitor (TFPI) is produced by endothelial cells and it inhibits 
TF, VIIa and Xa. 
Trachae – The portion of the respiratory tract located in the neck (also called the 
windpipe). 
Ventilation – movement of air between the atmosphere and the lungs. 
Ventricles – each of the two larger and lower cavities of the heart 
Veins – any of the tubes forming part of the circulation system by which blood is carried 
from all parts of the body towards the heart.   
“Vitamin K is a cofactor necessary for the production not only of blood clotting factors 
but also for proteins necessary in the formation of bone” (Kumar & Clark, 2002, 
p.233). Vitamin K deficiency results in an increase in prothrombin time and 
haemorrhage.  
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ABBREVIATIONS 
           
AGTW                                                           aircraft gross take-off weight 
AHU                                                              Aviation Health Unit 
AHWG                                                          Aviation Health Working Group 
APC                                                              Activated Protein C 
APCR                                                            Activated Protein C Resistance 
APG                                                              Air Plethysmograph® 
AT                                                                 Anterior Tibial (vein) 
ATIII                                                             Antithrombin III 
ATM                                                              Atmosphere 
CAA                                                              Civil Aviation Authority 
CFR                                          Code of Federal Regulations 
CI                                                                  Confidence Interval 
CMD                                                             Calf muscle pump dysfunction       
CMPF                                                            Calf muscle pump function                        
CNC                                                              Computer Numerical Control 
CO2                                                                Carbon Dioxide 
CT                                                                 Computed Tomography 
CVD                                                               Chronic Venous Disease 
CVI                                                                Chronic Venous Insufficiency                           
DVT                                                               Deep Vein Thrombosis 
EASA                                                             European Aviation Safety Agency 
EV                                                                  Ejection Volume 
EVF                                                                Ejection Volume Fraction 
FAR                                                                Federal Aviation Requirements 
FDP                                                                Fibrin Degradation Products 
FIII                                                                 tissue thromboplastin 
FIX                                                                 plasma protein 
FRDVT                                                          Flight Related Deep Vein Thrombosis 
FRPE                                                              Flight related pulmonary embolus 
FV                                                                  Factor V  
FVIII                                                              Factor VIII 
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FVL                                                                Factor V Leiden 
FVLM                                                            Factor V Leiden Mutation 
GECS                                                             Graduated Elastic Compression Stockings 
HRT                                                                Hormone Replacement Therapy 
IATA                                                              International Aviation Transport Association 
ICU                                                                 Intensive Care Unit 
LMWH                                                           Low Molecular Weight Heparin 
LSV                                                                Long Saphenous Vein 
NO                                                                 Nitric Oxide 
OC                                                                 Oral Contraceptive 
PAD                                                               Peripheral Arterial Disease 
PaO2                                                               Partial arterial pressure of oxygen 
PC                                                                  Protein C 
PE                                                                  Pulmonary Embolism                              
PEP                                                                Pulmonary Embolism Prevention 
PLS                                                                Post thrombotic Leg Syndrome 
PO2                                                                Partial pressure of oxygen 
PS                                                                  Protein S 
PSI                                                                 Pounds per square inch 
PT                                                                  Peroneal Tibial (vein) 
PVD                                                               Peripheral Venous Disease 
RBC                                                               Red Blood Cells 
RV                                                                  Residual Volume 
RVF                                                                Residual Volume Fraction 
SIGN                                                               Scottish Intercollegiate Guidelines Network 
SPJ                                                                  Saphenopopliteal junction 
SSV                                                                 Short Saphenous Vein 
SVPT                                                               Supine venous pump function            
SVT                                                                 Superficial Venous Thrombosis     
TF                                                                   Tissue Factor 
TFPI                                                                Tissue Factor Pathway Inhibitor 
TT                                                                   Tissue Thromboplastin 
UK                                                                   Urokinase 
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VFI                                                                   Venous Filling Index 
VTE                                                                 Venous Thromboembolism 
VTED                                                              Venous Thromboembolism Disease 
VV                                                                   Venous Volume 
WHO                                                               World Health Organisation 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
1.0. Introduction 
An association between air travel and the development of deep vein thrombosis (DVT) is 
well documented (Belcaro et al., 2001a; Belcaro et al., 2001b; Scurr et al., 2001; Belcaro 
et al., 2002; Cesarone et al., 2003a; Schreijer et al., 2006). DVT is the formation of 
thrombus, coagulated blood, in a deep vein.  Thrombus formation can result from 
multiple factors however DVT as a result of venous stasis is the focus of this study. 
Venous stasis (stagnation of blood resulting in poor circulation) can affect the deep veins, 
particularly in situations where people are seated for long periods in cramped conditions 
such as during air travel.  When a DVT occurs as a result of air travel this is referred to as 
flight related deep vein thrombosis (FRDVT).  At its worst, DVT can result in death by 
pulmonary embolism (PE). This occurs when a section of the thrombus, known as an 
embolus, breaks off from its site of formation and travels into the lungs where it can 
cause an obstruction which can be fatal.   
Recommendations to minimise the risks of FRDVT include exercises and the use of 
devices to improve flow of blood from the leg veins while seated.  With this concept in 
mind, the main hypothesis of this work was that it should be possible to develop a foot 
pump that is capable of mimicking the venous haemodynamics of walking whilst in the 
seated position.  Hence the device would prevent blood pooling in the veins of the lower 
limbs and the formation of DVT.  The device advocated is termed “The Tromped” and 
was first produced in prototype form.  The necessary parameters required to ensure 
sufficient venous return were initially established (Collins, 2002-2003).  The principle 
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was to exercise each lower limb whilst seated by means of two spring loaded foot pedals.  
This form of exercise activates adequate blood flow to prevent venous stasis. The 
Tromped design was then modified for use on board an aircraft. 
 
1.1. Aims and Objectives 
 
1.1.1 Research Aims 
The aims of this research were to: 
a) Develop a device to aid in the prevention FRDVT;  
b) Haemodynamically assess the efficiency of this device.   
 
1.1.2. Research Objectives 
To realise these aims the objectives of this research were to produce research data, 
conclusions and recommendations that: 
i. outline the causes and effects of DVT and FRDVT; 
ii. describe the symptoms of this disorder and those people whom are most 
likely to be affected; 
iii. Review current medical research on DVT and FRDVT in the context of 
aviation derived pathology;   
iv. Highlight the measures that can aid in prevention;  
v. Develop and evaluate the Tromped as an in-flight exercise device. 
 
1.2. Ethical Issue 
The research was conducted in accordance with the Declaration of Helsinki (1964), (refer 
to http://www.wma.net/e/policy/pdf/17c.pdf). 
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Ethics approval was sought from the (Medical Research) Ethics Committee in Beaumont 
Hospital, Dublin. Approval to conduct the assessment (refer to section 7.1) was granted 
and obtained in December 2006 (Appendix A).  Ethics approval was also sought from the 
Dublin Institute of Technology (DIT) to conduct the study entitled “The Tromped 
Footrest Experiment”. This study was carried out in DIT Bolton Street (section 8.1). 
Ethics approval was granted and obtained in September 2006 (refer to Appendix B). 
 
1.3. Outcomes of this research 
The planned aims of this research were to: 
i. prove the Tromped was as efficient or better than other methods designed to 
prevent FRDVT;  
ii. establish a collaboration between the Dublin Institute of Technology (DIT) and 
the Non-Invasive Vascular Unit, Beaumont Hospital to address and solve the 
problem of FRDVT; 
iii. carry out haemodynamic assessments of the exercise machines efficiency at all 
levels of redesign and manufacture; 
iv. use of the Tromped on board a commercial aircraft and so be compliant with the 
requirements of European Aviation Safety Agency (EASA), Certification 
Specifications For Large Aeroplanes, CS-25 and the Codes of Federal Aviation 
Requirements for Large Aeroplanes, (CFR, 25); 
v. offer conclusions and recommendations that will be of benefit to the airlines and 
other bodies concerning FRDVT. 
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1.4. Limitations 
The limitations of this body of research were as follows: 
i. The true incidence of DVT and FRDVT is unknown;   
ii. The lack of aviation industry acceptance of the issue and co-operation to 
conduct an in-flight assessment of the Tromped; 
iii. The lack of objective documentation surrounding the efficiency of mechanical 
devices and exercises recommended in FRDVT prophylaxis has the potential 
to undermine the design of an efficient form of prophylaxis 
 
1.5. Method of approach  
The research work undertaken in this programme required theoretical and experimental 
routes to be followed (Figure 1.1).  The former was necessary to determine the 
contributing factors of FRDVT so that criteria could be established to aid the design of an 
in-flight medical device.  The latter is new knowledge established in relation to FRDVT.  
 
1.6. Case Studies. 
This research has been conducted in an attempt to alleviate the real problem of FRDVT.  
Development of thrombi during flight can affect passengers‟ health but also can be fatal. 
Piet Fourie, was travelling from Los Angelus to Johannesburg with Virgin Atlantic 
Christmas Eve, 2002.  The woman in the seat in front of him reclined her seat and she 
also had a box positioned under her seat so Piet did not have adequate leg room. When he 
tried to walk at the back of the plane, people were sleeping on the floor.  As a result Piet 
developed a thrombus on that flight (“Man develops blood clot….”, 2003).  In the year 
2000, Emma Christofferson travelled from Sydney to Heathrow Airport.  Upon arrival at 
the airport she was pronounced dead at 28 years old.  The cause of death was established 
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as a flight related pulmonary embolism (PE) (Eklöf  et al., 2005).  A more in-depth 
description FRDVT and the associated dangers are provided in Chapter four.   
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Chapter two introduces the human vasculature system and the constituents of blood and 
the anatomy and physiology of which are outlined in conjunction with a brief description 
of the skeletal and musculature system directly affecting venous return.  An 
understanding of these factors and how they are linked was a prerequisite in 
understanding how to attempt prevention of both DVT and FRDVT by developing a form 
of prophylaxis.  In chapter three the pathology of DVT, PE and VTE are explained, as are 
the associated inherited and environmental risk factors.  Current practices of both 
diagnosing and treating this syndrome were identified.  A literature review of FRDVT 
was also undertaken.  The incidence of DVT and contributing factors associated with this 
flight related syndrome are investigated in conjunction with current forms of prophylaxis.  
Chapter four encompasses the methods, techniques and equipment used to conduct this 
research.  The development and production of a novel form of prophylaxis is described in 
chapter five; to be precise, how the initial test piece “demonstrator A” progressed and 
developed into the final in-flight prototype the Tromped footrest.  The final prototype 
was designed for use on board a commercial aircraft.  Each device was produced and 
their associated design constraints were discussed.   
Chapter six describes how two demonstrator devices were haemodynamically assessed 
(with different springs) in the seated position on a level examination couch.  Chapter 
seven haemodynamically considered Mediven® travel compression stockings, exercises 
the airlines advocate and Demonstrator A.  The natural progression of this research was 
to haemodynamically assess the Tromped footrest when used, seated in a commercial 
aircraft seat. This assessment is outlined in chapter eight.  Finally, research conclusions 
are offered in chapter nine.  
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CHAPTER 2 
ANATOMY AND PHYSIOLOGY OF  
THE VASCULAR SYSTEM    
2.0. Introduction 
The human body is made up of living cells that require oxygen and nutrients to maintain 
life (“Jeppesen, 2002).  It consists of a skeletal structure, muscle tissues and Fibres and a 
vascular system which transports blood flow to and from all the main organs.  Blood is 
transported to the organs by the arterial system (the arteries) and from the organs by the 
venous system (the veins) (Solomon et al., 1990, Monkhouse, 2001).  The heart and the 
respiratory system will be briefly discussed, as both of these systems are interrelated with 
the vascular system.  The cardiovascular system includes the heart, blood and blood 
vessels (Solomon et al., 1990; Monkhouse, 2001).  The respiratory system consists of the 
air passageway and the lungs.  The skeletal and muscular systems function together as a 
single entity to allow limb and body movement to occur.  The bones act as levers which 
transmit the mechanical forces generated by muscles as they contract (Solomon et al., 
1990).  Venous return in the lower limbs (towards the heart) is affected by the calf 
muscle pump function, requiring an explanation and description of the muscles in the 
lower limb.  This research is mainly concerned with venous return from the lower 
extremities and the pathology of venous thrombosis.   
 
2.1. The function and constituents of Blood 
Two fluids flow through the body, blood and lymph.  Blood carries oxygen (O2) and food 
to the cells, and carries carbon dioxide (CO2) from the cells.  The interstitial fluid known 
as lymph, flows towards the heart, carrying water and waste into the venous system 
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(Belcaro et al., 1995).   Living cells require materials to survive and to perform functions 
required to maintain life (Bullock, 1996).  In the human body, this is accomplished by 
blood transporting oxygen, nutrients, hormones and waste products (Bullock, 1996).  
Blood consists of red blood cells (RBCs) or erythrocytes, (Underwood, 2004), white 
blood cells (WBCs) or leukocytes and platelets all circulating in a straw like coloured 
liquid known as plasma (Bullock, 1996).  Plasma can be broken down into 92 percent 
water, seven percent protein and less than one percent of nutrients, respiratory gases, 
hormones and ions (Solomon et al., 1990).  
RBCs are rich in haemoglobin, which transmits oxygen from the lungs to the cells and 
carbon dioxide from the cells to the lungs (Radomski and Radomski, 2000; Underwood, 
2004).  Within the lungs, hemoglobin unites with oxygen, which it later releases in the 
tissues (Bullock, 1996).  Normal circulating blood volume contributes eight per cent of 
the total body weight (Solomon et al., 1990; Bullock, 1996).  WBCs defend against 
infection and platelets are responsible for blood clotting (Solomon et al., 1990; 
Underwood, 2004).  
The proteins in plasma can be broken down into three subgroups namely; albumins, 
globulins and fibrinogen.  Albumins account for 55 percent of plasma proteins and 
globulins 38 percent.  These are necessary to sustain blood volume.  Fibrinogen makes up 
the remaining seven per cent and it, in conjunction with the other plasma proteins, 
initiates the clotting process.  Fibrinogen (Factor I), has two purposes, to aggregate 
platelets and to form fibrin, a necessary constituent of thrombi (Bullock, 1996; Krupski, 
1997; Kumar and Clarke, 2002). 
Platelets are also known as thrombocytes and are formed in the bone marrow (Bullock, 
1996).  Their main function is to halt bleeding (haemostasis) as they physically move into 
the damaged area of the vessel, plugging it and releasing chemicals which will then 
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initiate the coagulation process (Solomon et al., 1990; Underwood, 2004).  Platelets 
adhere to damaged endothelium (the lining of the blood vessel) or to the resultant 
exposed sub-endothelial tissue (Radomski and Radomski, 2000; Woolf et al., 2002).  
Platelets range in size from two micrometers (µm) to four µm in diameter.  They remain 
in the venous circulation for seven to ten days before the phagocytes in the spleen 
removes them from the system (Krupski, 1997; Radomski and Radomski, 2000). They 
are contractible and adhesive cells (Underwood, 2004) and “…they interact with the 
blood vessel wall, other platelets, and the coagulation proteins” (Krupski, 1997, p. 261).  
The presence of fibrinogen and calcium is necessary for platelet - platelet interaction.  
Plasma fibrinogen is enough to allow aggregation, in its absence; platelets can release 
fibrinogen to support the occurrence of aggregation (Krupski, 1997). Aggregation is the 
adhesion of platelets to other platelets to form a mass of cells, which are known as 
fibrinogen bridges (Woolf et al., 2002).  Activated platelets promote thrombin 
generation, because they have negatively charged phospholipids on their surface which 
accelerate coagulation factor activation.  Platelets aid the activation of prothrombin by 
Factor Xa and Factor X by Factor IXa –VIIa complex (Woolf et al., 2002).  Thrombin 
also causes platelet activation (Krupski, 1997; Labelle and Kitchens, 2005) and will 
convert soluble fibrinogen to insoluble fibrin, activating clot formation (Labelle & 
Kitchens, 2005). 
Ten plasma proteins, namely prothrombin, FIX, FX, FXI, FXIII, (Hirsh, 1990), FV, 
FVIII, FVII, FVIIa and fibrinogen with one tissue protein, known as subendothelial tissue 
factor, all play a part in the pathology of clot formation (Figure 2.1) (Butenas and Mann, 
2002; Crowther and Kelton, 2003).     
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Source: Seeley et al., (2006, p.665)  
Figure 2.1. The Coagulation Cascade  
 
2.2. The Human Heart 
 
2.2.1. Anatomy of the Heart 
The purpose of the human heart is to maintain life. This is achieved by the continuous 
circulation of blood through the body, which is driven by contraction of the heart muscle 
(Strandness and Sumner 1975; Solomon et al., 1990).  The heart has the power to drive 
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the blood to all the body organs and lower extremities and also helps to return it to itself 
(Menzoain et al., 1997).  It forces more than 5 litres per min (l/min) of blood through the 
body per day.  The heart beats more than 40 million times a year, the purpose of which is 
to supply the tissues of the body with a consistent supply of nutrients and to permit the 
excretion of waste products from the tissues and blood stream (Damjanov, 2002; Kumar 
et al., 2005).  The heart is found in the thorax (chest) region of the body (Monkhouse, 
2001).  It is contained within a protective sac named the pericardium which is located 
between the two lungs, in an area named the mediastinum (Solomon et al., 1990; 
Monkhouse, 2001; Damjanov, 2002).  “The heart is a four-chambered hollow, muscular 
organ that has a conical shape” (Solomon et al., 1990, p.670).  The chambers are the right 
and left atria and the right and left ventricules (Figure 2.2) (Osman et al., 1973, p.128; 
Strandring, 2005). 
 
2.2.2. Physiology of the Heart 
The heart has a natural pacemaker, known as the sinoatrial node, responsible for 
generating electrical impulses which stimulate contraction of the heart (Sims, 2000). 
The right atrium receives blood from the superior and inferior vena cava (from the upper 
and lower body), which is depleted of its oxygen by the body‟s tissues (Strandring, 
2005).  Blood passes into the right ventricle where it is pumped into the lungs via the 
pulmonary trunk, here the blood is re-oxygenated before it is passed into the left atrium 
by the pulmonary veins.  Blood is then pumped into the aorta by the contracting action of 
the left ventricle.  The aorta returns the blood into the systemic system (Osman et al., 
1973; Solomon et al.,, 1990; Monkhouse, 2001).   
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      Source: Sims (2000).  
Figure 2.2. The Heart. 
 
The heart usually pumps at a constant force.  Blood flows from the aorta (the largest of 
the arteries) towards arteries which gradually become smaller.  Blood flow moves from 
the arteries to the arterioles then to the capillaries and finally the veins (Osman et al., 
1973).   
 
2.3. The Human Lungs 
 
2.3.1. Anatomy of the Lungs 
The lungs are located within the chest cavity on either side of the heart, enclosed by the 
pleura, chest wall, respiratory muscles and diaphragm.  The purpose of the lungs is to 
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supply adequate volume of oxygen to the body at all times by the exchange of gases 
between inspired air and blood.  The lungs branch out from the trachea (windpipe).  The 
right lung bud is divided into three branches (bronchi) and the left lung bud, which is the 
smaller of the two, is divided into two main bronchi.  There are three lobes on the right, 
upper, middle and lower and two on the left (Kumar et al., 2004; Monkhouse, 2001).  
The right and left bronchi then subdivide into what are called lobar bronchi which then 
go on to separate into terminal bronchioles, (Figure 2.3) (Bullock, 1996; Monkhouse, 
2001).  These terminal bronchioles branch into the respiratory bronchioles which contain 
alveolar ducts and alveoli, which is where the exchange of gases occurs (Bullock, 1996; 
“Jeppesen”, 2002).   
 
2.3.2. Physiology of the Lungs 
The ventilation process is the transfer of oxygen from the atmosphere through the trachea 
and bronchial tree (lungs) to the alveoli (Goldhaber and Elliot, 2003; Colbert, 2004).  
When an individual breathes in air, the diaphragm descends and the pressure in the 
thoracic area reduces and the volume of the lungs increases.  Pressure also reduces along 
the walls of the right atrium, to allow it to fill up with blood, from the main draining 
veins of the body (superior and inferior vena cava).  
There are four stages in the transportation of oxygen from atmosphere to the body cells: 
i. Ventilation process: oxygen flows from the atmosphere through the trachea 
and bronchial tree to the alveoli; 
ii. In the alveoli oxygen comes in contact with the alveolar capillary walls and 
passes to the blood.  This is known as pulmonary diffusion; 
iii. Oxygen is then carried by the blood from the lungs, to the heart where it is 
pumped via the arteries to the tissues; 
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iv. The oxygen diffuses from the tissue capillaries to the sites of utilisation of 
oxygen. 
(Goldhaber and Elliot, 2003; Colbert, 2004). 
 
Source: Bullock, 1996 
Figure 2.3 The Lungs.  
 
2.4. Skeletal and muscular systems 
“Muscles produce movements at joints by pulling on the bones to which they are 
attached.” (Tyldesley and Grieve, 1989, p.36).  The skeletal and muscular systems of the 
lower limb are important factors in venous return.  Commonly used nomenclature for 
anatomical structures include the following: anterior ~ to the front; medial ~ the midline; 
lateral ~ away from the midline and finally posterior ~ to the rear (Monkhouse, 2001).  
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2.4.1. Bones of the lower extremity 
 
2.4.1.1. Anatomy 
“The bones of the lower extremity consist of those of the pelvic girdle, of the thigh, of the 
leg, and of the foot” (Pickering and Howden, 1977). 
The skeleton of the leg consists of four bones which are known as the Femur, the Patella 
which is the bone placed in front of the knee, the Tibia and the Fibula (Figure 2.4) 
(Pickering and Howden, 1977; Monkhouse, 2001).  The femur (the heaviest bone in the 
body) is found in the thigh region.  The fibula is the lateral calf bone and the tibia is the 
medial calf bone.  
 
Source: Contamedia 
Figure 2.4. The Human Skeleton. 
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2.4.1.2. Physiology 
The main function of the bones of the lower limb is the transmission of weight (Moffat 
and Mottram, 1987).  The bones function as levers and are connected by synovial joints, 
thus enabling mobility.  Muscles attached to the bones provide the force to enable their 
movement (Winwood and Smith, 1985).   
  
2.4.2. Muscles of the lower limb 
Contraction of muscles within fascia collapses the vein resulting in blood moving toward 
the heart. 
 
2.4.2.1. Anatomy 
Muscle tissue is composed of cells designed to allow contraction.  Muscle cells are 
referred to as fibres, which when contracted become shorter and thicker in size, thus 
facilitating movement of the body parts attached to them (Solomon et al., 1990).  
Muscles are ensheathed by a fascia.  The muscles of the leg are divided into muscular 
compartments by fascia (Pickering and Howden, 1977; Stranden, 2000).  The most 
important areas for venous return are anterior and posterior compartments of the leg.  
Muscles allow precise movements, e.g. the calf muscles pull on the heel to raise the foot 
onto the toes.  The line of body weight lies in front of the ankle joints.  The calf muscles 
are required to maintain balance over the foot base (Tyldesley and Grieve, 1989).  
Movement of the foot is controlled by the muscles of the calf.  These are traditionally 
described in three main groups, the anterior, posterior and fibular group (Winwood and 
Smith, 1985). 
The anterior group consists of the Tibialis Anterior muscle, the Extensor Hallucis Longus 
and the Extensor Digitorum Longus and Peroneus Tertuis (as shown in Figure 2.5).   
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The posterior group of muscles consists of both superficial and deep layers.  The 
superficial muscles of the posterior group include the Gastrocnemius, the Soleus and the 
Plantaris.  A transverse section of the mid calf can be seen in Figure 2.7. 
The deep muscles include the Popliteus, Tibialis Posterior (Figure 2.6) Flexor Digitorum 
Longus and Flexor Hallucis Longus.   
The lateral group of muscles are the Peroneus Longus and the Peroneus Brevis (Figure 
2.8) (Winwood and Smith, 1985).   
 
 
Source: Moffat and Mottram, 1987. 
Figure 2.5. The Anterior muscles of the lower limb. 
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The Peroneus Longus arises from the lateral surface of the fibula.  It is inserted into the 
lateral side of the first metatarsal and the medial cuneiform.  This muscle is also a 
dorsiflexor and evertor of the foot and maintains the arches of the foot during walking.  
The Peroneus Brevis arises from the lower two-thirds of the lateral surface of the fibula. 
It is inserted at the base of the fifth metatarsal. It too maintains the arches of the foot and 
contributes to eversion (Romanes, 1986).  
 
 
Source: Winwood and Smith, 1985 
 
Figure 2.6. The Posterior superficial muscles of the lower limb. 
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Source: Winwood and Smith, 1985.  
Figure 2.7. Transverse Section of the mid calf demonstrating the anterior and the 
posterior group of muscles.  
 
Source: Moffat and Mottram, 1987. 
 
Figure 2.8. The Peroneal Muscles. 
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2.4.2.2. Physiology 
The muscles of the calf are the primary flexors of the foot at the ankle joint.  They are 
necessary to stand, walk and jump.  It is the gastrocnemius which provides the majority 
of the propulsive force during walking running and jumping (Palastanga et al., 1994).  
The soleus is one of two main plantar flexors of the ankle joint.  One of its main 
functions is to prevent the body falling forwards during standing.  Intermittent 
contraction of the muscle during standing aids venous return, this is known as the soleal 
pump as communicating vessels join both the deep and superficial venous systems which 
pass through its substance (Palastanga et al., 1994).  The main functions of the lower 
limbs are support in standing, swing and support in movement, transfer of the body from 
supine to sitting to standing and provision of sensory information via the soles of the feet 
from supporting surfaces such as the ground (Tyldesley and Grieve, 1989).  The 
hamstring muscles of the thigh work with the gluteus maximus in the buttock to create 
propulsion for walking.  When walking, the human heel comes into contact with the 
ground first, followed by the ball of the foot.  The Gastrocnemius and the Soleus muscles 
(Figure 2.6) contract drawing on the Calcaneus to lift the heel off the ground 
(Monkhouse, 2001).  Thus the term plantar flexion refers to the movement which raises 
the heels of the foot off the ground (Tyldesley and Grieve, 1989).  As the body is 
supported on the raised foot the opposite leg may be carried forward.  The peroneus 
muscles transfer the body weight to the ball of the foot.  The toes flexors are used to grip 
the floor and thrust forwards (Solomon et al., 1990; Pickering and Howden, 1977).  The 
soleus prevents the body from falling forward.  The Plantaris is an accessory to the 
Gastrocnemius when flexing the ankle of the free foot or bending the knee if the foot is 
on the ground (Pickering and Howden, 1977).  
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2.5. The Human Foot  
 
2.5.1. Anatomy 
The skeleton of the foot is divided into three divisions; the Tarsus, Metatarsus and the 
Phalanges (Pickering and Howden, 1977).  The seven tarsal bones are situated in the 
proximal area of the foot (Figure 2.9).  The calcaneus (heel bone) is the strongest bone in 
the foot (Seeley et al., 2006).  The metatarsals are the foot bones and the term phalanges, 
is used to describe the toes (Figure 2.9) (Solomon et al., 1990).  The area between the 
metatarsals and phalanges is known as the ball of the foot (Seeley et al., 2006).   The 
deep plantar flexors are three muscles whose tendons pass round the medial side of the 
ankle and enter the sole of the foot, Tibialis posterior, Flexor Digitorum Longus and 
Flexor Hallucis Longus.   
 
Source: (Seeley et al., 2006, p. 241) 
 
Figure 2.9. Skeleton of the Human Foot 
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These plantar flexors aid the calf muscles in propulsion of the ankle (Sumner, 2000).  
There are four ankle dorsiflexors (Figure 2.10); the Tibialis anterior, Extensor hallucis 
longus, Extensor digitorum longus and Peroneus tertius (Manganaris et al., 2001). 
 
2.5.2. Physiology 
The muscles of the feet and the calf instigate venous return to the thigh and the pelvis 
area (Menzoian et al., 1997).  The arches of the foot “…distribute the weight of the body 
between the heel and the ball of the foot during standing and walking.” (Seeley et al., 
2006, p.242).  During walking, weight transfers from the tibia and the fibula to the talus 
bone when the foot is placed on the ground.  This weight then transfers onto the 
calcaneus, prior to moving along the lateral arch system and into the ball of the foot 
(Seeley et al., 2006).   
 
Source: Southwest Orthopaedic Surgery Specialists, PLC   
Figure 2.10. Muscles of the dorsal and plantar surfaces of the foot.  
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The plantar plexus can be defined as “large dilated veins on the plantar aspect of the foot” 
(Gardner and Fox, 2001).  The human foot is unique in that blood flows from the deep 
veins to the superficial veins” (Ricci et al., 1997).  Compression of the plantar plexus 
instigates the flow of blood towards the heart (Sumner, 2000) (refer to section 2.6.2).  
Weight bearing, such as walking, forces blood from these veins into deep veins and 
superficial (Ricci et al., 1997).  
 
2.6. The Vascular System  
The vascular system consists of arteries which bring blood from the heart to the organs. 
The blood then passes through a network of small vessels to eventually drain into the 
veins which bring the blood back to the lungs for oxygenation and then back to the heart 
(Figure 2.11).  
 
Source: Seeley et al., (2006).  
Figure 2.11. The Vascular System 
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2.6.1. Blood Vessels 
 
2.6.1.1. Arterial supply to the lower limbs 
Arteries function by dilating and elongating with increased blood flow and narrowing at 
times of reduced blood flow, with structural changes occurring in the wall to make this 
possible (Sho et al., 2004).   
Blood vessel walls consist of the following three layers, (Figure 2.12):  
i. The Tunica Intima which is composed of an elastic lamina, that is lined by 
a layer of endothleial cells which are in contact with the blood flow (Cole, 
2001a); 
ii. The Tunica Media, which consists of smooth muscle fibres that circle the 
vessel, fibrous tissue and vasavorum which are blood vessels. The smooth 
muscle fibres regulate the blood flow of the artery by contracting or 
dilating (Cole, 2001a); 
iii. Tunica Adventitia, which consists of an elastic lamina enclosed by fibrous 
tissue. The elastin fibres run longitudinally and give elasticity to the 
arteries (Cole, 2001a). 
Arterial blood of the lower limb, originates from the Femoral Artery and its branches 
(Figure 2.13).  The femoral artery descends into the popliteal fossa where it becomes the 
popliteal artery.  Then descending down the leg the popliteal artery divides into the 
anterior, posterior tibial and peroneal arteries.  The dorsalis pedis (DP) artery is the 
continuation of the anterior tibial (AT) artery into the anterior part of the ankle, whereas 
the posterior tibial (PT) artery is found in the inside hollow of the ankle bone 
(Monkhouse, 2001).   
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2.6.1.2. Arterioles 
Arteries branch into smaller vessels known as arterioles, until the blood flows through 
tiny thin walled capillaries (Solomon et al., 1990).  Arterioles have medial smooth 
muscle cell contraction, the purpose of which is to adjust the diameter of the lumen and 
control the distribution of blood flow (Dobrin, 1997).   
 
Source: (Cole, 2001a) 
Figure 2.12. Disection of the artery walls 
 
This contraction regulates the arterial blood pressure before directing it towards the 
capillaries (Strandness and Sumner, 1975). 
 
2.6.1.3. Capillaries 
Capillaries allow the exchange of nutrients and waste products between blood and cells 
(Solomon et al., 1990; Dobrin, 1997).  They have a large cross sectional area but their 
walls are thin, which allows exchange of oxygen and diffusible substances between 
plasma and the tissues (Vander et al., 1998).  Blood flows from the capillaries (Figure 
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2.14), to postcapillary venules, to collecting venules and on into small, medium or large 
veins (Silverthorn, 1998).   
 
 
 
Source: Seeley et al., (2006) 
Figure 2.13. Arteries of the Lower Limbs 
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Source: Fox (1996) 
Figure 2.14. The Capillaries.  
 
2.6.2. Venous anatomy of the lower limbs 
“The function of the veins is to return blood from the peripheral capillary beds to the 
heart” (Tibbs, 1992).  Another function of veins is to control dissipatation of heat from 
the core of the body, by diverting the blood flow to the superficial cutaneous veins 
(Belcaro et al., 1995).  This can be important in lower limb swelling during long haul 
flight.   
Veins carry approximately 70 percent of the total blood volume at any one time (Belcaro 
et al., 1995; Dobrin, 1997).  Veins of the lower limbs are classified into three sets; 
superficial, deep and sinuses (Gray, 2001).  They have different characteristics to arteries; 
they have thinner walls, are collapsible and contain valves which permit unidirectional 
flow (Tibbs, 1992).   
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2.6.2.1. Superficial veins  
Superficial veins are found in subcutaneous tissue, which is just below the skin, (Sumner, 
2000).  They can perforate the deep fascia and connect to the deep veins (Tibbs 1992). 
The plantar cutaneous arch of the foot is formed by superficial veins in the sole of the 
foot.  These veins play a role in the venous pump system (Browse et al., 1988; 
Strandring, 2005).   
Superficial veins usually have thicker walls than deep veins. They are known as the long 
saphenous vein (LSV) and the short saphenous vein (SSV) (Porter and Moneta, 1995).  
The LSV (Figure 2.15) also known as the great saphenous vein, begins in a tiny plexus 
found in the dorsum and medial side of the foot. It passes in front of the ankle and runs 
subcutaneously up the inner leg and thigh to the groin, where it passes through an 
opening in the fascia lata and then terminates in the femoral vein (Gray, 2001; 
Monkhouse, 2001; Rautio, 2002). 
In the foot the LSV communicates with the internal plantar vein.  In the leg it 
communicates with both the posterior tibial (PT) veins (by branches which perforate the 
tibial origin of the Soleus muscle) and the anterior tibial (AT) veins (with the articular 
veins at the knee).  When passing through the thigh area the LSV communicates with 
femoral vein at one or more branches.  
The SSV (Figure 2.16) commences in the dorsum and lateral side of the foot.  It passes 
subcutaneously behind the ankle, along the tendo Achilles at such an angle that it travels 
towards the middle line of the posterior aspect of the leg. As the SSV ascends upwards it 
perforates the deep fascia at the lower end of the popliteal space, terminating in the 
popliteal vein.  The SSV communicates with deep veins in the dorsum of the foot and 
behind the lateral malleolus.  
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Source: Cleveland clinic (2007). 
 
Figure 2.15. Deep and Superficial anterior veins of the leg  
 
Source: Netterimages.com.  
 
Figure 2.16. Superficial posterior veins drain to the Popliteal Vein  
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2.6.2.2. The Deep System.  
The deep veins of the lower extremities (Figure 2.17) begin in the deep plantar arch of 
the foot (Menzoian et al., 1997).  Each of the deep veins accompanies the arteries.  Pairs 
of deep veins exist for both the tibial and peroneal arterteries and these deep veins are 
termed the Venae Comites.  The main function of these veins is the collection and 
conduction of blood.  Each of these venae comites has a diameter 35 per cent greater than 
the adjacent artery (Strandness and Sumner, 1975).  Larger arteries such as the popliteal 
and femoral arteries usually have only one accompanying vein.  
The lateral and medial plantar veins (which are the deep venous system of the sole of the 
foot) join together to form the posterior tibial veins (Figure 2.19) behind the ankle joint 
(Mozes and Glovicki, 2004; Strandring, 2005).  They accompany the PT artery and are 
joined by the peroneal veins (Gray, 2001).   
The AT veins are a direct continuation of the dorsalis pedis veins.  They drain the blood 
from the dorsum of the foot and they perforate at the interosseous membrane at the upper 
part of the leg and together with the PT veins they become the Popliteal vein.   
“The popliteal vein is formed by the junction of the venae comites of the AT and PT 
vessels; it ascends through the popliteal space to the tendinous aperture in the Adductur 
magnus, where it becomes the femoral vein.” (Gray, 2001).  From the popliteal veins, 
blood flows to the superficial and then common femoral veins (Porter and Moneta, 1995; 
White et al., 2000).    
The femoral vein accompanies the femoral artery in the thigh area.  It terminates beneath 
the crural arch where the external iliac vein commences.  The external iliac passes along 
the edge of the pelvis and unites with the internal iliac vein to become the common iliac 
vein (Gray, 2001).  
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The inferior vena cava is formed by the junction of the two common iliac veins on the 
right side of the intervertebral substance, between the fourth and fifth lumbar vertebrae. It 
travels upwards along the spine on the right side of the aorta artery until it perforates the 
tendinous centre of the Diaphragm.  From there it enters the pericardium until it 
terminates in the lower posterior side of the right auricle (Gray, 2001).  
If a deep vein becomes occluded venous return must flow by an alternative pathway; 
through another deep vein or overlying superficial veins.  These channels of alternative 
flow are known as collateral veins.  If this occurs these veins will become enlarged.   
 
 
Source: Martini et al., (1998). 
Figure 2.17. Deep Veins of the Lower Limbs 
 55 
2.6.2.3. Sinuses  
 
Sinusoidal veins are present in both the foot and lower limb and are situated within the 
“skeletal muscles” (Sumner, 2000). These veins within the foot are defined as “…dilated 
segments of the venous arcades …” (Browse et al., 1988, p. 32).  Between one and four 
large veins pass through the deep layer of the plantar plexus, usually under the arch of the 
foot.  These segments or chambers are surrounded by muscle, and have a large capacity 
and a thin wall so that the chamber can fill with little or no resistance when the muscle is 
relaxed (Figure 2.19).  In the calf the “...soleal sinuses are pouch-like areas that receive 
blood from the soleus muscles which lie posteriorly and distal to the gastrocnemius 
muscles and drain into the posterior tibial and peroneal veins.” (Cole, 2001b, p.2).   
Inflow of blood to these chambers comes from other deep veins, superficial veins via 
perforating connecting veins and venules draining muscle capillaries (White et al., 1996).   
 
2.6.2.4. Physiology of lower limb venous return 
The process of venous blood flow in the leg, against gravity, towards the heart is 
instigated by compression of the plantar plexus of the veins, which are situated between 
the deep and superficial intrinsic muscles of the foot (Menzoian et al., 1997; Sumner, 
2000).  The veins of the plantar plexus are 1.9 times the size of the PT vein, which they 
empty into upon plantar flexion or stretching.  This creates a high velocity of blood flow 
into the PT veins (White et al., 1996).  Contraction and subsequent relaxation of the calf 
muscles cause ejection of a volume of venous blood flow from the calf veins to the 
popliteal vein and subsequently to the femoral vein, the iliac vein and the IVC, before 
entering the heart, completing the process (Strandness and Sumner, 1975, O‟Donovan et 
al., 2005).  
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When a person is walking, the foot is in contact with the ground only 60 per cent of the 
time.  At the mid segment of the foot is a transverse arch.  This arch is high medially and 
low or virtually non-existent laterally so therefore the ball of the toes, the heel and the 
plantar surface of the foot, bear the majority of the weight of the body.  Walking is 
achieved when the calf muscles contract to facilitate heel strike off.  Muscle contraction 
is the main activator of venous pumps (Strandring, 2005). Stretching may promote 
pumping by causing intramuscular pressure (Stranden, 2000).  During normal movement, 
the venae comites are the channel employed to empty the foot pump (Gardner and Fox, 
1989).  Prior to the foot bearing any weight, (i.e. being placed on the ground), the ankle is 
dorsiflexed, causing the bulk of the calf muscle to descend within the fascial sheath, 
resulting in the emptying of the distal calf pump (Gardner and Fox, 1993).  
This is pertinent to the research programme, described in that the action occurs when the 
passenger places his/her foot on the uncompressed Tromped pedal.  Weight bearing is 
achieved by initial pressure on the foot pedal, emptying the foot pump into the deep veins 
of the calf which are relaxed.  This results in extension of the tarso-meta tarsal joints and 
flattening of the tarsal arch, which empties the foot pump (Stranden, 2000).  Depression 
of the pedal against resistance activates the calf muscles, emptying the proximal muscle 
pump (Gardner and Fox, 1989).  The foot pump will empty into the long and short 
saphenous veins if the deep veins of the calf are blocked, when the calf muscles may 
have tightly contracted, dependant on ankle positioning (Gardner and Fox, 1989).   
The flexing of the plantar area of the foot empties the proximal calf pump into the 
popliteal (knee area) and femoral veins (Gardner and Fox, 1989; Sumner 2000). The 
muscle group of the thigh compress the femoral veins which ejects the blood into the 
inguinal area (Gardner and Fox, 2001).  
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2.6.2.4.1. Venous Valves  
Venous valves “are bicuspid with gossamer thin highly flexible cusps” Tibbs, (1992, p. 
13).  Valves “…are folds of the intima that contain collagen and elastin but no smooth 
muscle…” and “…prevent retrograde venous flow with changes in position and muscular 
contraction…” (Strandness and Sumner, 1975, p.5).  There are numerous valves in each 
of the venae comites.  There are approximately seven in the peroneal, four in the popliteal 
vein and four or five in the femoral vein.  There can be as many as six valves in the LSV 
and only two within the SSV (Gray, 2001). Perforating veins have valves which allow 
flow only one direction (Tibbs 1992).  A valve can be seen in the ultrasound scan (Figure 
2.18) which was obtained from the Non-Invasive Vascular Unit in Beaumont Hospital, 
Dublin.  
 
Source: Non-Invasive Vascular Unit, Beaumont Hospital.  
  
Figure 2.18. Ultrasound image of Venous Valves 
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2.6.3. Calf muscle pump function 
In the normal venous circulation, the deep venous system carries 90 percent of the venous 
flow” (Cole, 2001b, p. 18).      
The pumping chambers of the lower limb empty directly due to each muscle contraction 
(Tibbs 1992).  When exercise has stopped, valves (Figure 2.20) above the compression 
site close, preventing reflux due to gravity, with the veins remaining partially collapsed 
until the vein segments are refilled by venous inflow from capillaries (Sumner, 2000).  
The soleal sinusoids empty venous flow into the PT vein.  The gastrocnemius sinusoids 
usually empty venous flow into the popliteal vein (Hirsh & Hull, 1987; Tibbs, 1992).  
 
Source: Giordano, 2000. 
Figure 2.19. Dynamics of venous blood flow in response to the calf muscle pump.  
 
Blood pools in the Soleal and Gastrocnemius sinusoids before it is ejected by the calf 
muscle pump (Menzoian et al., 1997).  The leg muscles are in effect a power source 
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whereby during exercise, these sinusoids act as bellows of the muscle pump mechanism 
(Sumner, 2000).  In a healthy limb, during the muscle contraction activity, all perforating 
veins are closed off from the deep veins by valves and fascial gates, allowing blood to 
flow in one direction.  Once the muscle has relaxed, free flow can occur in either 
direction depending upon pressure gradients.  Every time deep vein pressure drops as a 
result of one muscle contraction, blood from the superficial veins drains into the deep 
veins via a perforating vein (Tibbs 1992).   
The venous valves in the deep and superficial veins prevent the reflux of blood against 
the normal direction of venous flow.  If and when these valves collapse or fail, varicose 
veins may develop, as a result of blood pooling at the most dependent section of the vein 
and remaining there (Gardner and Fox, 1999; Fowkes et al., 2001).  In addition to these 
valves there are also peripheral venous valves which function to protect the capillaries 
and venules during exercise from large increases in pressure (Lee et al., 1999).  Venous 
valves can be imaged with ultrasound (Figure 2.20).  
 
Source: Giordano, 2000 
Figure 2.20. Valves in the veins.   
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Figure 2.20 demonstrates the operation of venous valves, preventing venous reflux (on 
the left of the diagram) and permitting venous return (on the right of the diagram).  If the 
valves at the ankle become incompetent, contraction of the calf muscle sends venous 
blood through the perforators and not to the heart resulting in a reverse flow and a 
subsequent high pressure reflux (Clain, 1980).  Distension of veins due to posture may 
result in impairment of venous valve function, resulting in reflux in one or more vein 
segments (Tibbs 1992; Lee et al., 1999).   
 
2.7. Venous Haemodynamics 
There are four aspects of normal venous hemodynamics.  Venous pressure and the role of 
gravity, venous volume and its relationship with compliance, pressure flow phenomena in 
collapsible tubes and venous valves and their contribution to the venous pump 
mechanism (Rautio, 2002).  
Venous flow is intermittent, so therefore it changes from periods of high velocity flow to 
almost flow cessation (Strandness and Sumner, 1975).  Venous flow is affected by 
gravity, venous pumping and arterial flow.  The peripheral pumping mechanism 
(provided by the calf muscles) alone will cause full venous flow against gravity.  This 
occurs when veins are compressed by the muscles.  A vein‟s ability to collapse means 
veins empty completely on compression so they can refill prior to the next pumping 
action.  “Veins are thin walled, elastic, collapsible tubes and not „pipes‟of fixed capacity” 
(Tibbs 1992, p.13).  Valves in the veins act against gravity by preventing the blood 
flowing backwards when directing it towards the heart (Tibbs 1992). 
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CHAPTER 3 
DEEP VEIN THROMBOSIS & FLIGHT RELATED DEEP 
VEIN THROMBOSIS.  
 
3.0 Introduction  
Normal venous function is the return of blood to the heart by means of the venous system 
(Strandness and Sumner, 1975; Sumner, 2000; Rautio, 2002).  
Blood remains in a fluid, clot-free state in healthy vessels (Underwood, 2004).  However, 
in the event of damage to a vessel wall a clot is normally produced.  The medical term for 
a clot is a thrombus.  “Clotting that occurs in an unbroken blood vessel is referred to as 
thrombosis” (Solomon et al., 1990, p. 661).  Venous thromboembolism (VTE) is a 
multicausal disease, in which inherited and acquired risk factors interact together to 
produce thrombi and/or emboli (Rosendaal, 1999). 
In this chapter the pathology of deep vein thrombosis (DVT), pulmonary embolism (PE) 
and venous thromboembolism by inherited and/or acquired risk factors is outlined.  The 
life long implications associated with DVT and the forms of prophylaxis currently 
employed to alleviate/prevent DVT and FRDVT are discussed, underlining the necessity 
for a universal solution to address the problem.  Other modes of travel related DVT will 
also be considered.  Implicating factors such as a passenger‟s designated seat on board 
aircraft, the use of compression stockings and other risk factors related to this syndrome 
will then be outlined.  Airline cabin environmental factors such as the effects of cabin 
pressure, hypoxia and humidity on the development of FRDVT will also be highlighted.   
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3.1. Thrombus Formation 
The endothelium is a single layer of cells separating blood from the vessel wall. The 
endothelial cells are responsible for maintaining blood in a fluid state or initiating plasma 
coagulation and platelet activation which are necessary to thrombi development (Browse 
et al., 1988; Gallagher and Sumpio, 1997; Radomski and Radomski, 2000).  A blood clot 
is “a gel consisting of insoluble fibres and trapped blood cells and platelets” (Solomon et 
al., 1990, p. 658).  There are three stages in the blood clotting process.  
When a vessel is damaged, a series of reactions occur which result in the formation of 
prothrombin activator.  The vessel wall damage (endothelial injury) exposes the inner 
part of the wall which is termed the extracellular matrix (ECM).  Prothrombin activator 
and calcium ions are responsible for the second stage where the prothrombin develops 
into thrombin (Woolf et al., 2002).  The exposed ECM activates platelets to change their 
shape and release the necessary substance to attract yet more platelets along with Tissue 
Factor (TF) which works with the platelets to activate the coagulation process (Mitchell, 
2005).  The final stage is when the thrombin converts fibrinogen into fibrin, which holds 
the blood cells, platelets and plasma within its threads, making the basis of the clot.  
When the platelets stick to the fibres they emit a substance called adenosine diphosphate 
(ADP), which attracts more platelets to the site of damage.  Platelets emit a 
prostaglandin, which activates other platelets (Solomon et al., 1990).  
One of the first signs of possible development of a thrombus (Figure 3.1) is platelet 
aggregation, which may occur in valve cusp pockets, vein junctions or in venous saccules 
(Ramaswami and Nicolaides, 1994).  These initial thrombi grow by layers of platelets 
which adhere to injured endothelial cells and subendothelium, along with red blood cells 
and fibrin gathering together in the direction of the blood flow (Ramaswami and 
Nicolaides, 1994; Kumar and Clark, 2002; Ulutin, 2002).  
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The main determinants thought to influence thrombi formation include blood flow, the 
vessel wall, coagulation factors, platelets and red blood cells (Kumar and Clark, 2002).  
This was first described in 1856 by Virchow and is known as Virchow‟s Triad (Galili and 
Bass, 2002).  
 
Source: Medlineplus. 
Figure 3.1. Venous Blood Clot. 
 
It is summarised below: 
i. Changes in blood flow; 
Stasis and/or reduced blood flow, will encourage the development of thrombi. 
Clotting may occur when blood flow is sluggish.  This condition is known as 
stasis (Solomon et al., 1990).  Stasis allows activated clotting factors to 
become concentrated in the veins and therefore interact with one another, with 
the end result of thrombus formation.  Comerota (1994a, p.32) stated “…it is 
logical that reduced flow might prolong the contact time of activated platelets 
and clotting factors with the vein wall thereby permitting thrombus 
formation,...”; 
ii. Changes in the vessel wall;   
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This may be caused by trauma or injury to the endothelial lining. Within two 
seconds of a vessel wall becoming damaged, the wall of the vessel contracts in 
what is termed a vascular spasm.  This is to reduce blood flow, enabling the 
platelets to come into contact with the collagen fibres of the wall which are 
exposed, so platelets can adhere to them (Solomon et al., 1990).  The 
damaged tissues emit substances known as tissue thromboplastin (FIII), which 
in turn activates the stable factor (FVII) to activate plasma thromboplastin 
(FIX) and FX so the repair process may begin (Solomon et al., 1990); 
iii. Alterations in the blood constituents; 
 A hypercoagulable state is one in which “…the normal balance between 
clotting and anticlotting mechanism becomes altered…” and so predisposes an 
individual to thrombus formation (Cho, et al., 2002). Hypercoagulability is 
concerned with changes in blood elements such as an increase in platelet 
count and adhesiveness.  In addition to this, deficiencies in Antithrombin III, 
proteins C and S all aid in the development of a thrombus (Comerota, 2000).  
The flow of blood through the circulation system ensures that the clotting factors cannot 
remain in the damaged area.  This is to ensure that the clotting process does not continue 
and completely obstruct a vessel, preventing flow (Solomon et al.,, 1990: Mitchell, 
2005).  Thrombi undergo one of the following four processes once formed; 
i. Propogation – the accumulation of more platelets and fibrin, which can lead to 
the vessel becoming occluded; 
ii. Embolisation – where the thrombus dislodges and moves to another site; 
iii. Dissolution – be removed by fibrinolysis; 
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iv. Organisation and recanalisation – thrombus induces inflammation and fibrosis 
and becomes recanalised.  In other words blood flow occurs again as the 
thrombus becomes part of the vessel wall (Mitchell, 2005). 
Fibrosis is the generation of fibrous tissue during healing of tissue or cells (Wilson and 
Waugh, 1998).  
Recanalization and valve obstruction can result in the muscular pump mechanism 
malfunctioning which can result in an increased pressure in the deep calf veins (Hirsh and 
Hull, 1987).  High pressure can result in blood flow being redirected from the deep 
system to the superficial venous system, during muscular contractions, resulting in the 
development of oedema (Hirsh and Hull, 1987).  Venous thrombosis can occur in any 
vein of the body.  However veins of the leg or the pelvis are the most common areas 
(Kumar and Clark, 2002).  
 
3.1.1. Deep Vein Thrombosis.  
If venous thrombosis occurs in a deep vein such as the popliteal or femoral vein it is 
termed a DVT (Weitz, 2000).  A DVT may be classed as a proximal thrombosis which 
occurs in the popliteal and thigh veins or a distal thrombosis which occurs in the calf 
veins.  Proximal DVT “…is a serious disorder with potentially life-threatening 
consequences…” as it is likely to progress into a pulmonary embolus (Riddle and Wells, 
2004, pp.729-30).   
The incidence of DVT is estimated as one in 1000 person years (Kelman et al., 2003). 
Left sided DVT episodes are more prevalent than right limb episodes, as there is a 
tendency for the left common iliac vein to be compressed by the right common iliac 
artery, which it crosses and so causes damage (O‟Sullivan et al., 2000).  
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Varma et al., (2004) report that mortality as a result of DVT at 20 percent.  Anderson and 
Audet (1998) reported that DVT occurred in 250,000 patients with 50,000 deaths in the 
Worcester, Massachusetts, study.  This study was conducted over 18 months in the mid 
1980s by reviewing the hospital discharge records of all patients with venous 
thromboembolism (VTE), including both recurrent and first-time episodes.  
 
3.2. Symptoms of DVT 
“Venous Thrombosis in the lower extremity may cause little or no acute pain unless the 
associated inflammatory reaction is significant, in which case there may also be localized 
tenderness along the course of the involved vein” (White et al., 2000, p. 6). 
Small non-occlusive thrombi produce no recognisable physiologic defects (Sumner, 
2000).  Some of the common symptoms of thrombi include pain in the calf, swelling, 
redness, warmth of the affected limb and possibly oedema in the ankle (Stranden, 2000; 
Mitchell, 2005; Clarke et al., 2006).   
Swelling may occur if thrombus is extensive and causes complete obstruction 
(Ramaswami and Nicolaides, 1994).  Swelling in the ankle and foot may suggest a 
thrombus is present in the deep veins of the calf.  Swelling of the thigh suggests thrombus 
in the ileofemoral area, (Figure 3.2) whilst swelling of the groin, thigh and calf suggests 
the presence of iliac thrombosis extending to the inferior vena cava (Ramaswami and 
Nicolaides, 1994).  
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Source: Medlineplus. 
Figure 3.2. DVT in the ileofemoral (groin) area 
 
3.3 Superficial venous thrombosis 
Thrombi may form in superficial veins such as LSV or the SSV.  Superficial venous 
thrombosis (SVT), also known as superficial thrombophlebitis, is a less serious condition 
than DVT.  Complications can occur where the thrombus may extend along the 
perforating vein to the deep veins however this only occurs rarely (Clain, 1980). 
Symptoms if any could be similar to those of a DVT (Mitchell, 2005).  
 
3.4. Thrombophilia 
Thrombophilia is defined as a tendency to have recurrent venous thromboembolism 
(Wood, 1996, p.1817). It is an uneven balance between procoagulants and anticoagulants 
present in the blood (Laffan, 1998).   Individuals with a history or family history of DVT, 
PE, miscarriage, who develop DVT at an unusual site, may have a genetic thrombophilia 
(Bucciarelli et al., 1999; Lowe and Rumley, 1999; Kumar and Clarke, 2002).   
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3.5. Lysis of thrombi 
Natural lysis of the thrombi may occur due to what is termed fibrinolytic activity.  
Plasmin and activated Protein C, work together to break down fibrin and fibrinogen into 
fibrin degradation products (FDP) (Labelle and Kitchens, 2005; Kumar and Clark, 2002). 
Plasmin can break down Factor V and Factor VIII coagulation factors.  Plasminogen 
activators come from plasma or blood cells or tissues, which convert the plasminogen 
into plasmin (Kumar and Clarke, 2002; Labelle and Kitchens 2005). 
Several factors play a role in determining how slowly or quickly a thrombus can lyse 
(Blombery and McGrath, 2000): 
i. The site where the thrombus developed; 
ii. The size of the thrombus and if it is fully occluding the vein; 
iii. The degree of fibrinolytic activity; 
iv. If anticoagulation treatment is being administered and if so for how long. 
The process of clotting is regulated by three natural anticoagulants.  Antithrombin III is 
activated by binding to heparin-like molecules on the endothelial cells.  Protein C and 
Protein S inactivate FVa and FVIIIa.  TFPI is released from the endothelium to inactivate 
Fxa and FVIIa (Mitchell, 2005).  Plasmin is activated by FXIIa, thrombin and lysosomal 
enzymes from damaged tissues. Its purpose is to dissolve fibrin and to reduce the size of 
clots when the healing process is occurring (Solomon et al., 1990).  If the thrombus is 
large, it may not fully lyse leading to a “reduction in the luminal diameter of the vein” 
and an increased risk of recurrent, future thrombi developing and/or valvular 
incompetence (Ramaswami and Nicolaides, 1994).   
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3.6. Post thrombotic syndrome 
The long term outcomes of DVT include resolution, valve damage, the post thrombotic 
syndrome (PTS), and/or recurrent DVT.  
“A history of DVT increases the risk of chronic venous insufficiency 25.7 fold, compared 
with those without a history of DVT.”  Blombery and McGrath (2000).  This increased 
risk of chronic venous insufficiency (CVI) may result from the following three factors; a 
remaining thrombus obstructing venous flow, an increase in venous valve incompetence 
as a result of previous thrombus and dilation of veins or calf muscle pump dysfunction 
(Nicolaides and Summer, 1991; Blombery and McGrath, 2000).  
A review of literature was conducted to determine the length of time before PTS 
presented with symptoms after an episode of DVT.  It was concluded “… most cases 
become clinically apparent within the first 1 to 2 years of the acute DVT” (Kahn et al., 
2000, p. 426).  Thirty percent of patients diagnosed with DVT could suffer from PTS 
(Hyers, 1999).  Common symptoms of chronic venous disease (CVD) range from 
moderate limb swelling to pain, discolouration and possibly ulcers (Neglén, 2003; 
Padberg et al., 2003).  The cost in treatment of venous ulcers in the United States is 
greater than one billion dollars and between four and 600 million pounds sterling, per 
year in the United Kingdom (Nicolaides, 2000). 
Both venous hypertension and valvular incompetence are precursors to PTS (Comerota, 
2000; SIGN, 2002).  Patients suffering from PTS may present with pain and swelling and 
some may even develop ulcers (Ramaswamai and Nicolaides, 1994; Meissner, 2002; 
SIGN, 2002).  
CVI is defined as “an abnormally functioning venous system caused by venous valvular 
incompetence, …which may affect the superficial venous system, the  deep venous system 
or both.”  (Porter and Moneta, 1995, p.639).  
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To begin with symptoms such as discomfort and swelling of the ankle may occur, with 
edema and pain increasing and the skin becoming inflamed.  As the disease progresses, 
ulcers may develop.  Ulceration may occur two to three years after a first episode of DVT 
(Tibbs, 1992).   
 
3.6.1. Cost Effectiveness of Prophylaxis 
As a duty of care and a preventative measure, patients undergoing surgery must wear 
TED stockings prior to, during and after surgery to prevent a thrombus forming.  This is a 
hospital procedure and one which recognises the risk of thrombus formation as a result of 
immobility.   
It is reasonable to argue that the use of prophylaxis should not be determined by how 
much it will cost, instead it should be provided to prevent an unnecessary death by PE 
(Hull et al., 1986).   
 
3.7. Flight Related Deep Vein Thrombosis 
When a thrombus develops during flight it is termed Flight Related Deep Vein 
Thrombosis (FRDVT).  FRDVT was termed Economy Class Syndrome, (ECS) in 1988 
by Cruickshank et al., (Belvís et al., 2005; Gispert et al., 2006).  Subsequently, it has 
been demonstrated to occur in first class passengers (Mohler, 1997; Galili and Bass, 
2002), aircraft pilots (Johnson and Evans, 2001; Shrivastava, 2003) and also following 
car and train travel (Ferrari et al., 1999, Belvís et al., 2005; Cannegieter et al., 2006).  
Death as a result of FRDVT has been reported in passengers as young as 28 years of age 
(Jameson, 2001; McDonald, 2003) and in travellers who have remained seated for the 
duration of a twelve hour flight (Paganin et al., 1996).  During air travel, two of 
Virchow‟s Triad factors are present, venous stasis can occur due to immobility from 
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sitting in an aircraft seat and hypercoagulation due to the cabin environment (Comerota, 
1994a).  
 
3.7.1. Incidence 
The reported incidence of FRDVT ranges between 0.24 percent and 10.34 percent 
(Belcaro et al., 2001a; Belcaro et al., 2001b; Scurr et al., 2001; Belcaro et al., 2002; 
Cesarone et al., 2003a). 
The Lonflit 2 Study determined the incidence of FRDVT was 0.24 percent in the stocking 
group on a flight of ten to 15 hours duration (Belcaro et al., 2001b).   
Twenty-two DVTs in 19 participants (three of these individuals presented with bilateral 
DVTs) and eight SVTs were diagnosed in the control group of 422 participants (Belcaro 
et al., 2001a). 
The Lonflit-flite study reports a FRDVT incidence of 5.4 percent (92 volunteers) in the 
control group (Cesarone et al., 2003a).  The Scholl Flight socks study determined the 
incidence of FRDVT and FRSVT (without stockings) as 2.12 percent and 1.06 percent 
respectively, on flights of seven to eight hours duration (Belcaro et al., 2002).  Belcaro et 
al., (2003b) determined the incidence of FRDVT in a high risk control group (flight 
eleven to thirteen hours duration) as 5.8 percent.   
Hughes et al., (2006) reported an incidence of FRDVT of 4.68 percent in a study of 576 
patients whom were admitted for VTE.  Sixty of these patients had travelled by air, with 
43.3 percent travelling for at least ten hours duration.   
The Mediven stocking trial determined the incidence of FRDVT was 10.34 percent in 
those not wearing compression stockings on a flight of greater than eight hours duration 
(Scurr et al., 2001).   
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FRDVT alone is not life threatening (although it may result in long-term lower limb 
disease), it is its potential to cause pulmonary emboli that can have serious consequences. 
 
3.8. Pulmonary Embolism  
When a venous thrombus becomes dislodged from its site of formation, it becomes an 
embolus.  This embolus may then move through the venous system until it becomes 
lodged again (Solomon et al., 1990; Goldhaber, 1998; O‟Donovan et al., 2005).  
Pulmonary embolism (PE) occurs when the embolus becomes trapped in the pulmonary 
arteries of the lung (Figure 3.3) (Solomon et al., 1990; Damjanov, 2002).   “Acute PE 
impairs the efficient transfer of O2 and CO2 across the lungs” (Goldhaber and Elliot, 
2003).  If an embolus is large enough to occlude the artery, it may cause death 
(Ramaswami and Nicolaides, 1994).  This is known as pulmonary arterial obstruction.  
One of the affects of this is redistribution of blood flow.  When the platelets release 
serotonin, pulmonary vascular resistance increases, creating alveolar dead space 
(Goldhaber, 1998).  As the dead space increases resulting from the embolus, the breathed 
gas cannot enter the gas exchange units of the lung, thus impairing the necessary removal 
of CO2 in the body by the lungs.  The gas exchange units of the lung are known as the 
respiratory bronchioles, alveolar ducts and alveolar sacs.  If the blockage is large enough, 
it may even prevent venous blood entering the lungs and so it remains in the venous 
system (Goldhaber and Elliot, 2003).   
When people develop PE unexpectedly it may be due to an asymptomatic thrombus 
travelling into pulmonary vessels, which causes cardiogenic shock, followed by 
circulatory failure and death (SIGN, 2002).  One associated hazard of PE is that as 
patients become older, the presence of a thrombus can mimic other illnesses such as acute 
coronary syndrome.   
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Source: Medlineplus 
Figure 3.3. Pulmonary Embolus 
 
So if a patient presents with two coexisting illnesses it can be difficult to accurately 
diagnose PE (Goldhaber, 2004).  This may result in an underestimation of the incidence 
of PE related to travel.  It is reported that PE‟s originate in the deep veins of the legs in 
90 percent of cases (Hull et al., 1986; Perrier, 2000 and Loud et al., 2001).   
The incidence of PE is 500-1000 per 1000000 person years (Kelman et al., 2003).  It has 
been estimated to occur in greater than 600,000 patients per year in the United States of 
America and resulted in death for 100,000 of these patients per year (Tapson, 2001).  
 
3.8.1. Flight related pulmonary embolus (FRPE)  
FRPE is the term used to describe a PE which has developed as a result of long haul 
flights.  FRPE was first reported by Homans in 1954, two cases occurred directly due to 
long haul flights and another two cases of PE resulted from travel by car (Dalen, 2003).   
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Doctors in Kings College London have claimed that 30,000 people die each year in 
Britain from PE and they estimated that about 1000 of these are due to flying (Wright, 
2003, p.1).   
Incidence as low as 0.39 cases per million per year have been reported (Pérez-Rodríguez 
et al., 2003).  Symptoms presented at varying times; from during flight to post 
disembarkation in the airport and up to eight weeks post flight.  FRPE in this study was 
attributed to flights of greater than six hours duration, with the majority travelling greater 
than eight hours duration (Pérez-Rodríguez et al., 2003).  
Lapostolle et al., (2001) reported the incidence of FRPE as 4.8 cases per million.  This 
incidence increasing with the total distance travelled, i.e. in passengers who travelled 
greater than 5000 km, the incidence of PE was 1.5 cases per million, while those who 
travelled greater than 10,000 km the incidence of PE increased to 4.8 cases per million.  
This study defined a flight as “the period between take off and landing (including 
stopovers”).  Of the 135.29 million passengers from 145 countries that arrived at that 
airport, only 56 passengers were documented as having PE.  Symptoms presented at 
varying times as in the Pérez-Rodríguez study.  Eight passengers during flight, 16 
passengers developed symptoms upon landing and the remaining 32 post travel. Sadly, 
one incidence resulted in death (Lapostolle et al., 2001).  
A ten year study conducted by Caillard and Clerel (2001) at the Aeroports de Paris 
emergency unit, which concluded in the year 2000, revealed that 109 patients presented 
with symptomatic PE.  Eighty three women and 24 men with a mean age of 57.3 years 
were diagnosed.  Thirty eight of the passengers had no risk factors and no previous 
history of DVT/PTE.  Ninety five percent travelled for greater than six hours and 75 per 
cent greater than twelve hours.  Only emergency cases have been documented.  
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The incidence of FRPE was reported as 6.94 percent by Hughes et al., (2006).  This study 
was a follow up study from the New Zealand Air Travellers Thrombosis (NZATT).  It 
examined admissions in Wellington, Auckland and Green Lane hospitals for flight related 
VTE, in the period between 1997 and 2001.  Recent air travel (at least ten hours duration) 
was recorded in 60 of the 576 cases which met the inclusion criteria. Twenty seven cases 
of FRDVT and 40 FRPE cases were identified, with both DVT and PE present in seven 
of these individuals.  Again varying time and presentation were reported.  Sixty five 
percent of the 60 individuals presented with symptoms to the hospital within one week 
(Hughes et al., 2006).  
Eklof (1996) and Ferrari et al., (1999) have both stated that PE may develop in 
passengers several weeks post travel.  This is very likely as FRDVT can be asymptomatic 
with symptoms not appearing for as long as four weeks after the flight (Gorshtein, Levy 
& Shoenfeld, 2002; Watson, 2005).   
According to Murphy (2001) “two thirds of travel-related VTE presents after patients 
leave the airport”.  As a result many people may die directly from the consequence of 
FRDVT and yet this reason may never be attributed as their cause of death. 
 
3.8.2. Symptoms of PE.  
Symptoms of PE may include chest pain, dyspnoea or haemoptysis. (Hull et al., 1986; 
Goldhaber, 1998).  Dyspnoea (breathlessness) can be as a result of cardiac or respiratory 
causes (Kumar and Clarke, 2002).  Haemoptysis (coughing up blood) is defined as “…the 
expectoration of gross blood or blood-streaked sputum” as stated by Flores and Sandur 
(2006, p.37).  It is not always possible to identify the initial source of the embolus 
(Ögren, et al., 2005).  However a PE which originated in the proximal veins of the legs is 
usually larger than those that originated in calf veins (Hirsh and Hull, 1987).  
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3.9. Venous Thromboembolism 
Venous thromboembolism (VTE) is the term used to describe DVT and/or PE (Cook et 
al, 2004; Klatsky & Baer, 2004; Grand‟Maison, et al., 2005; Ögren et al, 2005).  There is 
a significant difference between deep and superficial VTE.  Deep VTE describes a 
thrombus which has formed in a deep vein that may embolise and travel to the lungs. 
Where as a superficial VTE describes a thrombus forming in a superficial vein which 
seldom embolise or extend to the deep system.  Research on post mortem studies reported 
that 50 percent of cases of DVT and PE were asymptomatic (Kesteven, 2000). 
 
3.9.1. Flight related venous thromboembolism (FRVTE) 
FRVTE is the term used to describe both a FRDVT and FRPE.  
The Lonflit-flite study determined the incidence of flight related DVT events was 5.43 
percent in the control group (Cesarone et al., 2003a).  Kelman et al., (2003), recorded 
hospital admissions for flight related VTE up to 100 days post flight.  During the study 
period, 9.4 million passengers flew into Australia, corresponding with 16,205 hospital 
admissions for VTE.  Of these, 5,508 were post international flights, with the incidence 
of VTE (0.05 percent) four times greater in the first two weeks (Kelman et al., 2003).  
The report “Travellers Thrombosis Review of Deep Vein Thrombosis associated with 
Travel” (2001) published by The Aerospace Medical Association Air Transport Medicine 
Committee references the work of Sarvesvaran (1986) in which twelve of 104 deaths 
which occurred during or soon after flight were due to VTE (Bagshaw, 2001). 
 
3.9.2 Incidence of VTE 
The annual incidence of VTE in the northern European population was estimated at 1.6-
1.8 per 1000 (Hansson et al., 1997; Nordstrom et al., 1999).  In the United States there 
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are between “100,000 to 300,000 cases per year” of VTE (Bockenstedt, 2003, p. 1203).  
It affects approximately one in 1000 people each year (Margaglione et al., 2000).  These 
incidences are for all causes of DVT and PE. 
In 2003, International airlines collectively carried 1.6 billion passengers (IATA, 2004).  
“the occurrence of DVT and PE probably constitutes one of the main medical 
repercussions of air travel” (Ferrari et al., 1999, pp. 442-3).  The actual incidence of 
FRDVT is unknown, however the annual incidence of VTE increased by 12 percent after 
one long haul flight (Kelman et al., 2003).  FRVTE is just one element of this disease 
spectrum.  
In the Ferrari study thirty nine of 160 VTE patients had a history of recent travel.  The 
incidence of combined travel related DVT was reported as 24.37 percent.  Travel by car 
resulted in 71.79 percent of all travel related DVT, travel by air at 23 percent and travel 
by train accounted for approximately five percent (Ferrari et al., 1999).   
The difficulty of determining the true incidence of VTE is compounded by the length of 
time before symptoms developed after flight, reported from 96 hours after the beginning 
of a trip to up to 35 days later (Kesteven, 2000).  This variation is also reported for the 
more serious consequence of PE established by the study conducted at the Ramόn y Cajal 
Hospital.  Two passengers presented with symptoms during flight and eleven post 
disembarkation, in the airport with one case failing to present until eight weeks post flight 
(Pérez-Rodríguez et al., 2003).   
 
3.10. Inherited risk factors associated with the development of DVT 
Some inherited deficiencies make the individual more likely to develop DVT.  This 
places the individual at a higher risk of FRDVT, particularly if the condition is 
undiagnosed.   
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Inherited risk factors include deficiency in natural inhibitors of coagulation or clotting 
(Samama et al., 1994):  
i. Factor V Leiden is the most common inherited risk factor predisposing 
individuals to venous thrombosis (Koppel et al., 2001; Simioni et al., 
2002; Arsov et al., 2006).  Factor V Leiden is generally associated with 
venous thrombolic events rather than arterial events, (Nicolaes and 
Dahlbäck, 2002).  It is more common in individuals suffering from DVT, 
than individuals who are diagnosed with PE.  Meyer et al., (2001, p.14) 
suggest the reason for this could be that the thrombi will not embolise in 
the presence of this mutation as “the thrombus is less susceptible to the 
fibrinolytic system”. It may increase the risk of DVT development by 3.5-
5 fold (Köppel et al., 2001; BTS Guidelines, 2003).  It was thought to only 
occur in white people (Rosendaal, 1999).  However Klatsky and Baer, 
(2004), reported a low prevalence of the Factor V Leiden mutation among 
Asian groups.  They believe that carriers of the mutation have a “50- to 
100-fold” greater risk of a VTE episode occurring (Klatsky and Baer, 
2004, p. 494).  This mutation may be present in five percent of Caucasians 
in both Europe and North America (Hyers, 1999).  Women taking oral 
contraceptives whom are carriers of Factor V Leiden have a greater 
potential to develop VTE (Aznar et al., 2000).  
ii. Activated Protein C (APC) resistance is a direct result of the Factor V 
Leiden mutation (de Visser et al., 1999; Köppel, 2001.) Only discovered 
in 1993 by Dahlback and co-workers (Frederick et al., 2001), it can be 
identified in approximately 50 percent of patients with thrombosis (Günay 
et al., 2001). Nicolaes and Dahlbäck, (2002) and Anderson and Spencer, 
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(2003) take a less definite view by claiming that APC resistance is present 
in 20-60 percent of patients with VTE. It is common in approximately 
“…5% of the general population…” (Desmarais et al., 1996, p.1374).  
Resistance to APC is a result of a reduced anticoagulant response of 
plasma to APC. It is associated with a three to seven fold increased risk of 
VTE (de Visser et al., 1999). Those who have a poor anticoagulant 
response to APC have a seven fold increased risk of DVT developing 
(Kester et al., 1993).  
iii. Antithrombin (AT III) deficiency, not only inhibits thrombin but 
inactivates clotting factors such as IXa, Xa, XIa, XIIa and VIIa (Crowther 
and Kelton, 2003). There are two types of this deficiency. Type 1 is a 
reduced production of the antithrombin protein with Type 2 being a 
production of an abnormal protein. (Crowther and Kelton, 2003; 
Rosendaal, 1997).  “Patients with AT III deficiency have thrombotic 
problems develop during the second or third decade of life, with 65% of 
affected individuals experiencing some form of thrombosis by age 30” 
(Bongiovanni, 2002, p.213).  
iv. The role of Protein C (PC) is to ensure coagulation and fibrinolysis 
remains balanced.  “PC is activated on endothelial cells by thrombin 
bound to thrombomodulin” (de Visser et al., 1999, p.1271; Bongiovanni, 
2002).  Thrombotic events are usually of a venous nature and not arterial.  
Protein C deficiency and Protein S deficiency both increase the risk of 
VTE developing, (Bongiovanni, 2002; Cho et al., 2002), however this 
type of deficiency is not highly prevalent (Tibbs 1992).  
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These inherited deficiencies can be triggered by the following acquired factors, shown in 
table 3.1.  
 
Table 3.1. The incidence of factors which trigger the first episode of thrombus in 
patients with AT-III and Protein C deficiency  
 
 
 
 
 
 
Source: Samama et al., 1994. 
 
There is a well documented relationship between AT-III, Protein C and Protein S 
deficiencies.  Some of their common clinical features include; a first thrombus between 
20 and 40 years of age, a thrombus developing in an unusual site, such as in the 
mesenteric veins in the abdomen, and a higher tendency for recurrence (Samama et al., 
1994; Grand‟Maison et al., 2005).  Bucciarelli et al., (1999) concluded that the risk of 
VTE occurring is greater in individuals who have AT–III deficiency than carriers of 
Protein C or S deficiency.  Prothrombin 20210A gene mutation is a precursor of VTE 
(Aznar et al., 2000; Bongiovanni, 2002). It is more prevalent in southern European 
inhibitants than elsewhere (Aznar et al., 2000).  
 
3.10.1. Inherited coagulation associated with flight.  
Scurr et al., determined an incidence of gene mutation Factor V Leiden and Prothrombin 
G20210A (PGM) were present in ten percent of European populations, based on a study 
into the incidence of FRDVT.  Duplex ultrasound of the lower limbs and blood tests were 
Triggering factors AT-III deficiency % Protein C deficiency % 
Pregnancy 28 20 
Surgery 13 15 
Oral Contraceptives 4 7 
Immobilisation - 9 
Others - 3 
Unknown 42 46 
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taken before and after flight to determine presence of Factor V Leiden and PGM and the 
absence of DVT.  Twelve asymptomatic calf DVT in the control group (115) and four 
SVT in the stocking group (116) were diagnosed post flight (Scurr et al., 2001).  
Schreijer studied the impact of inherited conditions plus oral contraception to establish 
the relative risks.  Seventy one healthy volunteers 15 males and 56 females (ranging from 
29 to 39 years) were recruited.  It was established that eleven had Factor V Leiden 
mutation, another 15 were taking the contraceptive pill, a third sub group of 15 volunteers 
with Factor V Leiden mutation were also taking oral contraceptives and the fourth sub 
group (30 volunteers) had no apparent VTE risk factors. 
Three studies were conducted, (each eight hours duration); on a Boeing 757, the cinema 
and their normal daily routine.  Cabin pressure was between 1800m and 2100m.  
Cigarettes, alcohol, drugs (other than the contraceptive pill) and the use of GECS, heparin 
or aspirin were forbidden. Everyone was encouraged to remain seated for as long as 
possible. These restrictions applied in all three parts of the study. 
Median concentrations of thrombin-antithrombin (TAT) complex levels were identified 
before, during and after the three different studies.  (TAT are markers of activated 
coagulation).  TAT baseline levels were higher post flight than post cinema or the daily 
life study. Volunteers with the Factor V Leiden mutation taking the contraceptive pill had 
higher TAT values than the other subgroups of volunteers.  Elevated D-dimers post flight 
were most prominent in the FVLM group who were taking the contraceptive pill. 
Therefore “……a combination of a genetic predisposition (Factor V Leiden) and an 
environmental factor (oral contraceptives, hypobaric hypoxia) is probably the basis for 
venous thrombosis associated with air travel” in this subgroup (Schreijer et al., 2006, p. 
837). 
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3.11. Acquired risk factors associated with the development of DVT 
Acquired risk factors include changes in coagulation factors and fibrinolytic functions 
(Samama et al., 1994; Heit et al., 2001).  These changes may be a result of changing the 
environment that a person may be exposed to, such as hospitalisation or flying long haul 
or changing health status.  The following outlines the main acquired risk factors: 
i. Stasis of blood flow resulting from immobilisation is a well documented 
acquired risk factor (Comerta, 1994a, Tibbs, 1992, Kesteven, 2000).  This 
may be caused by old age and the inability to walk (Porter et al.,, 1995), 
due to medical conditions or a result of the environment someone is placed 
in, such as flying long-haul.  One interesting medical study, conducted by 
Hamer et al., (1968), investigated the relationship between immobility and 
the partial pressure of oxygen (PO2) within valve pockets of the veins.  
This study showed that when venous flow within valve pockets became 
stagnant, the PO2 levels fell.  The resulting fall in PO2 levels results in 
damage to the cells of the vein walls, a factor which leads to the 
development of thrombi within valve sinuses (Strandness and van Breda, 
1994).  While in-flight there is a general reduction in PO2 (Galili and Bass, 
2002; AMA, 2003). 
ii. All forms of cancer increase the risk of DVT development (Bastounis et 
al., 1996; Hyers, 1999).  Increased risk of DVT in cancer patients is 
reported between 2.5 to 4.1 fold (Samama et al., 1994; Lee and Levine, 
2003).  This risk can further increase due to radiation and chemotherapy 
(Joung and Robinson, 2002; Liebman, 2005).  The worrying factor with 
respect to cancer is that thromboembolism is also noted to be a long term 
cancer risk with a four fold increase in diagnosis over the general 
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population in the first year of patient‟s admission for VTE (Baron et al., 
1998).  Hence passengers with undiagnosed cancer may be increasing 
their FRDVT risk by travelling.  
iii. Times of pregnancy and puerperium are considered to be one of the 
greatest risk factors of VTE development (Tibbs, 1992, Porter and 
Moneta, 1995).  Puerperium is a period of about 6 weeks following 
childbirth (Zotz et al., 2005).  “Pregnancy causes a hypercoagulable state 
and venous stasis in the lower limbs, which increases the risk of VTE” 
(Kingman and Economides, 2002).  “…(PE) is still the leading Direct 
cause of maternal death in the United Kingdom.” (Lewis and Drife, 2002).  
During pregnancy there is a four–to tenfold increased risk of VTE (SIGN, 
2002; Brenner, 2005).  One of the problems with pregnancy is that 
symptoms which mimick DVT and PE symptoms, namely swelling and 
pain of limbs, chest pain and dyspnoea, commonly occur in the pregnant 
woman and may or may not be related to a thrombus (Ginsberg et al., 
2001).  
 
3.11.1. Surgery related issues 
i. During surgery, the patient is in the supine position.  The PT veins, 
gastrocnemius veins and soleal veins are all subject to increase in 
diameters.  Pressure created from an individual lying on an operating table 
can “lead to vessel wall hypoxia” (Nandi et al., 1998).   
ii. Immobility occurs in the perioperative state, (the period immediately 
before or after an operation).  Post-operative patients are further 
susceptible to clotting as “venous sludging during anaesthesia is thought 
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to induce a nidus of blood clot behind a venous valve” (Kesteven, 2000, p. 
S33).   
iii. Venodilation of the lower limbs is a cause of a post operative DVT 
episode (Scurr, 1994).  “Passive venodilation stretches the endothelium 
beyond the support of the tunica media” (Agu et al., 1999, p.993).  The 
resulting tear in the intima, means that contact of activated platelets and 
clotting factors with thrombogenic subendothelial collagen occurs 
(Krupski, 1997; Agu et al., 1999).  
iv. Hip replacement therapy may cause a “twisting” of major veins, which 
may predispose the patient to post operation DVT (Anderson and Audet, 
1998).  According to Bergqivst (2003/2004, p.360) elective hip surgery 
predisposes the patients to “…a prolonged coagulation activation and a 
decreased venous emptying for a few weeks…”.  
v. With orthopaedic patients, traction and plaster casts inhibit postoperative 
movement, which leads to the development of venous stasis and the risk of 
thrombus formation (Hirsh and Hull, 1987). 
vi. Surgery heightens the risk factor within the period of 45-90 days post 
surgery (SIGN, 2002).  Patients who have had orthopaedic surgery should 
avoid long haul travel post surgery (Nicholson et al., 2003). Patients in the 
critical care units of hospitals have either a moderate or high risk of 
developing VTE (Geerts and Selby, 2003; Cook et al., 2004).  The study 
conducted by Heit, et al., (2001) found that the incidence of VTE in 
hospitalised patients is 100 – fold greater than in community residents. 
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3.11.2 Female related issues 
Oral contraceptive use and hormone replacement therapy have both been demonstrated to 
predispose women who are taking these medications to thrombus formation: 
i. Oral Contraceptives (OC) contain oestrogen which interacts with antithrombin 
III, reducing its efficiency, thus increasing the risk of VTE (Tibbs, 1992).  The 
risk of women developing spontaneous VTE when using second generation 
OC is reported as 15 per 100,000 a year (SIGN guidelines) and 30 per 100,000 
per year when using third generation OC.   Women who suffer from 
coagulation disorders, who smoke and who are obese while taking OC have 
an increased risk of developing thromboembolisms (Barton et al., 2002).   
ii. Hormone Replacement Therapy (HRT) is provided to postmenopausal 
women, who suffer from symptoms due to an estrogen deficiency.  It can be 
administered orally, transdermally (through the skin) or locally (in the 
vagina), depending on necessity.  Women treated with HRT are at an 
increased risk of VTE (Spiliotopoulou and Grouzi, 2003; Greer and Walker, 
2004).  The reason why HRT „provokes an increased risk of VTE is unclear‟ 
(Greer and Walker, 2004).  Apparently the haemostatic system (which is 
responsible for preventing excessive bleeding) becomes altered by the 
menopause, leading to an increase in some of the coagulation factors.  HRT 
produces a reduction in antithrombin, which will lead to an increased risk of 
thrombus formation.  HRT produces a reduction in fibrinogen and Factor VII 
activation but enhances fibrinolysis (solubilisation of fibrin in blood clots) and 
increases the resistance to Protein C, (Spiliotopoulou and Grouzi, 2003; Greer 
and Walker, 2004,) all of which should result in a decrease of formation of 
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thrombin.  It must be noted that studies investigating the effects of HRT on 
coagulation factors have differing conclusions. 
 
3.11.3. Other health related issues 
i. Obesity, according to some experts, is one of the most important risk factors 
of PE.  A person is described as obese if his/her body mass index (BMI) is 
greater than 30 kilogram per meter squared (kg/m²) (Lowe and Rumley, 
1999).  It is calculated by dividing the individual‟s weight (kgs) by their 
height in metres squared (m
2
) (Marik and Varon, 1998; Padberg et al., 2004).  
Obesity actually limits lung capacity by up to 30 per cent in patients with 
gross obesity, due to increased chest wall resistance and increased airway 
resistance (Marik and Varon, 1998).  A BMI of greater than 30 kg/m² 
increases the risk of VTE by 10-fold, after long distance travel by car, train or 
bus (Cannegieter et al., 2006).  Critically ill obese patients, being treated in 
the intensive care unit (ICU) have a higher chance of developing VTE (Marik 
& Varon, 1998).  Obesity rates have rapidly increased by “three-fold or more 
since 1980” (WHO, 2002, p.60).   
ii. Stroke-patients with paralysis resulting from a stroke have a high risk of DVT 
developing in the paralysed limb as a result of venous stasis (Agu et al., 1999; 
Nicolaides et al., 2002; Mazzone et al., 2004).  VTE is a major cause of death 
in stroke patients (Scholten et al., 2000).   
iii. Prandoni, et al., (2002), found that a residual thrombosis is a risk factor for 
recurrent VTE.  As the years progress the risk of recurrent VTE decreases as 
does the mass of a residual thrombus. Another study conducted established 
that 58 of 313 outpatients presented with a recurrent episode, between six and 
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36 months after the first thrombotic event. Forty one of these 58 events 
developed in the presence of a residual thrombus (Prandoni, 2004).   
 
3.11.4. Travel related issues 
Long periods of immobility imposed by any mode of travel constitute a risk for DVT 
(Ferrari et al., 1999).  For the purpose of this dissertation, a long haul flight is considered 
to be a flight of four hours or longer.  Ferrari and co-workers established that a flight of at 
least this duration posed a risk factor for FRDVT (Ferrari et al., 1999).  A World Health 
Organisation report into flight related DVT corroborates their findings and concludes that 
“a flight of more than four hours increases the risk of deep vein thrombosis in the 
general population by between three and five times.”  (Templeton, 2005).  Venous stasis 
as a result of sitting, while travelling by land and air are causative factors.   
One hundred patients, suffering from PE, in a Spanish Hospital were interviewed to 
determine risk factors for PE over two years.  Mode and duration of travel was 
established prior to hospital admission.  In this study a prolonged journey was defined as 
five hours duration or more.  Each patient‟s medical history was examined and blood 
samples were taken to identify any coagulation abnormalities.  Nine of the 100 patients 
had a travel related PE.  Six travelled by land and the others by air, with a mean journey 
time of 8.8 hours.  No patients had any coagulation abnormalities (Gispert et al., 2006).   
 
3.11.4.1. Seated Position 
Sitting in one position for long periods of time has been implicated in FRDVT 
development due to resultant venous stasis.  When humans are upright, approximately 
“70% of the circulating blood volume is below the heart” (Miller et al., 2005, p. 925).  
Both the calf muscle pump (refer to section 2.6.3.) in conjunction with respiratory muscle 
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pump (section 2.3.1) facilitate the return of blood to the heart (Miller et al., 2005).  
However the consequence of stasis (due to long periods of immobility) is that platelets 
come into contact with the endothelium, and the resultant activated clotting factors 
cannot be removed due to the lack of blood flow, thus creating an environment for 
thrombus formation (Kumar et al., 2005).  Wright and Osborne in 1952 demonstrated that 
sitting in one position reduces the venous velocity by two thirds.  Passengers on board 
any form of transport who are required to sit for long periods of time will be at risk of 
DVT (Ferrari et al., 1999).  
The normal economy class seat pitch on most commercial aircraft is between 711.2 mm 
and 878.4 mm (Murphy, 2001).  This restricts leg room for all except small individuals. 
Moreover, as most passengers use space below the seat for storage, leg room may be 
further reduced.  Further reduction may occur if passengers recline their seats in order to 
sleep.  As a result of the reduced space, normal leg movement is reduced and the muscle 
pump action of the lower limbs is curtailed resulting in inadequate return of blood from 
the legs.  Swelling of the legs after sitting or standing can be as a result of an increased 
venous pressure, due to gravity, in the dependent parts of the body, when there is no 
increase of blood volume (Partsch et al., 2004, p.737).  Sitting with crossed legs can 
damage the endothelium of the veins in the legs which can act as a precursor to DVT 
(Aryal and Al-khaffaf, 2006).  One study conducted by Hamer, concluded that PO2 levels 
drop as a direct result of venous stagnation in valve pockets, due to immobility 
(Strandness and van Breda, 1994).  This may act as the site for DVT formation.  
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3.11.4.2. Window or aisle seats 
Passengers seated in the window and central seats have been documented to have an 
increased risk of FRDVT as all DVT events in three studies occurred in non-aisle seat 
subjects (Belcaro et al., 2001a, b, 2002).  
 
3.11.4.3. First class or economy class 
The reduction in leg movement due to restricted seat pitch is not present in first or 
business class seats, due to additional leg room provided.  Normal business class seat 
pitch ranges between 787.4mm (compared to 711mm of economy class) to 863.6mm 
(Hodson, 2002; Seatguru, 2007).  This led to the belief that the occurrence of FRDVT 
was an “economy class syndrome”.  Subsequently FRDVT and PE have been reported in 
both business and first class travel passengers (Hughes, et al., 2003).  However the cause 
reported by Mohler was a patient travelling first class with increased risk factors (six 
weeks post operation) (Mohler, 1997).  
Also former presidents Nixon and Qualyle both developed flight related pulmonary 
embolus (FRPE) without documented additional risk factors (Mohler, 1997; Galili and 
Bass, 2002).  This led Lapostolle et al., (2001) to establish that there is no direct relation 
between the incidence of PE and class of travel. 
 
3.11.4.5. Seatbelts 
Governments have the power to make change by introducing legislation to provide an 
intervention such as mandatory seatbelt wearing.  An intervention may be “any health 
action - any promotive, preventive, curative or rehabilitative activity where the primary 
intent is to improve health” (WHO, 2002, p.8.).  
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The European Aviation Safety Ageny (EASA) and the Federal Aviation Authority (FAA) 
have the power to enforce compulsory seat belts when the pilot deems it necessary.  The 
purpose of this is to protect each passenger from a risk of harm, i.e. during turbulence 
(Nicholson, Cummins & Giangrande, 2003), or in the event of a crash landing.  This is 
the enactment of aircraft legislation (EASA CS-25.785).  Enforcing this requirement 
necessitates a reduction in passenger movement and hence provides the environmental 
factors which activate thrombus formation, such as Virchows‟ Triad (Section 3.1), which 
consists of venous stasis, vessel wall injury and hypercoagulability all of which seem to 
be present during air travel (Galili and Bass, 2002). 
 
3.11.5. Risk factors associated with FRVTE.  
Various studies have defined low, moderate and high risk factors associated with FRVTE 
(as shown in Table 3.2) 
 
Table 3.2 Additional risk factors for FRVTE. 
Low Risk Factors Moderate Risk Factors High Risk Factors 
Age >40 Ώ Previous VTE Ώ ά Previous VTE  Ώ ά 
Minor surgery Stroke Coagulation disorders 
Bed rest (> than 3 days) Knee surgery Cancer  
Obesity ά Heart failure Ώ Joint replacement 
Varicose veins ά Antithrombin deficiency Major surgery 
Pregnancy Protein C and Protein S 
deficiency 
Major trauma 
 Factor V Leiden Ψ Hip fracture Ώ 
 HRT Ώ Oral contraceptive plus 
Factor V Leiden β 
Sources: (Kesteven, 2000; ά - Belcaro, 2001a; Ψ - Scurr et al., 2001;  Ώ - Gispert, 
Drobnic & Vidal, 2006; β - Schreijer et al., 2006; Philbrick et al., 2007) 
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3.11.5.1. Low versus High Risk 
The LONFLIT Study consisted of a low risk group (355 participants) and a high risk 
group (389) to determine the incidence of FRDVT.  Age ranged from 20-80 years (mean 
46).  Low risk subjects were classed as individuals with “no known clinical disease” 
(Belcaro et al., 2001a, p.370) who had not taken any form of medication in the two 
weeks prior to the study taking place.  High risk group consisted of those with a previous 
DVT, varicose veins, known coagulation disorder, obesity or those limited in mobility.  
The average flight duration was 12.4 hours long.  An ultrasound scan of the femoral and 
popliteal veins was conducted within 24 hours of the flight concluding, to document the 
presence or absence of DVT.  All thrombi were detected in the high risk group (13 DVTs 
and six SVTs) (Belcaro et al., 2001a).    
 
3.11.5.2. Coagulation factors  
Flights of eight hours duration were found to cause an increase in two coagulants, Factor 
VII and Factor VIII, while decreasing activated partial thromboplastin time (aPTT) 
(Schobersberger et al., 2003).  The study concluded that “an activated coagulation plus a 
suppressed fibrinolysis could favour venous thromboembolism” (Schobersberger et al., 
2003, p. 24).   
Bloods were taken 48 hours prior to the first flight of one hour duration, from Innsbruck 
travelling to Vienna.  All 20 participants then travelled by air for eight hours 20 minutes 
to Washington.  Everyone was seated in the last three rows of economy class during this 
flight.  A second test was conducted after at least five hours in-flight.  All participants 
stayed for two nights in Washington before taking a return flight to Vienna, upon which a 
third test was conducted after five hours flight. Upon landing in Vienna a fourth test was 
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conducted in the airport.  Two more tests were conducted in Innsbruck, the first the day 
of return and the last three days after arrival (Schobersberger et al., 2003).  
One hundred patients over a two year period, suffering from PE, in a Spanish Hospital 
were interviewed to determine which risk factors were associated with the onset of each 
patients PE.  Questions regarding mode and duration of travel were asked.  A prolonged 
journey was defined as five hours duration or more.  Each patient‟s medical history was 
examined and bloods were taken to identify any coagulation factors (Gispert et al., 2006). 
Nine of the patients had taken a prolonged journey, six by coach/car and three had flown.  
All nine patient‟s d-dimers levels were greater than 552ng/ml, which was considered 
within the normal range.   
 
3.12. Diagnosis of DVT  
Both non-invasive and invasive forms of diagnosis are discussed in this section.   
 
3.12.1. Non-Invasive Diagnosis to establish the presence of thrombi 
 
3.12.1.1. D-dimer assays 
The presence of D-dimers is utilised to establish the presence of thrombi.  Following 
fibrinolysis of thrombi, plasma D-dimer fragments are present (Bockenstedt, 2003; 
Schobersberger et al., 2003).  They are generated from fibrin during degradation and are 
markers of “…thrombus formation and its subsequent resolution.” (Hughes et al., 2005, 
p.2445).  Blood assays are the method used to determine D-dimer levels. 
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3.12.1.2. Thrombin-antithrombin III assays  
High levels of thrombin-antithrombin III complex (TAT) present in plasma can also be 
an indicator of the presence of thrombi (Hommes et al., 1994).  This assessment is also 
conducted by taking bloods from the patient. 
 
3.12.1.3. Compression Ultrasonography  
A transducer is positioned in contact with the skin, above the vein or veins to be tested, 
by the investigator.  “…..failure to compress the lumen of the vein fully” with the 
transducer is evidence of the presence of a thrombus in the deep veins (Cogo et al., 1998 
p.18).  This is the first step in U/S diagnosis of a proximal DVT (Riddle and Wells, 
2004).  Compression ultrasonography of the femoral vein, popliteal vein and calf 
trifurcation is highly sensitive and successful at diagnosing thrombosis.  It is less 
sensitive in the calf area of the lower limb (Wood, 1996, Cogo et al., 1998) but the 
sensitivity has increased with newer ultrasound systems. 
The absence of thrombi when using an ultrasound machine (Gardner and Fox, 1989) is 
noted due to the following criteria: 
i. Spontaneity; the resting flow in a vein, a spontaneous signal is available from the 
major veins but may be absent from the superficial veins (Gardner and Fox, 
1989).  Absence of this signal in the proximal veins signals the possible presence 
of obstruction in the deep veins (Nicolaides and Kalodiki, 1994; Cole, 2001b). 
ii. Phasicity refers to the variation of flow with respiration.  In the supine position 
there is normally an increase in flow on expiration and a decrease of flow on 
inspiration (Gardner and Fox, 1989).  Loss of phasicity may indicate obstruction 
in the deep veins (Nicolaides and Kalodiki, 1994; Cole, 2001b). 
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iii. Augmentation; the increase in the velocity of venous flow after compression of 
the foot or calf.  If a venous obstruction exists, augmentation is not detected 
between the area of compression and the point of detection (Gardner and Fox, 
1989; Cole, 2001b).   
 
Figure 3.4 is an ultrasound scan of a vein which contains non occlusive thrombus.  The 
vein is the black circle surrounding the thrombus in centre (highlighted by the yellow 
arrows).  
 
 
Source: The Non-Invasive Vascular Unit, Beaumont Hospital. 
Figure 3.4. Cross-Sectional image of a vein (dark circle) containing non-
occlusive thrombus (yellow arrows). 
 
Figure 3.5 is an ultrasound scan of a thrombus within a superficial vein (Note: no 
accompanying artery).  
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Source: the Non-Invasive Vascular Unit, Beaumont Hospital.  
Figure 3.5 Cross-Sectional image of a thrombus occluding a superficial vein 
(surrounded by a dotted line). 
 
3.12.1.4. Thermography 
Liquid crystal thermography (LCT) is another non-invasive method used to diagnose 
DVT.  The liquid crystal thermal detector is positioned in contact with the skin above the 
vein or veins to be tested.  Liquid crystals are deposited onto a flexible latex membrane 
which is supported by a flexible detector which can conform to the shape of the limb 
being assessed.  These liquid crystals change colour to represent differences in 
temperature on the limb being assessed (Harding, 1990).  The detectors can measure 
temperatures in the range of 20 to 38º C.  DVTs cause an increase in temperature in the 
affected limb, as the blood in that area is forced to seek another pathway.  The patient is 
positioned in the supine position in a calibrated temperature controlled room of 20º C 
with the limb exposed for ten minutes prior to assessment.  One disadvantage associated 
with LCT is that causes other than DVT may also increase temperature.  
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3.12.2. Invasive diagnosis of DVT  
 
3.12.2.1. Invasive ascending venography 
Invasive ascending venography is considered the “gold standard” diagnostic test for 
DVT.  It involves placing a needle in a vein in the foot and injecting a contrast medium 
which can be imaged on an x-ray film.  Thrombi show as filling defects (Hirsh and Hull, 
1987).  It has many disadvantages associated with it, in terms of expense and high failure 
rates in swollen legs (Keeling et al., 2004; Pookarnjanamorakot et al., 2004).  This 
procedure is invasive and can be uncomfortable for the patient (Hirsh and Hull, 1987).  
There is a radiation dose and the risk of an allergic reaction and the possibility of renal 
toxicity exists (Comerota, 1994b, p. 63).   
 
3.12.3. Diagnosis of pulmonary embolus 
The following methods are the main diagnostic tools used, (Dixon, 2001): 
i. Ventilation-perfusion (V/Q) scintigraphy, which is known as the lung scan is the 
technique largely used to diagnose the presence of a PE (Wood, 1996 Goldhaber, 
1998).  This procedure involves a patient inhaling a technetium-99m labelled 
aerosol or a radioactive gas to demonstrate the distribution of pulmonary 
ventilation (Goldhaber, 1998).  An intravenous injection of technetium-99m 
labelled micro particles of macroaggrated human serum albumin is made, so the 
distribution of blood flow in the lung can be displayed (perfusion).  Mismatch 
between ventilation and perfusion occurs in the presence of PE.  The size is 
proportionate to the size of the embolus.  
ii. Spiral computed tomography (CT) angiography, is achieved by injecting an 
iodinated contrast medium, which identifies the presence of emboli by the 
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presence of filling defects (Goldhaber, 1998; Dixon, 2001).  Multiple x-ray 
images are taken and with the aid of a computer an image of the lungs is 
reconstructed. 
iii. Helical CT Pulmonary angiography is considered the “gold standard” in the 
diagnosis for PE (Dixon, 2001; Lingamanaicker et al., 2001).   
iv. Magnetic resonance imaging is a costly procedure, however one advantage is that 
radiation is not experienced by the patient.  This procedure can be conducted non-
invasively and invasively with a contrast medium (Schmitz et al., 2006).  It 
provides a detailed image of the lungs and vasculature structures, thus allowing 
imaging of the pulmonary emboli. 
 
3.13. Treatment of DVT  
The aim of DVT treatment is to prevent the thrombus from enlarging or embolizing 
(Miller-Keane, 1997).  
 
3.13.1. Anticoagulant therapy.  
This method can be effective when treating a DVT and reducing the risk of PE (Turpie, 
1994; Sharafuddin et al., 2003) and is used to prevent primary and secondary DVT 
events.  This section outlines pharmacological methods used to prevent and treat DVT in 
clinical settings: 
i. Dextran is a glucose polymer which is available as two fractions of different 
molecular weights:  Dextran-40 and Dextran-70.  They exert antithrombotic 
effects by a number of different ways.  Dextran is a plasma volume expanding 
agent which reduces blood viscosity, increases blood flow and therefore reduces 
venous stasis.  Dextran is used in surgical patients over a four to six hour period 
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and then administered for two to five days after surgery.  Dextran is as effective 
as low dose heparin for the prevention of PE (Bergqvist, 2004).  
ii. Thrombin blockers work by inhibiting thrombin (Weitz, 2000).  Desirudin is 
successful in the prevention of asymptomatic deep vein thrombosis after knee or 
total hip replacement surgery.  Lepirudin is used to treat patients with VTE, with 
heparin associated thrombocytopenia (SIGN, 2002). 
iii. Heparin can also be used in DVT prophylaxis.  Heparin is administered 
subcutaneously and begins to work immediately. Heparin is a naturally occurring 
anticoagulant, preventing thrombi and further extension of already existing 
thrombi in the vessels. It allows the natural lysis process to work normally as it 
works in conjunction with the plasma cofactor antithrombin III. This binds to 
heparin and together they inhibit thrombin and factor Xa (Kakkar and Cohen, 
1994). A review of more than 70 randomised trials, involving more than 16,000 
patients, showed that the perioperative use of low-dose heparin prophylaxis 
prevented approximately 50 per cent of all PE, and 66 per cent of DVT (Haas & 
Haas, 1994, p.149).  
iv. Coumarins are a Vitamin K antagonist used for long-term treatment of VTE.  
Warfarin is a coumarin which is used to decrease the plasma concentrations of 
FVIII and Protein C (Wood, 1996).  Warfarin is administered orally. It takes 
longer to work then heparin however it is the oral anticoagulant of choice with 
patients undergoing orthopaedic surgery (Goldhaber and Fanikos, 2004).  A study 
comparing the effectiveness of long term placebo versus low-intensity warfarin 
therapy for prevention of recurrent VTE was conducted over 4.3 years.  Of the 
253 patients receiving placebo, 37 developed a recurrent VTE.  Fourteen of 255 
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patients receiving low-intensity warfarin therapy developed a recurrent VTE 
(Ridker et al., 2003).  
Recommended treatment durations are: 
i. six to twelve weeks for symptomatic calf vein thrombosis; 
ii.  three months in patients presenting with a proximal DVT or acute PE;  
iii. six months in patients presenting with idiopathic proximal vein thrombosis or 
recurrent VTE (Hirsh et al., 2001a).  
 
3.14. Prophylaxis. 
There are two general means of prophylaxis; pharmacological agents and mechanical 
methods, which will be discussed in this section.  The former methods of prophylaxis are 
used to reduce the coagulation process (Sochart and Hardinge, 1999) whereas the aim of 
mechanical methods is to reduce venous stasis (Sochart and Hardinge, 1999, O‟Donovan 
et al., 2005).  Mechanical methods unlike pharmacological prophylaxis are attractive as 
they do not increase the risk of bleeding (Nicolaides et al., 2002; Morris and Woodcock, 
2004).   
 “…routine prophylaxis reduces morbidity, mortality and costs in hospitalised patients at 
risk of DVT and PE” (SIGN guidelines, 2003, p.1).  If prophylaxis can reduce the 
occurrence of DVT and PE in hospitalised patients, it is reasonable to argue that it should 
be used for passengers on board aircraft and other forms of transport who are also at risk.  
 
3.14.1. Medicines 
Aspirin is an antiplatelet drug which is administered orally.  It works by inhibiting the 
normal role of platelets in initiating the formation of thrombi (Turpie, 1994).  Aspirin is 
attractive as it is easily obtained, but may interfere with other medication and can cause 
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gastrointestinal haemorrhage (Derry and Loke, 2000)  Aspirin has been demonstrated to 
reduce the incidence of PE and DVT by as much as 33 percent in patients post hip 
fracture (PEP Trial Collaboration Group, 2000).  
However aspirin has not been shown to be effective at preventing FRDVT (Cesarone, 
2002; Hughes et al., 2003).  “The Impact of Flying on passenger health: a guideline for 
healthcare professionals”, was conducted by the British Medical Association and Board 
of Science and Education (for the benefit of doctors and healthcare professionals).  This 
report states that patients should be warned against the use of aspirin “just for the 
prevention of travel-related DVT” (BMA, 2004, p. 12).  
 
3.14.2.. “Alternative Medicines” 
The following products are available for purchase without prescription and can be taken 
to reduce the risk of travel related DVT: 
i. Pycnogenol is a natural substance taken from French maritime pine bark.  It is 
taken orally in tablet form. Pycnogenol® causes the blood vessels to relax, which 
aids the flow of blood.  It prevents platelets from clotting unnecessarily (BMA, 
2004).   
ii. Flite Tabs consists of 150mg of pinokinase, (made from fermented soya) which 
consists of Pycnogenol® (made from the extract of marine pine bark) and 
Nattokinase.  The Kinotase has an anticoagulant effect on the blood, while 
pycnogenol ensures an anti-inflammatory effect on the leg blood vessels 
(Johnston, 21/10/03).   
iii. Vascular Guard is available in capsule form.  It contains “natural vitamin E, 
lycopene and antioxidant extracts of pine bark and grapeseed to enhance blood-
vessel function and bilberry to maintain blood flow to the extremities” (Harper-
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Deacon, 2006, p.49).  The recommended dose is two capsules per day, a few 
weeks before travelling and then for one week after the return journey (Harper-
Deacon, 2006). 
iv. Zinopin capsules contain French pine bark and ginger root which work together to 
boost circulation.  These capsules, developed by Dr. John Scurr, relax blood 
vessels and improve circulation, thereby reducing stasis and possibly DVT (Scurr, 
2005).  
No controlled studies were conducted to determine the incidence of possible side effects 
from these products.  The only study to determine the effectiveness of Flite tabs was the 
Lonflit-Flite Study.  It was conducted to determine the incidence of FRDVT in high risk 
subjects.  Participants in the Flite tab group (which contains 150 mg of pinokinase) were 
given two capsules two hours prior to flying, with 250 ml of water and another two 
capsules six hours later, again with 250 ml of water.  Ultrasound scanning of major and 
superficial veins, D-dimer and fibrinogen tests were performed before and after flight 
Participants in the study group (94) displayed no signs of VTE, while five of the 92 
participants in the control group presented with a DVT and another two presented with a 
SVT (Cesarone et al., 2003a).  Cesarone and colleagues determined that one dose of 
Enoxaparine (a form of LMWH) taken two to four hours before flight prevented FRDVT, 
however one SVT did occur.  This study established that aspirin was not as effective as 
LMWH at preventing FRDVT or FRSVT (Cesarone et al., 2002).  Three hundred high 
risk individuals for DVT were randomised into three groups; a control group, an aspirin 
group and a LMWH group.  The control group were given no prophylaxis.  Everyone in 
the aspirin group took 400 mgs of aspirin orally for three days, beginning twelve hours 
prior to flight.  With one dose of enoxaparine injected two to four hours before flight to 
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all those randomised into the LMWH group.  This dose of enoxaparine was weight 
adjusted, for example 1000 IU per ten kg of body weight.  Side effects to aspirin did 
occur, however they disappeared when the treatment was stopped (Cesarone, 2002).   
 
3.14.3. Mechanical Methods 
Mechanical methods used to prevent DVT are based on preventing venous stasis 
(Auguste et al., 2004).  
 
3.14.3.1. Graduated Elastic Compression Stockings  
“Compression stockings improve the drainage of superficial venous blood, thereby 
reducing the risk of over-distension” (Thaler et al., 2001).   A graduated elastic 
compression stocking (GECS) exerts varying degrees of constant compression at 
different segments of the limb.  The highest compression is at the ankle area, decreasing 
all the way up towards the knee or the proximal area of the thigh, depending on whether 
the stockings are knee or thigh length (Agu et al., 1999).  Knee length stockings are more 
commonly prescribed than thigh length as they are less expensive and more comfortable 
(Agu et al., 1999). 
External compression reduces the cross sectional area of the lower limb, along with the 
diameter of the veins.  The resulting effect is to increase the velocity of blood flow (Agu 
et al., 1999; Partsch, 1999; Morris and Woodcock, 2004) as the arterial inflow to the 
veins remains constant (Partsch, 1999).  An external pressure of 15mmHg results in a 20 
percent reduction in the veins cross sectional area with significantly increased blood flow 
through both the deep and superficial venous systems (Agu et al., 1999).  Thus GECS 
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reduce venous stasis which is one of the three factors described by Virchow (Agu et al., 
1999).  
The hosiery is designed so that it is elastic both lengthwise and width-wise.  In graduated 
compression stockings there are three different levels of compression along the stocking; 
at the ankle, calf and knee.  These compression values vary according to the manufacturer 
and the country of origin.  The British Standards Institution set out their standards in 
1985, whereas the Germans (or European Standards) followed the German Hohenstein 
Compression Standard (refer to Table 3.3).  Knee or thigh length GECS may be 
prescribed to patients depending on the diagnosis (Hsieh and Lee, 2005).  These 
stockings are available in various colours so that they are almost indistinctive from 
normal socks.  Flight socks sold without prescription are usually Class I.   
 
Table 3.3. International Graduated Elastic Compression Stocking Values.  
  Class I (mmHg) Class II (mmHg) Class III (mmHg) 
British 14-17 18-24  25-35  
German 20-30 25.2-32.3 36-46 
Source: Harper et al., 1995; Thaler et al., 2001.  
 
GECS are medically prescribed. Patients with peripheral vascular disease are advised 
against wearing GECS.  This is established by a simple non-invasive examination entitled 
an ankle brachial index (ABI) (Agu et al., 1999).  The assessment is conducted with the 
patient in the supine position.  Inflatable pressure cuffs are placed on the lower 
extremities and the upper arm.  These cuffs are inflated until they occlude the arteries; as 
the cuff deflates, systolic pressure is determined when a pulse sound reappears.  The ABI 
for each limb is then determined by dividing the higher systolic pressures (PT or AT 
artery) by the highest brachial artery systolic pressure (either right or left arm) (Schmitz 
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et al., 2006).  If a value of less than 0.7 is recorded, (≥ 0.9 normal value) PAD is 
diagnosed.  PAD patients are not permitted to wear GECS as they risk impairment of 
subcutaneous tissue oxygenation (Agu et al., 1999).  
Table 3.4., describes some of the most commonly used GECS.  
 
Table 3.4. Brands of graduated elastic compression stockings available.  
 
Brand name Type and Grade Compression value at the ankle 
Mediven Travel UK Grade II 18.4 – 21.1 mmHg 
Scholl Flight Socks UK Grade I 14 – 17 mmHg 
Sigvaris Traveno 
Stockings 
Switzerland, Grade I 14 – 17 mmHg 
Source: Hsieh & Lee (2005).  
 
A number of studies have been conducted to determine the effectiveness of GECS of 
various grades preventing FRDVT and FRPE.   
GECS of compression value 25mmHg at the ankle (brand unknown) significantly 
reduced the incidence of FRDVT and prevented FRSVT (on flights of ten to 15 hours).  
One DVT was diagnosed in the stocking group (411 participants), demonstrating an 
incidence of FRDVT in the stocking group of 0.24 percent in comparison to 5.2 percent 
in the control group (Belcaro et al., 2001a). 
Mediven stockings, United Kingdom, Grade II, efficiently prevented FRDVT (Scurr et 
al., 2001).  Two hundred and thirty-one volunteers completed the study, 115 were 
randomly assigned to the stocking group, 116 to the control group (no stockings).  
Twelve asymptomatic calf DVT were diagnosed by ultrasound and D-dimer assays in the 
control group and four superficial thrombi were detected in varicose veins, in the 
stocking group.  This study concluded that “Approximately one in ten passengers not 
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wearing elastic compression stockings developed symptomless DVT after airline travel” 
(Scurr, et al., 2001, p. 1487).  
Sigvaris Traveno (14-17mmHg) stockings (on flights of similar durations) while reducing 
oedema also prevented DVT (Cesarone et al., 2003b).  
Scholl Flight socks, 14-17mmHg, (lower compression grade than either the Mediven or 
those used by Belcaro, (2001a) also prevented FRDVT and FRSVT on flights of seven to 
eight hours and eleven to twelve hours duration (Belcaro et al., 2002).  The incidence of 
FRDVT and FRSVT (without stockings) was 2.12 percent and 1.06 percent respectively, 
on flights of seven to eight hours duration (Belcaro et al., 2002).  Part 1 of the study 
consisted of a flight (seven or eight hours) from London to New York.  One hundred and 
three participants were randomly assigned into the stocking group and 108 into the 
control group.  Part 2 of the study consisted of a flight from London to Phoenix which 
lasted approximately eleven to twelve hours.  Eighty-three were assigned to stockings 
and 82 to the control group (Belcaro et al., 2002).  Unfortunately Scholl stockings worn 
by a high risk group were not effective at preventing DVT development on flights of 
eleven to thirteen hours duration.  The incidence of FRDVT in a high risk control group 
was 5.8 percent.  Scholl stockings reduced this incidence to 0.97 percent (Belcaro et al., 
2003b).  This is presumably due to the increased risk associated with these patients and 
the lower compression grade of Scholl GECS.  This underlies the usefulness of GECS, 
but highlights the need for relevant prescribing. 
 
3.14.3.2. The skywalker
TM 
The skywalker is manufactured from light-weight plastic. It consists of two foot-pedals 
(Figure 3.6)   
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When unfolded it is approximately ten and half inches wide and six inches long with a 
height of over three and half inches.  The pedals are placed on a curved pivot (Figure 
3.7).  The user places one foot on each pedal before consecutively pressing one pedal at a 
time.   
This device has been “Clinically proven to increase blood circulation, prevent swollen 
ankles and relieves the numb and tired feeling in your legs” as stated on the Aviation 
Health website:  http://www.aviation-health.com/shop/product_info.php?products_id=55.  
However no documented evidence could be found to support this claim. 
 
 
Source:Skywalker.   
Figure 3.6. The Skywalker 
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Source: Skywalker 
Figure 3.7. The Skywalker (curved pivot) 
 
3.14.3.3. The Airogym  
The Airogym was designed for aircraft passengers by senior pilot Paul Richards, 
following an emergency landing required by a passenger suffering with flight related PE 
(http://www.airogym.com/whatisit.php). 
It consists of an air chamber connected between two cushions (Figure 3.8) made from a 
composite material.  It is light in weight and can be carried in a handbag or suitcase.  As 
the right foot presses down on the cushion, the air is transferred to the left foot cushion.  
The airogym acts by compressing veins in the foot which should initiate venous return. 
It was established that the Airogym is effective in activating the calf muscle pump, 
increasing the peak flow velocity of blood in the femoral vein by three fold, during use 
(www.airogym.com/trials.php).  The airogym however can slide on smooth surfaces 
during use (Collins, 2002/3).  
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Source: Non-Invasive Vascular Unit, Beaumont Hospital. 
Figure 3.8. Image of the Airogym, with right foot on cushion resulting in transfer of 
air to the left side of the airogym. 
 
3.14.3.4 The Veingaurd Exercise Cushion 
The Veingaurd cushion was designed in Great Britain by Hughes DVT Cushions Ltd 
(Medical Approval, 2007).  
The Veingaurd Compact Anti-DVT Exercise Cushion (Figure 3.9) is designed to promote 
leg exercise. It slips into its own pouch, which could fit in a handbag and can be inflated 
if needed (HELP AT HOME, 2002). 
This device is made from a flame retardant P.V.C. Both an inflation valve and a pressure 
relief valve are fitted into the design, specifically for use on board aircraft (“Veingaurd 
Anti-DVT Cushion”, 2007). 
A pilot study established that this device when used can increase the venous return 
approximately ten fold (Medical Approval, 2007). 
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Source: Veingaurd™ 
Figure 3.9. The Veinguard Exercise Cushion.  
 
3.14.3.5 The LymGym
TM
  
This device was developed following a conference in 1999, which highlighted the 
problem of travel related thrombosis.  Doctors Osman and Hodgkinson, of Ipswich 
Hospital, in the United Kingdom were involved in its design (Osman et al., 2006).      
It is an inflatable foot cushion (Figure 3.10).  Compression of one side of the Lym Gym 
at a time enhances venous return in the seated position, similar to both the airogym and 
the veingaurd exercise cushion.  
It was established by Doppler ultrasound that the Lym Gym™ increased peak blood flow 
velocity by eight fold, when used, compared to the peak flow velocity of all participants 
remaining passive in the seated position (Caruana et al., 2003).  
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Source: Lymgym™ 
Figure 3.10. The Lym Gym.  
 
3.14.3.6. The Novamedix Foot Pump  
Gordon Cook invented the foot pump, with Novamedix Ltd the assignee 
(www.google.com/patents). 
External Compression Foot pumps, (IPC device) applied to the foot and ankles are used 
to increase the venous flow in the lower limbs and reduce VTE (Fleming et al., 2000; Dai 
et al., 2002).  Intermittent Pneumatic Compression Devices (IPCs) also stimulate 
fibrinolysis by compressing the calf and/or thigh muscles of the leg, at regular intervals 
(SIGN, 2002).  Upon compression, the veins collapse (Dai et al., 2002).  Generally 
inflation pressures range at 35-40mmHg at ten cycles per minute.  IPCs were developed 
for use before or during surgery and then replaced with compression stockings post 
surgery (Hull et al., 1986; Goldhaber, 1998).  The blood is squeezed from the veins 
which lie under the cuff, so that it flows against gravity into the proximal veins.  
Deflation of the cuff ensures the deep veins have time to refill, prior to re-inflation of the 
 111 
cuff (Morris and Woodcock, 2004).  The Novamedix A-V Impulse System thus mimics 
the natural physiological processes ensuing blood circulation in the legs.  The Foot Pump 
is one such system designed for hospital patients. A foot pad (Figure 3.11) is placed on 
the limb, which consists of an inflation pad, within a fabric covering.  The pad is inflated 
by an air compressor, (Figure 3.12) which causes emptying of the plantar venous plexus.   
 
Source: AV – Impulse System  
Figure 3.11. Novamedix Inflation pad foot cover     
This device produces an impulse every 20 seconds and has been shown to create a 
significant increase in velocities in both the popliteal vein and common femoral vein 
(Killewich et al., 1995).  IPC devices “…have been proven clinically effective for DVT 
prophylaxis.” (Killewich et al., 1995, p. 604). 
This system would be unusable for use on board an aircraft due to the air compressor 
which inflates the foot pads. 
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Source: AV – Impulse System 
Figure 3.12. Novamedix A-V Impulse System. 
 
A study carried out by Killewich et al., (1995), recorded the results obtained from 30 
limbs (15 volunteers) which had foot pumping performed using the A-V Impulse Pump. 
Foot pumping took place for five to ten minutes.  Then the venous velocities were 
measured with a HDI-UM nine Ultra-sound machine at two points.  The popliteal veins 
behind the knee joint and the Common femoral vein, two centimetre cephalad to the 
saphenofemoral junction with the patient in the supine position and then later after more 
foot pumping measurements were recorded in the reverse Trendelenburg position.  
(Killewich et al., 1995).   
While all the devices available show an increase in venous return none of them match the 
normal venous function when walking. 
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3.15. Prophylaxis used in the aircraft cabin  
 
3.15.1. Walking 
Activation of the plantar venous plexus in conjunction with contraction of the calf muscle 
pump, during walking, permits venous return to the heart in a healthy individual (Sochart 
and Hardinge, 1999).  
 
3.15.2. Impact of inflight exercises  
Many inflight magazines and audio channels promote inflight exercises.  The effect of 
exercise as a prevention for FRDVT was investigated in the LONFLIT 2 Study.  
Travellers were advised to move (three minutes every hour), stretch their limbs for two 
minutes every hour and to avoid restricting their leg room.  This was unsuccessful in 
preventing thrombi formation demonstrated by an incidence of 4.5 percent DVT in the 
control group (Belcaro et al., 2001a).  Another study showed volunteers an exercise video 
explaining about DVT and its prevention. The exercise consisted of standing and moving 
legs for 5-10 minutes every hour and drinking water regularly.  However five (limbs) 
DVT and two (limbs) SVT were detected by ultrasound in the control group (Cesarone et 
al., 2003a). 
 
3.16. Cabin Environment  
Dr. Suzanne Cannegiester, a co-author of the study conducted by Schriejer et al., (2006) 
stated “There is something extra in a plane that would increase the risk more that just 
sitting still” in a car, or other form of transport for up to eight hours (Reuters, 2006).  
Thirty one of the 60 cases of DVT/PE had no other obvious risk factors other than long 
haul travel itself (Hughes et al., 2006). 
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It is essential that both passengers and the crew of any aircraft are exposed to an adequate 
cabin environment during flight.  The Environmental Control System (ECS) is 
responsible for maintaining comfortable atmospheric conditions at all times inside the 
cabin area.  The primary role of the ECS is to ensure a prerequired environment for 
aircraft instruments and equipment and personnel (the pilots, their crew and the 
passengers).  The ECS achieves and maintains this required environment through the 
provision of cabin pressurisation, engine bleed air and environmental control.  
 
3.16.1. Cabin pressurisation 
Pressurisation “…is accomplished by flowing more air into the cabin than is needed and 
allowing the excess air to leak out.” („Jeppesen…”, 2002, pp.14-22).  The excess air leaks 
out by both controlled and uncontrolled means. Controlled leakage is via an outflow 
valve and a safety valve. Uncontrolled leakage occurs through openings and by air 
escaping from door and window seals etc („Jeppesen…”, 2002).  
 
3.16.2. Engine bleed air 
There are two types of engine bleed air systems, namely the open loop and closed loop 
systems.  The open loop system continuously bleeds large amounts of air from the 
aircraft engines.  Two air conditioning packs cool the air which is then distributed 
through a number of valves and fans to cool aircraft equipment and the occupants before 
releasing it overboard.  The closed loop system differs in that equipment and the aircraft 
interior are cooled, the air is recycled and the process begins again (Moir and Seabridge, 
2003).  
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3.16.3. Environmental control 
The innermost shell of the earth‟s atmosphere is known as the troposphere.  This shell 
begins at ground level and extends to an altitude of 9144m at the north and south poles, 
but extends further at the equator to a height of 18,288m.  For every 305m upward 
increase in altitude there is a proportionate decrease in temperature of 1.98 degree Celsius 
(°C).  The troposphere has a constant gas composition of 21 percent oxygen, 78 percent 
nitrogen and a remaining one percent which is made up of other gases.  Zero point zero 
three percent of which is carbon dioxide (“BTS ..”, 2002).  
An aircraft flies within the troposphere.  In order for it to withstand the atmospheric 
pressure experienced at such altitudes, the internal aircraft cabin must simulate an altitude 
equivalent to 2438m (8000ft).  This creates a differential pressure of approximately of 
0.5atm or 50kPa (Moir and Seabridge, 2003).  Aircraft in flight at altitudes such as 
12,200m are not pressurised to replicate atmospheric conditions at sea level, 
(Hinninghofen and Enck, 2006), as the resultant differential pressure would result in the 
aircraft collapsing inwards.  
Cabin temperature controllers are responsible for ensuring the control of the temperature 
of the cabin and cock pit, at 17 - 18°C on average.  Cabin pressurisation is maintained at 
safe values by cabin pressure valves.  These are installed in the cabin walls to control the 
pressure depending on the aircrafts altitude.  So once the cooled air passes through the air 
conditioning packs, it then moves through the control outflow valves, which control the 
pressure of the cabin.  These outflow valves ensure that the interior cabin simulated 
altitude of 2,438m is never exceeded (Moir and Seabridge, 2003; BMA 2004). The 
resultant reduced barometric pressure in the aircraft cabin is another unnatural condition 
experienced by passengers.  
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At sea level ambient pressure is approximately 760 mmHg or 101kPa.  The partial 
pressure of oxygen (inspired oxygen) PO2 is 149 mmHg (19.6 kPa) and the arterial 
pressure of oxygen (PaO2) experienced is 94mmHg to 98 mmHg (Refer to table 3.5.) 
(Peacock, 1998; Jeppesen…”, 2002, Cummin and Nicholson, 2002).   
During flight the ambient pressure at 12200m is approximately 140mmHg or 18.7kPa, 
which is insufficient to allow normal breathing in passengers. The interior cabin pressure 
experienced by passengers will be the equivalent to an altitude of approximately 1524 – 
2438m above sea level (Cummin and Nicholson, 2002; Hodkinson et al., 2003).  An 
altitude of 1524m, is the equivalent of breathing 17.1 percent oxygen at sea level, or at 
2438m the equivalent of 15.1 percent oxygen at sea level (BTS.., 2002).  These 
corresponding ambient pressures range from approximately 632 mmHg or 84.3 kPa at 
1524m to approximately 565mmHg or 75.3 kPa at 2438m.  Thus the ambient cabin 
pressures result in a reduction of the PO2, available to passengers, even though the 
concentration of oxygen (at 21 per cent) remains as normal (Cummin and Nicholson, 
2002).   
Table 3.5. Pressure versus altitude values. 
 Ambient Pressure Partial pressure of 
oxygen (PO2 ) 
Arterial Pressure of 
Oxygen (PaO2) 
Sea Level 760 mmHg 149 mmHg 94mmHg 
2,250m 565 mmHg 109 mmHg 55mmHg. 
12,200m 140 mmHg   
Source: (Cummin and Nicholson, 2002; Jeppesen…”, 2002; AMA, 2003)  
 
3.16.4. Hypoxia 
Inhaling air at high altitudes, with reduced atmospheric pressure, results in a reduction of 
alveolar oxygen and a reduced oxygen supply to the body and the brain.  This is known 
as hypoxia.  Pressurising the aircraft cabin during flight reduces this problem however it 
does not completely alleviate it (Moir and Seabridge, 1992).  
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A Report prepared by the Institute for Environment and Health (IEH) for the Department 
of the Environment, Transport and Regions in January 2001 states “Although the 
percentage of oxygen in cabin air remains unchanged (21%) at all flight altitudes, the 
partial pressure of oxygen and its availability to the body decrease with increasing 
altitude” (IEH, 2001, p13).  
Lennon (2004) wrote in an Irish Independent article that there can be as much as a 25 per 
cent reduction in oxygen available to passengers which results in an increase of 
coagulation factors by increasing the number of red blood cells produced by the body 
over days.  If a passenger took two connecting flights this could result in an increase of 
red blood cell count.  The reduction in the barometric pressure experienced in the aircraft 
cabin is responsible for dehydration and low arterial pressure of oxygen (Kelman et al., 
2003).  This has been established by Schreijer et al., (2006) as one of the underlying 
factors contributing to the pathology of FRDVT.  
The Aerospace Medical Association‟s (AMA) Medical Guidelines for Airline Travel, 2nd 
ed., (2003) states that the PO2 experienced at a cabin altitude of 2438m is 108 mmHg, 
with the PaO2 experienced being 55mmHg. This means therefore that there is a 
subsequent reduction of PO2 by approximately 41 mmHg and a PaO2 of approximately 39 
mmHg. Refer to Tables 3.5 and 3.6.  
 
Table 3.6. Levels of arterial pressure of oxygen within the body. 
Arterial Pressure of 
Oxygen PaO2   
Sea Level Altitude of  2438m 
when flying 
Inspired air  150mmHg 110mmHg 
Arterial blood 100 mmHg 64mmHg 
Capillary blood  60 mmHg 46mmHg 
Venous blood  37mmHg 32mmHg 
Source: Kingman and Economides, (2002) 
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What this means is that passengers experience approximately 90 per cent blood oxygen 
saturation.  In a sense passengers with normal healthy lungs are experiencing hypoxia due 
to the reduction in oxygen available to the blood (Galili and Bass, 2002; AMA, 2003).  
The majority of passengers can carry on as normal with the exception of passengers 
suffering with anaemia, pulmonary and coronary diseases.  
As inhaled atmospheric air is transported towards the lungs, the levels of PO2 reduce at 
each stage (Table 3.5), which is otherwise known as the Oxygen Cascade (Goldhaber and 
Elliot, 2003; Colbert, 2004).  A reduction in PO2 levels can cause an increase “in platelet 
adhesiveness” increasing the tendency of thrombus formation (Colbert, 2004).  An 
individual‟s rate of oxygen consumption at rest is 220-260ml/min (Roy, 2002).  At high 
altitudes, the density of the air is less than at sea level.  The consequential affect of this is 
that greater volumes of air are required to supply the adequate volumes of oxygen to the 
body (Schoene, 2001).  
An experiment was conducted with 15 participants, placed in a hypobaric chamber with 
internal ambient pressure of 75.8kPa to replicate a typical aircraft cabin pressure during 
flight.  They determined that the oxygen saturation of haemoglobin (SaO2) was indeed 90 
percent after individuals were exposed to this ambient pressure level for 30 minutes. 
Simons and Krol (1996, p. 416) stated “There is considerable interindividual variation in 
the responses to a lowered partial O2 pressure”.  In other words, some people seated in 
cramped conditions may suffer with hypoxia and/or drowsiness together with reduced 
respiratory activity.  
The Boeing 747-400 and B777 create a cabin altitude, equivalent to an atmospheric 
altitude of between 1,524m and 1829m at an altitude of 10,688m, in flight.  The arterial 
oxygen saturation experienced by passengers at that cabin altitude is approximately 
70mmHg in a healthy individual (Bagshaw, 1996) and not 55mmHg as stated by Galili 
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and Bass (2002) and Aerospace Medical Association, (2003).  Bagshaw is an airline 
employee and so is open to a suggestion of bias.   
Relative humidity at sea level is approximately between 30 and 40 percent. An aircraft 
cabin (which mimics an altitude of 2438m) will have relative humidity levels between 
eight and ten percent (Simons and Krol, 1996; Possick and Barry, 2004).  “The low cabin 
humidity of 8-12% increases fluid loss, which leads to dehydration” (Galili and Bass, 
2002, p.1020).  At a cabin altitude of 2438m the cabin ambient pressure experienced is 
75.8kPa and this value is the maximum acceptable cabin altitude provided by airlines 
cruising at altitudes of up to 13,106m according to Simons and Krol (1996).  Also 
reduced oxygen levels during flight along with dehydration may predispose an individual 
to FRPE (Gispert et al., 2006).  
 
3.16.5. Dehydration 
Dehydration can increase blood viscosity (Samama et al., 1994).  It can also lead to the 
development of headaches, tiredness and fatigue (Hunt and Space, unknown).  
 
3.16.5.1. Aircraft Cabin 
The reduction in the barometric pressure experienced in the aircraft cabin is responsible 
for dehydration (Kelman et al., 2003).  The change experienced in the aircraft cabin 
results in a dry atmosphere.   
Distension of the gastrointestine as a result of lower ambient cabin pressure can result in 
reduced respiratory activity through restriction of diaphragm movement (Simons and 
Krol, 1996).  The increased abdominal pressure can also reduce the efficient return of 
blood to the heart from the lower limbs, due to pressure on the IVC (main vein returning 
blood from the legs to the heart, via the abdomen) (Miller et al., 2005). 
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3.16.5.2. Alcohol and diuretics 
This in conjunction with a low fluid intake (such as water) and drinking alcohol and/or 
coffee increases the risk of haemoconcentration (Carruthers et al., 1976; Eklof et al., 
1996).  Haemoconcentration increases the risk of clot formation. 
 
3.16.5.3. Humidity 
A reduction in humidity may affect clotting factors (Lennon, 2004).  
 
3.16.5.4. Intake of Fluids  
Dehydration should be avoided by the consumption of water and a low intake of alcohol 
(Goldhaber and Fanikos, 2004).  Participants of the LONFLIT 2 Study were advised to 
drink at least one glass of water every two hours to avoid salty food and to wear 
comfortable clothes.  However these attempts to prevent thrombi formation were 
unsuccessful).  One DVT in the stocking group was diagnosed with 22 DVTs and eight 
SVTs diagnosed in the control group (Belcaro et al., 2001b). 
Excessive alcohol may result in passengers sleeping through the flight thus limiting their 
mobility and hence inactivation of the calf muscle pump, which is responsible for 
returning blood towards the heart.  
 
3.17. Oedema 
Oedema results from increased fluid in the interstitial tissue spaces (Gardner and Fox, 
1993; Kumar et al., 2005).  Impaired venous return and venous obstruction in the lower 
extremities due to prolonged immobility can result in oedema (Kumar et al., 2005).  
Prolonged sitting during long haul flights constitutes a risk factor for oedema.  Swelling 
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at the ankle and in the calf region of passengers is not an uncommon occurrence during 
flight (Belcaro et al., 2002; Cesarone et al., 2003a, b).  
Scholl stockings were effective in reducing the severity of oedema and preventing DVT 
(Belcaro et al., 2002).  The efficiency of Scholl Flight socks (14-17 mmHg) was 
investigated on flights of seven to eight hours duration and eleven to twelve hours 
duration.  Eighty percent of the control group (179) presented with signs of oedema and 
an increase in ankle circumference and volume, on flights of seven to eight hours 
duration.  One hundred and forty two of the stockings group completed the study.  
Volunteers in the control group had a higher incidence of oedema (Belcaro et al., 2002).   
Sigvaris Traveno (14 -17mmHg) elastic stockings have been demonstrated to be effective 
at preventing oedema on flights of seven or eight hour‟s duration but not on flights of 
eleven to twelve hours.  The incidence of oedema in the control group was 89 percent on 
flights of seven to eight hours (Cesarone et al., 2003a).  
Part II of the study was conducted on flights of eleven to twelve hours duration. The 
control group did present with oedema, with an odds ratio of 8.9 compared to 2.56 for the 
stocking group.  Eighty-three percent of the control group did present with an increased 
ankle circumference and ankle volume, while the stocking group did not (Cesarone et al., 
2003b).  
 
3.18. Discussion  
This chapter outlined the failure associated with the development, incidence, treatment 
and prophylaxis of DVT and PE.  Not only can FRDVT result in chronic sequelae it can 
also be life threatening. In the context of FRDVT prophylaxis, mechanical methods 
would seem most attractive, however no ideal device has as yet been described. 
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Air volume systems, Lym Gym, Airogym and Veinguard all aim to increase flow in the 
seated position by movement of air in a partially inflated system.  Changes in air pressure 
occur at different altitudes, resulting in inconsistent work achieved by movements.  This 
increases the difficulty in quantifying the amount of work required to effectively achieve 
the CMPF, thus reducing venous stasis adequately. 
Thus a mechanical device independent of cabin pressure seems more appropriate.  The 
Skywalker‟s pedals are not securely attached to the base. The semi-circular pivot is 
detachable which means the design does not conform to aviation standards. 
A device such as the Novamedix A V impulse system, in its present form is unsuitable 
for use during flight due to the air compressor. 
Hence there is a need for a more suitable inflight device along mechanical lines that will 
adequately activate the calf muscle pump function and result in sufficient venous return. 
Long haul “…air travel is an important risk factor for VTE requiring hospital admission 
and represents a significant public health problem in New Zealand” (Hughes et al., 2006, 
p. 78).   
The age matched control group, of 160 patients, used in the study conducted by Ferrari et 
al., (1999) cannot be viewed as a desired control group due to the fact they were all 
medically ill and admitted to hospital for medical treatment. Also the study group had a 
greater proportion of obese patients than the control group.  
The true incidence of FRDVT and FRPE is unknown.  The study by Lapastolle et al., 
may have underestimated the incidence of PE during air travel as non severe and those 
cases presenting outside the airport plus passengers who died in-flight or were found to 
be dead on arrival were not included in this study (Lapostolle et al., 2001). The true 
incidence of FRPE may also have been underestimated in the study conducted by Pérez-
Rodríguez et al., (2003).  Those who died in-flight and at the airport were not 
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documented. Also passengers who did not complete prior connecting flights (Asian 
passengers who had prior connections from London/Paris) possibly due to FRPE 
episodes were not included in this study. The possibility that some passengers had 
asymptomatic FRPE and so were not treated or referred to Ramón y Cajal must also be 
considered.  According to Kumar et al., (2005), 60 to 80 percent of PE were 
asymptomatic due to their size.  
It has been established that compression stockings do not prevent FRSVT (Scurr et al., 
2001; Hughes et al., 2003).  Results presented by Scurr et al., (2001) were criticised by 
Hirsh and O‟Donnell (2001b, p.1462) for two reasons. The first being that “no assurance 
was given that there had been no communication between volunteers and technicians. 
This shortcoming could have been avoided by having a 3
rd
 party present during 
ultrasonography. Furthermore, the diagnosis of calf-vein thrombosis was not confirmed 
by venography, and since D-dimer results were negative, the thrombi were either very 
small or were false-positive findings”.   They go on to say how unlikely it was that not 
one passenger who wore stockings developed a FRDVT.  The NZATT study has been 
criticised for its lack of use of controls.  Authors of the study did state that the “absolute 
proportion” of FRVTE due to lack of controls could not be determined (Hughes et al., 
2003).  
It appears that fewer deep thrombi occur in first class compared to economy class.  In the 
studies discussed, the last three rows of economy class seats were implicated in increased 
coagulation of all passengers.  Passengers seated in the window and central seats of 
economy class are at greater risk of developing FRDVT as all DVT events occurred in 
subjects seated in window or central seats in both the LONFLIT and LONFLIT 2 studies 
(Belcaro et al., 2001a, b).  
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Both economy and first class travel on long haul flights has been associated with FRDVT 
and FRPE (Mohler, 1997; Lapostolle et al., 2001, Hughes et al., 2003).  Two of the nine 
volunteers who developed a VTE in the NZATT study travelled business class. Their 
mean age was 59.5 years, which in itself is a risk factor for VTE (Klauser et al., 2004, 
p.896).  
Both Dudley Miller (2004) and Lapostolle et al., (2004) state the necessity for control 
groups in studies into FRDVT, as without them inconclusive results are determined 
(Klauser et al., 2004, p.896).  
Factor V Leiden and prothrombin gene mutation are common inherited risk factors for 
FRDVT (Scurr et al., 2001).  It was determined by Schreijer and co-authors that TAT, D-
dimer and prothrombin Fragment 1+2 levels were all higher post the three exposures in 
the FVLM and in the oral contraceptive group of volunteers.  There was no difference 
between F1 + 2 levels in either of the subgroups of volunteers after any of the three 
studies (Schreijer et al., 2006).  However TAT and d-dimer levels remained normal after 
eight hour flights in the study conducted by Schobersberger et al., (2003). 
The occurrence of oedema in the lower extremities during long haul flight may be a 
predisposing factor of FRDVT as the authors of one study hypothesised that it “could” 
cause compression of the veins (Belcaro et al., 2002). However in both control and the 
stocking groups, the presence of oedema was not sufficient to trigger thrombus formation 
in the LONFLIT4 Concorde Sigvaris Traveno Stocking study (Cesarone et al., 2003b). 
Many experts in FRDVT have disagreed with the findings of the study conducted by 
Kraaijenhagen et al., (2000), which invalidates the relationship between long haul flights 
and the development of DVT and PE (Ferrari and Morgan, 2001; Burnand et al., 2001).  
Two different studies (The BEST Study, 2003 and The Lonflit-Flite Randomized Control 
Trial, 2003), researching into D-dimers, published in the same year, have published 
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contradictory findings. This phenomenon must strengthen the requirement for a database 
which will display actual events and any genetic associations contributing to DVT and 
PE.  However D-dimers were elevated post flight, decreased post cinema and remained 
unchanged after daily activity in the study conducted by Schreijer et al., (2006).   
Authors of the Lonflit-flite study concluded that D-dimer and Fibrogen testing were not 
effective for early detection or prediction of thrombi (Cesarone et al., 2003a). Whereas 
Hughes et al., (2005, p.2448) stated that increased plasma D-dimer levels “…are 
associated with recognised risk factors for VTE such as age, female gender, hormone 
use, obesity, co-morbidity and thrombophilia states…”.  Three of the seven females who 
presented with a thrombotic event were taking oral contraception (Cesarone, 2002).   
The authors of the LONFLIT and LONFLIT2 study concluded it was probable that the 
majority of their study participants who were diagnosed with a thrombus, (as a result of 
taking part in the studies) would not have sought medical care as they considered some 
form of swelling “as normal” post long haul flight (Belcaro et al., 2001ab).  Even short 
haul flights of two to four hours duration have been implicated in the development of 
oedema (Belcaro et al., 2002).  Scholl socks were effective at reducing the presence of 
edema (Belcaro et al., 2002). Sigvaris Traveno stockings significantly reduced the 
occurrence of oedema on seven hour flights.  In comparison, on flights of eleven hours a 
limited amount of edema, even with stockings was present (Cesarone et al., 2003b).  
Episodes of DVT and SVT were asymptomatic in a number of studies (Scurr et al., 2001; 
Belcaro et al., 2002).  However in the study conducted which compared aspirin to 
LMWH, 60 percent of all thrombotic events were asymptomatic (Cesarone, 2002).   
It is understandable that sufferers of FRVTE would present themselves to Kings College 
Hospital as there are four airports, Heathrow, Gatwick, Standstead and London City in 
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the surrounding area.  Yet as sufferers of FRDVT or PE may be asymptomatic, it is 
certain that this figure of 1000 flight related deaths per year is greatly underestimated  
Jet lag may be a contributing factor to the occurrence of FRDVT.  Some passengers 
suffering from jet lag upon their arrival at their destination may try to sleep to overcome 
the effects and thus become immobile once again. These two periods of immobility may 
encourage a thrombus to grow in size.  Passengers who take sleeping tablets to induce 
sleep on a long haul flight should be persuaded that this could be a dangerous course of 
action, as sleeping limits movement of the muscles, enhancing the possibility of thrombus 
development due to venous stasis.  Passengers should also be encouraged to avoid 
alcohol to aid sleep as this not only reduces movement but may also results in 
dehydration.  Finally, conditions experienced during flight in addition to possibly 
cramped seating conditions in cars or buses while travelling from the airport to the final 
destination, all may contribute to DVT.  
Few accidents occur during flight (ACARE, 2002).  The measure of wearing a seatbelt is 
to prevent harm during flight.  If passengers are instructed to wear a seat belt for their 
personal safety then why is some form of prophylaxis such as the Tromped or the 
Airogym Cushion to aid in the prevention of harm by FRDVT also not provided by 
airlines?  If engineering solutions to problems such as FRDVT are not introduced how 
can these solutions lead to the health improvements, which they were designed to 
achieve?   
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CHAPTER 4    
 METHODOLOGY 
 
4.0 Introduction 
This chapter explains the research methodology, methods and design employed. The 
research involved comprehensive reading of medical literature concerning the human 
body and the pathology of venous thrombosis and methods of prevention (chapters one to 
three).  Literature relating to the normal operation of an aircraft and both the 
requirements and regulations of aircraft manufacture and safe operation was also referred 
to (chapters three and five).   
A form of prophylaxis for FRDVT was designed and developed (named the Tromped), 
with the final aim of incorporating this device into commercial aircraft (chapter five).  
These devices were haemodynamically assessed for their viability with the help of 
recruited volunteers.  Approval by both the Beaumont Hospital medical ethics committee 
and the DIT ethics committee was sought and given to conduct the final two 
haemodynamic assessments (chapters seven and eight respectively).  Beaumont Hospital 
ethics committee required clarification to determine if the Tromped prototype was indeed 
a medical device (section 5.11).  
 
4.1 Methodology 
The methods used allowed for a wide-ranging study of the issues which are of concern to 
the flying public, airlines, aircraft manufacturers and the international medical society.  A 
method of research, recording, design, testing and analysis of results was used.  
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4.2. Troubleshooting with Springs 
Four demonstrator devices were developed using commercially available springs.  These 
springs were made from spring steel and each had a different resistive value.  These 
springs were blindly selected and one was placed into each demonstrator device.  
Following the first medical assessment, it was determined by Air Plethysmography that 
D2 and D3, produced a sufficient mean ejection volume fraction (EVF) (Collins, 
2002/2003).  These springs were tested in Lufthansa Technik Aermotive Ireland, using a 
Chatillion Digital Force Gauge, LTC-100 (DFGS).  Each spring was placed separately on 
the stainless steel lower compression plate where its height and the force required to 
compress the spring were recorded (Figure 4.1).    
The force required to fully compress the spring in D2 was 99.21 newtons (N).  This jig 
produced a mean EVF of 65.99 percent and a mean residual volume fraction (RVF) less 
than the required 35 per cent at 21.54 per cent.  The force required to fully compress the 
spring in D3 was 80.97 N, which produced a mean EVF of 62.17 percent.  The mean 
residual value fraction was less than the 35 per cent required at 33.71 per cent.  
When conducting the medical study all ten volunteers reported that the spring parameters 
of D3 were preferable to those of D2, in terms of ease of use.  Even though less effort 
was required to compress the device pedal, they still achieved the required venous return 
in the seated position.  Hence the spring parameters of D3 were used in the subsequent 
assessments conducted.   
As a force of 99.21N was required to fully compress the spring of D2, a range of 80.97N 
to 86.75N force was considered for further testing so the spring will not be fully 
compressed.  The height of the desired spring, diameter of the coils and the required 
compression value needed were known. Specifications such as spring deflection height, 
the number of spring coils, spring wire gauge and the type of environment the finished 
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spring would be subjected to were required.  Calculations were performed to determine 
the design specifications for the desired spring used in D3 (Section 4.2.1).  
 
   Source: Lufthansa Technkik Airmotive Ireland. 
Figure 4.1. LTC 100 Chatillion Digital Force Gauge.  
The compression values determined by the DFGS represented the force required to 
compress the front edge of the pedal to meet the front edge of the base. It did not 
represent the exact downward force required to compress the spring which was situated a 
few centimetres away from the edge of the pedal.  To determine the exact compression 
value of the spring, it was removed from the Tromped, and a simple harmonic test was 
conducted.  Using weights, a spring deflection height of 38.4mm was achieved by 
applying a force of 82.04N.  This was 0.98N greater than the compression value initially 
obtained.  The same spring was then tested in Lufthansa Technik Aermotive Ireland to 
determine the required load to produce a deflection height of 38.1mm (as produced when 
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the pedal is compressed to meet the Tromped base).  The same DFGS (that tested D2 and 
3) was used to determine the force required to fully compress the spring in its free state.  
A load of 111.669N fully compressed the spring to a height of 25.4mm.  The force 
required to deflect the spring to a height of 38.1mm was determined as 84.98 N, as seen 
in Graph 1 (Appendix C).  A difference of 2.93N was recorded between the two methods 
used to test spring deflection and force. The DFGS is constantly used to test springs used 
in aircraft engines. As this method was used to test the compression values of D2 and 3 
the values obtained by the DFGS were accepted as the true values.  
The recorded errors of the Chatillion Force gauge are +/-0.89N. The accuracy of the 
DFGS series is +/-0.15% of full scale +/-1 least significant count (LSC) (AMATEK, 
2001).  
 
4.2.1. Compression Spring Calculations for prototype Option II 
The spring used in D3, is an oil Tempered spring, with a modulus of Rigidity, G, of 
78×10³ N/mm².  The diameter of the spring material, inside diameter of the coil and the 
outside diameter of the coil were all measured. 
The diameter of the spring wire material was recorded as 2.3368 mm by a 150mm Digital 
Calipers. Its accuracy is +/-0.02 mm (<100mm).   
D1 or inside diameter of the coil was 25.4 mm. 
D2 or outside diameter of the coil was 30.07 mm. 
N = 10 (coils in the spring). 
Length of the spring was 101.6 mm  
The force on the spring W, to fully compress the spring was 111.7 N. 
The load required to deflect the spring to a height of 38.1mm was 84.975 N ≈ 85 N.  
If: W = applied load                                  d = diameter of the spring wire 
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G = Modulus of Rigidity                      N = number of coils in the spring 
D = diameter of the spring coils,          x = deflection 
The spring force is calculated using equation 6.1, (SAE 1996, p.189).  W was substituted 
for P (load or force) and x (to represent for deflection) was substituted for F, so that F 
would not be misconstrued as the force or load.  The Load (W), “is the force required to 
compress the spring to a specified loaded length” (SAE, 1996).  
Spring Force: 
3
4
8ND
Gxd
W                                                                   Eqn 4.1.  
(SAE, 1996, p.189) 
 
D is calculated by finding the mean of D1 and D2 as follows: 
2
)( 21 DDD                                                                                     Eqn 4.2. 
So 
2
)07.304.25(
D  
D = 27.73 mm. 
The following calculation was performed to confirm the correct Modulus of Rigidity of 
the spring.  The deflection height, x, of compression Spring 3, is determined using Eqn. 
5.1., transposed:  
4
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WND
x                                                                                        Eqn 4.3.  
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Therefore 
6
8
1032.2
10449.1
x ,                x= 62.45 mm.  
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Determined from the previous equation, a force of 84.97 N would deflect the spring by a 
height of 62.45mm.  However the Chatillion digital force gauge showed that a force of 
84.97 N deflected the spring by a height of 63.39 mm.  A difference of one mm clearance 
was not significant, thus it was accepted that the modulus of rigidity quoted for the spring 
material was approximately correct. 
  
4.3. Medical Ethics 
The Non-Invasive research conducted for the purpose of this work followed the criteria 
set out by the Declaration of Helsinki (1964).  The assessments conducted can be 
classified as non-therapeutic research however the Tromped and Mediven® Travel 
Compression Stocking Assessment was considered as a Clinical Trial by the Beaumont 
Hospital Ethics Committee, as the Tromped was classed as a medical device by a 
representative of the Irish Medicine Board (IMB).  Each subject acted as their own 
control, in all three haemodynamic assessments conducted.  
The research conducted was non-invasive, which involved direct interaction with all 
participants and so is classed as intrusive research (Kirk, 1995).  It consisted of an air 
chamber being placed around each participant‟s right calf, from knee to ankle, (refer to 
section 4.5.), to allow quantification of the calf muscle pump action during various 
manoeuvres. 
Prior to conducting any of the three assessments, information leaflets containing the 
following were provided for each potential participant.  “If research is involved, 
disclosures should generally cover the aims and methods of the research, anticipated 
benefits and risks, any anticipated in-convenience or discomfort, and the subjects‟ right 
to withdraw, without penalty, from the research”. (Beauchamp and Childress, 2001).   
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All participants in the three assessments were of an age and mental capacity to provide 
informed voluntary consent for participation in the studies.  They were not patients of any 
institution at the time before or during assessment.  Thus they were capable of disclosing 
information that would have excluded them from the assessment and understood the 
requirements of the assessment prior to their involvement. They all provided informed 
consent to the investigator (CC).  “For consent to be truly voluntary it should be stressed 
to the patient that he or she is quite free to refuse to participate without any adverse 
response or sanction occurring and that the patient can also withdraw during the course 
of the trial if he wants to” (Kirk, 1995, p.239).  Participants were not coerced, all were 
aware of their right to withdraw from the study at any time.   Neither, monetary or any 
other inducement to participate was offered to those who conducted the three 
assessments.  All information provided to participants prior to and during each 
assessment was valid and accurate.  Explanation of the study was provided in the 
information letters given to participants. Prior and during the course of the study, verbal 
instructions were given to each participant.    .   
 
4.4. Haemodynamic Assessment‟s methodology  
Non-invasive procedures were conducted to test the efficiency of the Tromped.  It was 
also beneficial to use non-invasive equipment as recruitment of participants may have 
become an issue if the procedures were invasive.  Duplex ultrasound, Air 
Plethysmographs and photoplethysmograph machines are used in the medical field to 
assess valvular competency of the lower limbs, non-invasively (Needham, 2005).  All 
three test categories were researched and both Duplex Ultrasound and 
photoplethysmography were immediately eliminated.   
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4.4.1. Duplex Ultrasound 
It would have been required to hold an ultrasound probe on either the popliteal vein 
(which is found at the crease of the back of the knee) or on the skin above the femoral 
vein at all times during the assessment.  There would also have been an associated 
technical difficulty maintaining adequate contact between the ultrasound transducer and 
the skin overlying both these areas when the participant would be required to conduct 
manoeuvres in the seated position.  Also Duplex measures velocity and would not 
provide quantifiable measurements of venous volume or changes in the limb.  
 
4.4.2. Plethysmography  
Air Plethysmographs and photoplethysmographs assess valvular competency by 
measuring the volume of the lower limbs while the participant stands or remains in the 
supine position and conducts various foot manoeuvres (Needham, 2005).  
Photoplethysmography was not ideal as its use has dramatically reduced in the last ten 
years for testing of valvular efficacy (Needham, 2005) and also the equipment itself was 
not readily available.  
 
4.5. Air Plethysmography 
Air Plethysmography was used to conduct haemodynamic assessments using the 
Tromped because it is a non-invasive technique it is reproducible, measures calf volume 
and provides quantifiable results.  The technique is used to determine relative volume 
changes in the lower limbs in response to postural alterations and muscular exercise 
(Nicolaides and Sumner, 1991).  Air Plethysmography is also known as 
pneumoplethysmography (Schmitz et al., 2006).  As the Air Plethysmograph is 
calibrated, whole leg volume change as a result of exercise can be recorded in absolute 
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values (ml) and as relative units.  Segmental volume changes measured by strain gauge 
do not represent changes in the whole leg and so this cannot be used with exercise, tiptoe 
and walking.  The Air Plethysmograph consists of a 355mm long tabular polyvinyl 
chloride air-chamber which surrounds the whole lower limb from knee to ankle 
(Nicolaides and Sumner, 1991; Needham, 2005).  The APG 1000 (ACI Medical, San 
Marcos, California) is recognised as an accurate evaluation of venous hemodynamics 
(Criado et al., 1998).  It measures volume changes over the region surrounded by an air 
chamber (calf of a human limb in this instance) as shown in Figure 4.2.  “An increase in 
volume of the part contained within the plethysmograph causes air to be compressed 
resulting in a pressure rise” (Strandness and Sumner, 1975).  This rise is then recorded 
by the transducer, which records the change in volts and then translates and records it as 
millilitres of blood on the APG plotter (Strandness and Sumner, 1975).  
 
Source: Nicolaides and Sumner, 1991 
Figure 4.2. Diagrammatic representation of the APG. 
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4.5.1. Method of assessing venous function using Air Plethysmography 
The chamber was inflated to seven mmHg and connected to a pressure transducer, an 
amplifier and a recorder, as shown in Figure 4.2.  This pressure of seven mmHg ensures 
adequate contact between the chamber and the leg.  The air plethysmograph was 
calibrated by pressing the syringe plunger which reduced the volume of the system by 
100 ml (Nicolaides and Sumner, 1991).  The resultant pressure change was stored in the 
system its purpose was to generate a calibration curve Bays et al., (1994).  As the volume 
change of a gas within a closed system is related to both pressure and temperature a 
controlled room temperature was necessary (Comerota, et al., 1995).   
The plunger was then pulled back to its original position.  All of this occurred with the 
patient in the supine position, with the right leg elevated by 45º and with the right knee 
slightly rotated, (as shown in Figure 6.1.), which allows emptying of the patient‟s veins 
(Nicolaides and Sumner, 1991; Needham, 2005).  When the volunteer lies in the supine 
position, elevation of the leg means that the blood flows to the abdominal and thoracic 
veins, as a result of gravity, emptying the lower limb veins of blood (Tibbs, 1992). 
The volunteer was instructed to stand with all of his/her weight on the left leg.  At this 
time an increase in the right leg standing venous volume (VV) was recorded as a result of 
the venous filling (Nicolaides and Sumner, 1991; Bays et al., 1994).  A wide variety of 
normal VV values are reported ranging from (80 –170ml) (Bays et al., 1994; Padberg et 
al.,, 2004).  Patients presenting with CVI will have values ranging from 100 – 350ml 
(Nicolaides and Sumner, 1991).  However the Venous Filling index is the most important 
indicator of venous competency as it is an excellent predictor of venous reflux (Criado et 
al., 1998).  It is a measure of the average filling rate.  Normal refilling times in a healthy 
individual is usually greater than 16 seconds (Needham, 2005).  A VFI of two ml/s or less 
occurs in normal limbs with competent veins (Christopoulos et al., 1989; Nicolaides and 
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Sumner, 1991; Bays et al., 1994).  A VFI of 30 mls/s can occur in limbs with reflux 
(Nicolaides, 2000).   
 
Source: Non-Invasive Vascular Unit, Beaumont Hospital.  
Figure 4.3. The APG pressure transducer, amplifier and recorder.  
 
Ambulatory venous pressure (AVP) “is estimated with a tip-toe exercise” (Fukuoka, 
Okada & Sugimoto, 1998, p. 674).  This movement will measure the Ejection Volume 
(EV), which “is a measure of the venous pump function and depends on patency of veins 
and normal venous function” (Mantoni et al., 2002, p.580).  Normal values range 
between 60-150ml (Bays et al., 1994).  The normal ejection volume fraction (EVF) is 
greater than or equal to 60 percent (Nicolaides and Sumner, 1991; Nicolaides, 1999). 
Refer to Figure 4.4 to view an EV recorded on the APG trace. The Ejection Volume 
Fraction (EVF) is the percentage of calf blood volume emptied with a single calf muscle 
contraction during tiptoe exercise.  The Residual Volume (RV) and subsequently the 
Residual Volume Fraction (RVF) are calculated as a result of the patient conducting ten 
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consecutive tip-toe movements.  The RV is a measurement of the amount of blood 
remaining in the veins after exercise, in this instance, ten consecutive tiptoes (Nicolaides 
and Sumner, 1991).  The normal residual volume fraction is less than or equal to 35 
percent and it is the most useful non-invasive index of the efficiency of the calf muscle 
pump (Christopoulous et al., 1989).  
 
4.5.2. Standard APG assessment procedure 
The standard APG assessment has been described and validated to demonstrate relative 
volume changes in the lower limbs in response to postural alterations and exercise and 
thus quantify calf muscle pump function (Christopoulos et al., 1987).  
i. The patient was asked to lie in the supine position on an examination couch 
with a cushion height of 468mm off the ground, to coincide with commercial 
aircraft seating heights.  The volunteer must place their hands by their sides so 
as not to press on the Inferior Vena Cava (IVC).  
ii. The volunteer must remain in this position for at least ten minutes before the 
test may begin.  The room was maintained at a controlled temperature of 20º 
Centigrade, to obtain equilibrium and prevent vasoconstriction (Cole, 2001b). 
iii. The 355mm tubular polyvinyl chloride air chamber was placed around the 
volunteer‟s right leg as shown in Figure 6.1. and the APG® was calibrated. 
iv. The volunteer was instructed to lie in the supine position with his/her right leg 
elevated to the 45º angle and right knee slightly bent while the calf veins 
emptied of blood. 
v. After a stable baseline was recorded the volunteer was asked to stand with all 
of her/his weight positioned on the left leg, with the aid of an orthopaedic 
frame.  An increase in the leg venous volume (VV) was observed. 
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Source: Non-Invasive Vascular Unit, Beaumont Hospital. 
Figure 4.4. Base line and movement recorded on APG trace.  
vi. When a steady base line was observed in the standing volunteer, he/she was 
asked to stand on both tiptoes with all their weight on both legs, holding this 
position for five seconds.  The volunteer then returned to the initial standing 
position, with all the body weight concentrated on the left leg. 
vii. This procedure was repeated until two similar values were recorded on the 
graph paper.  The EV, (the amount of blood propelled up the leg) was 
recorded as a decrease in volume.  The EVF was calculated as a result of calf 
muscle contraction, as shown in Equation 4.5. 
viii. When a steady base line was recorded the volunteer conducted ten 
consecutive tiptoe movements before returning to the supine position with the 
Baseline  
Ejection volume 
Ejection volume 
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right leg elevated, resting on the support to empty the veins.  The volume of 
blood remaining in the veins after exercise was the residual volume (RV).  
The RVF is calculated by using equation 4.6.   
 
4.6 Mathematical Modelling 
The venous filling index is obtained by using equation 4.4 (Christopoulos et al., 1987): 
VFI = 
%)90(
%)90(
VFT
VV
                                                                                         Eqn 4.4. 
The EVF was calculated from the following equation (Christopoulos et al., 1987): 
EVF = 100
VV
EV
                                                                                           Eqn 4.5. 
The RVF was calculated from equation 6.6 (Christopoulos et al., 1987): 
RVF = 100
VV
RV
                                                                                          Eqn 4.6. 
The Mean x , of each value (for example the standing venous volume obtained from the 
first assessment), was calculated from equation 4.7 (Reilly, 2000):                                                                                                        
x =   
10
1507016613513075100150100110
                       Eqn. 4.7.                                          
x = 118.6 mls. 
 
This was repeated for each of the different manoeuvre values.  
The standard deviation was determined using the following formula (Reilly, 2000): 
n
d 2
                                                                                                      Eqn. 4.8. 
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Where xxd ; x is a patients recorded value (standing VV, for example), x is the 
mean of all ten patients values for one particular movement or value (standing VV of the 
first assessment for example) and n the number of patients. 
2d = [(110-118.6)
2 
+ (100-118.6)
2 
+ (150-118.6)
2 
+ (100-118.6)
2 
+ (75-118.6)
2 
+ (130-
118.6)
2 
+ (135-118.6)
2 
+ (166-118.6)
2 
+ (70-118.6)
2 
+ (150-118.6)
2 
] 
2d = 9646.4 
10
4.9646
  = 31.05 
The “Student‟s t-test” was used to compare the mean value obtained for each movement 
in the seated position, standing and walking, to determine if there was any significant 
statistical difference.  The paired Student‟s t-test was used to compare the control 
manoeuvre to the assessment manoeuvres to determine if a significant difference existed 
(Reilly, 2000).  
The t-test formula (Reilly, 2000) used was        
2
2
1
2
21
n
s
n
s
xx
t                           Eqn 4.9.  
Where s
2 
= 
2
21
22
2
11
2
11
nn
snsn
.                                                                   Eqn. 4.9.1 
When 221 nn  = degrees of freedom                                                            Eqn. 4.9.2 
n = the number of patients, therefore 1n  and 2n both equal 10.  1s and 2s  were the 
standard deviation results of the two particular ejection volumes being compared. 1x  and 
2x were the mean values of the two ejection volumes being compared.   
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4.7. Haemodynamic evaluation of the Tromped prototypes 
Figure 4.5. represents the order of haemodynamic assessments conducted, involving the 
various prototypes of the Tromped.         
                                                            
    Version 1 of Tromped prototype - 4 Test Jigs with springs of varying compression  
strengths to determine which if any of the springs, could produce a sufficient EV.  
 
 
Version 2 Tromped prototypes, DA and DB  
 
 
Assessment determining the efficiency of DA, compression stockings,  
feet movements advised during flight and walking. 
 
 
Tromped Version 3, Assessment determining the efficiency of the 
Footrest Tromped when used in situ in an aircraft seat 
 
Figure 4.5. Order of Haemodynamic Assessments conducted 
 
4.8. The Tromped and Mediven ® Travel Compression Stocking Sizes 
These below knee stockings (UK grade II) had a compression of 18.4 -21.1 mmHg 
(Hsieh and Lee, 2005).  The instructions accompanying them state “Measure the 
circumference above the ankle at its narrowest part”.  
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Table 4.1. Knee length Mediven® Travel stocking sizes. 
Ankle Circumference (mm) Mediven® travel stocking sizes 
180 – 200 Small 
200 – 230 Medium 
230 – 260 Large 
260 – 290 Extra Large 
290 – 320 Extra extra large 
Source: Mediven® Travel stocking 
 
 
The size of a participant‟s right ankle when measured on the day of the study determined 
which Mediven® knee length travel compression stocking size they required to wear.  All 
ankle measurements were taken using a spring loaded measuring tape.  
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CHAPTER 5  
DEVELOPMENT OF THE TROMPED PROTOTYPES 
 
5.0 Introduction 
Development of The Tromped began with a simple design (which established 
haemodynamic effects in the seated position) and eventually progressed to a 
commercially viable prototype design for use on board an aircraft.  All demonstrator 
models were assessed to evaluate their ability to effect venous return (when used in situ) 
similar to that achieved in the ambulatory position.  
 
5.1 The first Tromped prototype  
The first Tromped demonstrators were produced using aluminium sheet of strength 2024 
T4, using conventional fabrication techniques.  All four demonstrators produced had the 
same dimensions.  The bases of the demonstrators were 177mm wide and 375mm long.  
The depth of the demonstrator base was 25mm.  The pedals (310 mm long, 106mm wide 
and 18mm deep) were attached to the base at one end by a hinge and at the front end by 
the compression spring.  Four different springs, selected to provide a range of foot 
pressures were inserted into each of the demonstrators.  Physical parameters of all of the 
springs were determined following the haemodynamic assessment using a Chatillion 
Digital Force Gauge (Table 5.1).  The displacement of a compression spring is a reliable 
method of measuring the linear force generated by induced plantar flexion.  Compression 
springs have an automatic stop once fully compressed, which limits stress levels. 
Compression springs are manufactured from materials suitable to withstand the physical 
changes experienced during airline travel and exhibit long fatigue lives, suitable for 
multiple compression cycles (Carlson, 1980). 
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Once the top of the pedal lined up with the top end of the base the appropriate hinge 
position could be determined, and so measurements of the hinge‟s dimensions were 
transferred to the underside of the pedal and on the upperside of the base.   
 
Table 5.1. Force required to fully compress the Tromped demonstrators. 
 Spring 
height 
(mm) 
Load required to 
compress the pedal 
(N) 
D1 100 56.94 
D2 125 99.21 
D3 100 80.97 
D4 100 55.16 
Source: Collins, 2002-2003. 
Holes were drilled into the pedal to coincide with the holes on the hinge, which was then 
riveted to the underside of the pedal.  A hole was also drilled in the upper side of the base 
to accommodate the hinge measurements and the hinge was riveted to the base (Figure 
5.1).  Once the pedal was securely attached to the base by the hinge, a gauge setting with 
an angle of 25º (which provided a reasonable elevation to the foot, without inducing 
discomfort) was used to determine where the spring should be positioned.  Consequently 
all demonstrator pedals were at the same angle, although some of the springs were of 
differing heights. Each spring was wire locked to a square shaped mat fashioned from the 
aluminium sheets.  A circle larger in circumference than the spring was cut out of the 
upper side of the base so that it would allow sufficient clearance for the compression 
springs.  Once in the correct position, the spring mat was riveted to the underside of the 
base.  The upper end of the spring was wired locked to the under side of the pedal.  
Finally the upper and lower sides of each base were riveted together as were the two sides 
of each of the pedals.  Each demonstrator was marked with its own code to allow 
identification for experimental purposes (Collins, 2002-2003).  
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Figure 5.1. The first Tromped demonstrator.  
 
5.2. Hemodynamic Assessment of the first Tromped prototype 
Hypothesis: “can any of the springs when compressed in the seated position produce 
sufficient venous return to mimic normal ambulatory calf muscle pump function, and 
thus potentially reduce the incidence of FRDVT?” 
 
5.2.1. Location 
This assessment was conducted in the Non-Invasive Vascular Unit, Beaumont Hospital, 
Dublin.   
 
5.2.2. Participants. 
The ten healthy volunteers recruited to conduct this assessment comprised of six males 
and four females. Ages ranged between 20-69 years (mean age 40.2 years ± 17.2 years) 
were assessed.   
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5.2.3. Method 
The standard APG assessment of calf muscle pump function was performed, requiring 
the volunteer to move from the supine to the standing position to perform tiptoe 
manoeuvre to stimulate calf contraction.  APG allows non-invasive measurement of 
changes in volume enabling measurement of calf muscle pump function in terms of EVF.  
Each demonstrator was assessed in the seated position, with tiptoe movement replaced by 
compression of the demonstrator pedals.  Compression of these pedals required plantar 
flexion of the ankle, to increase venous return from the deep and superficial system.  
Plantar flexion requires the volunteer to rise the heel off the ground and place weight on 
the ball of the foot.  As Tromped use mimics dynamic plantar flexion manoeuvre, calf 
blood flow will increase as the contractions per minute increase.  
 
5.2.4. Normal Values 
In the standard APG assessment, a VFI of less than 2ml/s, an EVF of greater than 60 
percent and an RVF of less than 35 percent would be considered normal (Christopoulos 
et al., 1987; Christopoulous et al., 1989).  
 
5.2.5. Results 
All of the results are expressed as mean +/- standard deviation, n = 10. EVFs obtained are 
presented in Figure 5.2 and Table 5.2. 
All volunteers had normal venous function, determined by their venous filling index 
(VFI) and RVF.   
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Figure 5.2. EVFs obtained from demonstrators 1 - 4.  
 
Table 5.2. EVFs obtained from demonstrators 1 – 4.  
 Control D 1 D 2 D3 D 4 
EVFs 
(%) 
61.02 54.1 65.99 62.17 46.05 
SD 16.08 12.83 13.83 11.63 9.84 
 
EVF achieved by control and exercise devices as measured by Air Plethysmograph 
represented as a fraction of the venous volume and expressed in percentage (%) and 
reported as Mean +/- SD.  
Tip-toe manoeuvre in the standing position acted as control and achieved a mean EVF of 
61.01 ± 16.08%.  Only demonstrator two (D2) and D3 achieved a greater than 60 percent 
EVF, which is comparable with normal standing values (Table 5.2., Figure 5.2).  Mean 
RVF of 21.74 ± 11.25 % is achieved by control movements.  Demonstrator one, D2 and 
D3 produced an RVF less than 35 percent, (Table 5.3, Figure 5.3).  Even though D2 had a 
lower RVF (21.54 ± 18.87%) compared to D3 (31.66 ± 22.62%), all ten participants 
reported D2 to be least user friendly device of all demonstrators.  D3 was reported as the 
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most user-friendly by all ten volunteers and so this spring‟s compression value was 
chosen for use in further prototype designs (Collins, 2002-2003).   
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Figure 5.3. RVFs obtained from Demonstrators 1 - 4.  
 
Table 5.3. RVFs obtained from Demonstrators 1 – 4.   
RVF achieved by control and exercise devices as measured by Air Plethysmograph 
represented as a fraction of the venous volume and expressed in percentage (%) and 
reported as Mean +/- SDM.  
Compression of D2 and D3 produced adequate EVFs while D1, D2 and D3 produced 
adequate RVFs in the seated position.  User preference was for D3.  As this device 
adequately achieved venous emptying in the seated position these parameters were 
chosen for further investigation.   
 Control D1 D2 D3 D4 
RVFs (%) 21.75 31.66 21.54 33.71 40.75 
SD 11.25 22.62 18.87 25.02 18.37 
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5.3. Aircraft seat design 
The Anthropometric Study to Update Minimum Aircraft Seating Standards was produced 
by Quigley et al., (2001) of ICE Ergonomics, on the request of the Joint Aviation 
Authorities (JAA). The aim of this study was to provide regulatory information in areas 
such as seating dimensions on board.  Seat spacing is a safety issue.   
The trend in the increase in people‟s sizes is likely to continue and so the new 
requirements should take this into account.  Recommendations considered a passenger‟s 
views on seat access, egress and spacing.  Passengers of different heights and weights, 
ranging in age from 15 to 76 years of age with flight durations from 3.75 hours to 22 
hours, seated in all seats were included.  Members of the JAA currently do not have 
regulations regarding aircraft seat spacing, except the UK Civil Aviation Authority 
Airworthiness Notice 64. This notice regulates the minimum seat space dimensions on 
aircraft (Table 6.4) over 5700kg MTWA, which holds 20 passengers or more (Quigley et 
al., 2001). 
 
Table 5.4. The current minimum seat space requirements of the UK Civil Aviation 
Airworthiness Notice 64.  
 
Dimension Description  Minimum 
A Minimum distance between the back support cushion of a 
seat and the back of the seat or other fixed structure in front 
660mm  
(26 inches) 
B The minimum distance between a seat and the seat or other 
fixed structure in front.  
178mm 
 (7 inches)  
C The minimum vertically projected distance between seat 
rows or between a seat and any fixed structure forward of 
the seat. 
76mm 
 (3 inches) 
(Source: Quigley et al., 2001, p. i). 
Currently the only EASA regulations covering seat spacing is the minimum seat space 
requirements of the UK Civil Aviation Airworthiness Notice 64. 
o Note: UK AN64 is based on data for fifth percentile (%ile) to 95%ile range of 
passengers. The report recommends that the range should be increased to one 
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percentile to 99%ile for safety reasons to allow for the gradual increase in peoples 
sizes. As a result, this study developed minimum recommendations (fifth and 
95%ile) and ideal recommendations (first and 99%ile).  
Section 5.0 Evaluation of AN64 states: 
“In this section the minimum dimensions in AN64 are assessed against the 
anthropometric data for UK, European and world populations. The suitability of these 
dimensions are then tested using a human-modelling CAD system (SAMMIE CAD) and 
recommendations for revisions to the current and newly identified items are developed. 
The results of the assessment were used to develop recommendations for both improving 
and extending AN64 in respect of fit, ease of access / egress, postural flexibility and 
movement, comfort and the potential for alleviating factors associated with Deep Vein 
Thrombosis (DVT). 
As EASA was responsible for undertaking this report to consider forms of alleviating 
factors related to DVT, stakeholders of the aviation industry may be considering the legal 
implications of FRDVT.   
UK AN64 only considers aircraft seats when in the upright position.  
Recommendations, as stated in the report: 
i. Dimension A be increased to at least 711mm 95%ile 
ii. Dimension A be increased ideally to 747mm 99%ile. 
iii. Dimension A is not sufficient to allow taller passengers to adopt the 
„brace‟ position and should be increased to at least 885mm.  The brace 
position is defined as “the upper body should be bent forward as far as 
possible with the chest close to the thighs and knees, with the head 
touching the seat in front” (Quigley et al., 2001, p.41)  
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iv. Dimension A concerned with the minimum seat space a large passenger 
can fit in, does not consider if a seat in front is reclined.  The reclined seat 
may use 15-50 mm of space or more, depending on the type of seat back, 
the amount of rotation and the height from the floor.  So when the seat in 
front is reclined this inhibits the posture of the passenger and may lead to 
the development of DVT due to a restriction of venous flow, as occurred 
in the case of Piet Fourie (Section 1.6.) (Quigley et al., 2001).  
v. Dimension B at armrest level should be increased to between 228.6mm 
and 254mm (nine and ten inches) at armrest level and 211.32mm 
(8.32inches) at cushion level. 
vi. Dimension C would need to be increased from 76.2 – 304.8mm (three to 
twelve inches) to allow a 95%ile passenger to stand without bending. This 
is impractical from an aircraft design point, 
vii. Seventy six point two mm of space hinders the passenger from standing 
upright, with their knees and ankles being forced forward by position of 
the seat cushion and their hips being pushed backwards by the top of the 
seat backs. 
viii. Larger build passengers would even be more off balance when trying to 
access/egress the row of seats. 
ix. A shorter passenger will also experience difficulty as his/her buttocks will 
come into contact with the arm-rests.  If the passenger has a large chest it 
too will be compressed, in this case by the back of the seat in front. 
x. This report recommends the consideration of a flip up seat which would 
increase the amount of space between rows for movement. 
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xi. To allow sufficient foot clearance to access/egress the seat, a figure of at 
least 350mm is needed with the ideal foot clearance of 360mm 
recommended. 
This report has found that the seat base heights are too high for smaller female passengers 
and lowering the seats would cause problems for taller passengers so a foot/leg rest is 
recommended and a Tromped could be incorporated into this footrest.   
 
5.4. Seat design for Tromped Operation 
With the aforementioned seat design parameters in mind primary research on an aircraft 
to facilitate integration of the Tromped into aircraft cabin structure was conducted.  
Dimensions of economy class seats, (their height and width etc) on board a Boeing 757 
were recorded with a spring loaded measuring tape (Figure 5.4).   
i. The height from the floor to the top of the seat cushion was recorded as 457.2mm.   
ii. The width of the first row, which consisted of three seats, was 1447.8mm in total.   
iii. Cushion width 
 The far inner seat had a cushion width of 457.2mm,  
 the middle seat a cushion width of 444.5mm  
 and the aisle seat width of 457.2mm.  
iv. The straight length of the bar under the front row of seats was 1143mm but taking 
in curvature it was approximately 1219.2mm in length.  
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Figure 5.4. Dimensions of the aircraft seats.  
 
This bar was ten mm wide and 26 mm in depth at the outer aisle seat.  However in some 
places, this bar had different dimensions.  For example positioned under the middle and 
inner seat, it increased in size to 20mm width and 30 mm depth.  Facing the back end of 
this aircraft, there were 21 rows of seats on the left side and 20 on the right.  The bar 
under the last eleven rows of seats on the left and ten on the right showed the same 
increase in size to the measurements underneath the middle and inside seat as discussed.  
Due to the positioning of both the seat tracking and seat legs on the Boeing Aircraft a 
swivel type connection will be a necessity, so that the Tromped can be used in the 
available foot space and in the most comfortable position for the passenger. 
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5.5. Design Implications  
The Main factors which influenced the design of the Tromped were: 
i. Commercial practices, i.e. contemplating the most practical way in which a 
commercial product could be implemented into aircraft design.   
ii. Safety, by considering which form would more likely be accepted under the strict 
regulations and requirements of (EASA), CS-25 and the CFR-25 (section 7.2).   
iii. Different markets; different commercial Tromped options i.e. airline installed or 
purchase by individuals for airline or home use, those immobile due to health 
reasons or old age or work environment.   
A schematic outlining the Tromped prototype development process is shown in Figure 
5.5.  One obvious implication for Tromped integration is that the connection method to 
the bar which runs under the seats will have to have two different size fixings.  In order 
for the Tromped to be used by all passengers, (except those seated in the first row of 
seats), it must be attached to the bar under the seat in front of the user.  The design of this 
bar in respect of its positioning and height off the aircraft floor means that it is not 
possible to be attached and stored under the seat where the user would sit, without 
impairing ingress and aggress of that passenger.  The design features of the Tromped 
were incorporated into an aircraft footrest (refer to Section 5.11) an established feature of 
aircraft design. This report recommends that “The upper surface of a footrest (for smaller 
passengers) should be about 350mm (14inches) below the front edge of the seat cushion” 
(Quigley et al., 2001, P.62). 
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Figure 5.5. Schematic of Tromped design progression.  
 
5.5.1. Tromped version 2, Option I 
The aim of the initial “version 2”, prototype design concept was to incorporate the 
Tromped into the aircraft floor frames (Figure 5.6) so that it would be part of the fixtures 
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and fittings of the aircraft.  There is approximately a 508mm gap between two parallel 
frames of seats.  Therefore: 
i. The Tromped with its current dimensions would be cumbersome.  It could 
hamper easy access from the seats, especially in the case of the window 
seat passenger; 
ii. Secure bolts would be required at each end of the connections to secure 
the Tromped to the frame of the seat and it would be difficult to secure 
two such bolts on one frame;  
iii. The length of the carpet panels may not be long enough to allow for two 
or three devices of this size; 
iv. In the event of a crash, the structure of the Tromped attachment may be 
forced upwards through the floor adding to the potential for serious harm 
to passengers.  
 
Source: Boeing.com 
Figure 5.6 Aircraft seats attached to the floor seat tracking 
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5.5.2 Tromped version 2, Option II 
The second option considered was that the Tromped be permanently fixed to the bar, 
which runs the length of the seats.  The user would pull the Tromped (Figure 5.7) out 
from under the seat in front of them and fold out the pedals, which would be designed to 
fold back, when not in use.  After use the Tromped would be pushed back under the seat.  
A special hinge on the connecting bar between the Tromped and the seat would have to 
be incorporated into this design reducing mobility, both during storage and use.  One 
possible type of connection between the rail under the seats and the tromped could be an 
R-A-M Strap-On Rail Mounting Ball, which fits all sizes of 19.05mm to 50.8mm round 
rails.  This design is preferable to Option I, as it can be stored under the seat, not 
hampering access in and out of the seats.  This design format would comply with the 
Ergonomics Report (Quigley et al., 2001).  Option II would be marketed to the airlines 
themselves to purchase and supply to passengers. 
 
 
 
Figure 5.7. Diagram of design Option I and II. 
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5.5.3 Tromped version 2, Option III 
Option III considered the Tromped as a stand alone product available for use on aircraft.  
It could be stored i.e. in an overhead bin for example.  It was designed in such a way that 
the pedals and their corresponding bases would fold over so that the width will halve in 
size. The problem with this design was that there would be a piece of material (the bar 
which connects the two pedals) overhanging (refer to Figure 5.8). 
The third design was least favoured for this research. 
 
Figure 5.8. Diagram of Tromped design Option III. 
 
5.5.4 Tromped Version 2, Option IV 
The fourth concept or design was one of a slipper or shoe.  The toe of this shoe 
permanently positioned at a higher angle than the heel, due to the spring positioned 
beneath the toe area (refer to Figure 5.9).  The user would slip his/her foot into the shoe 
and press down with the ball of the foot.  The base of the shoe could be manufactured 
from rubber and the shoe itself from a material such as polyester.  Option IV could be 
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stored in an overhead cabin and be marketed by the airline companies.  This option could 
also be offered to the individual traveller who could carry it on board the aircraft and 
store it in hand luggage when not in operation.  
 
 
Figure 5.9. Diagram of Tromped design Option IV. 
 
5.5.5. Summary 
Tromped design version 2, (Figure 5.7) was considered for use in Option I and Option II.  
The difference between the two was the method of incorporation into the aircraft fixtures 
and fittings.  Option I was to be incorporated into the seat tracking of the floor, with 
Option II being attached to the bar which runs under the seats.  Design Option III (Figure 
5.8) and IV, the Tromped shoe, (Figure 5.9) were designed to be stored in the overhead 
bins of the aircraft when not in use.  It was decided, that the Tromped Option II, be 
manufactured in prototype form.  Further haemodynamic assessments using the Air 
Plethysmograph with another group of ten healthy volunteers would be conducted.   
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5.6. Manufacture of the second prototype  
A streamlined, light weight version of option II was produced.  The shape of both the 
pedal and the base were modelled on the shape similar to that of a shoe.  This reduced the 
amount of material used so that the finished prototype was both compact and light. 
The second Tromped prototypes were designed in 3D and then machined by the 
Computer Numerical Control (CNC) system.  This is “…the automated control of 
machine tools by a computer and computer program.” (Mattson, 2002, p.2).  A CNC 
Vertical Milling machine was used to produce the undersides of the two bases and two 
pedals after input of a set of instructions into the CNC machine.  These instructions were 
in the form of Numerical symbols (which represented the dimensions of Demonstrator A 
(DA) and Demonstrator B (DB), the types of tools required to manufacture the devices 
and choice of coolant (Thyer, 1991; Mattson, 2002).  
Two prototypes of differing shoe lengths were designed, to be tested using springs of the 
same compression value (Figures 5.10 and 5.11).  The two prototypes were labelled DA 
and DB.  DA had the larger dimensions of the two demonstrators.  Both demonstrator 
base A and B were made from standard aluminium alloy sections of depth 20mm, width 
100mm and length of 600mm.  The Tromped pedal bases were made from standard 
aluminium sections of depth 10mm, width 100mm and length 600mm.  The upper plates 
of both bases A and B and upper plates of pedals A and B were cut out from 3mm deep 
sheets of Aluminium T4 2024.  Sixteen wedges were made from these sheets of 
aluminium T4 2024 and a hole was drilled in each angle which coincided with the holes 
drilled in the bases of the two Tromped bases and the two pedal bases.  The bases of the 
Tromped demonstrators were jointed to their upper sides and the pedal bases to the upper 
sides with self tapping screws.  The base and pedal were joined by means of a flap hinge 
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at the rear end and by the spring at the front edge.  Finally a slip proof material (with a 
sticky underside) was cut out in the shape of the pedals and stuck to their surfaces.  
 
Figure 5.10. Prototype DA and DB.  
 
Figure 5.11. Side view of Prototype DA 
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The demonstrators each consisted of one pedal and base so that it and the spring could be 
assessed.  DA was 242mm long and 100mm at its widest part. The pedal of DA was 
230mm long by 80mm wide.  DB was 220mm long and 90mm at its widest part.  The 
pedal of DB was 205.5mm long by 85mm wide.  As the revised design (Version 2) is 
smaller in length than the first prototype demonstrator (Version 1), this necessitated a 
different spring position.  The demonstrators of differing dimensions were produced and 
fitted with one spring each with the same characteristics, to determine if a smaller pedal 
would have any implications on the EVF and RVF produced.  Both springs were 
positioned 30 mm away from the front edge of the base and pedal.  The correct spring 
characteristics for DA and DB were then determined (section 4.7.3).  
 
5.7. Springs 
A spring is defined as an “elastic body which has the primary function to deflect or 
distort under load, and to return to its original shape when the load is removed.”  (SAE, 
1996, p. 131).  
 
5.7.1. Air Springs 
Air Springs consist of a contained column of air placed inside an elastomeric bellows or a 
sleeve.  The sleeve or bellows buffer the cyclic motion and provide isolation against 
vibration.  Air springs can be used as primary suspension springs or as a secondary 
component inside a coil spring.  
Advantages of Air Springs over air cylinders or other types of springs: 
i. Lower cost than a pneumatic cylinder with the same or nearly the same 
capabilities 
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ii. more compact as the minimum height is generally less than the available 
stroke 
iii. Air Springs lack seals or guides and as a result they can be installed more 
easily than other springs 
iv. No form of lubrication is required and so it is a clean operating system with 
little maintenance required 
v. As air springs are designed without seals, there is less friction generated than 
other forms of springs  
vi. An air spring can survive abrasive and corrosive environments better than 
other springs which require some form of sealing  
(“About Air Springs” 28/01/04).  
 
5.7.1.1. Air Spring limitations 
During flight there is a reduced barometric pressure experienced within the interior of the 
aircraft cabin as previously described (section 3.16).  As an aircraft takes off the cabin air 
pressure decreases, resulting in the expansion of gases, which could have extreme effects 
upon air springs.  Gases can expand as much as 35 percent within a pressurised aircraft 
cabin of interior altitude of 2438m (Hinninghofen and Enck, 2006).  When the aircraft 
descends for landing, the cabin air pressure increases so gases will contract (WHO, 
2005).  Thus, for these reasons air springs were not considered.    
 
5.7.2. Disc Springs 
Disc Springs (Beleville Washers) can be made from pretempered material.  “They can 
support heavy loads with small deflections” (Carlson, 1980, p. 121).  Belville springs 
were considered for use in the Tromped Footrest, as the spring parameters (free length, 
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101.6mm) of DA could not be suitable due to the smaller size of the footrest prototypes 
(dimensions 145mm ×110mm).  DAs pedal was 232mm long compared to 90mm of the 
Tromped footrest pedal. 
Disc springs were investigated for their viability. Eventually which disc spring would 
produce the required load was determined.  The parameters of a Disc Spring are 
explained below (SAE, 1996, p. 325): 
C = Spring Rate, N/mm                                         D = diameter, mm 
E = modulus of Elasticity N/mm
2  
                        F = Force/Load (N) 
H = Dish free height, mm                                      L = overall height = T+H, mm 
N = number of Load Cycles,                                n = number of disk springs in parallel 
I = number of disk springs in series                   R = diameter ratio 
I
e
D
D
                        
T = material thickness                                        W = Energy Storage Capacity 
S = Deflection, mm 
 
A Disc spring of De = 0 6mm, DI =3.2mm, T = 0.30mm, Cone Height = 0.15mm, Total 
Height = 0.45mm, would create a force of 119N if 75 per cent deflection was chosen. An 
order for 18 of these springs was made, however the smallest order which would be 
accepted was for 100 of these springs.  Upon procurement, it was obvious that these 
springs were too small to be attached to a pedal which was designed to compress a 
spring.  The sophisticated set up of Disc Springs in series or parallel, within a cylinder 
and tests to determine their feasibility would have provided no gain in FRDVT 
knowledge.  Therefore it was decided that another form of spring or a different 
compression spring was the only viable option.  Advice was given from a spring 
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manufacturer to continue using a compression spring of a shorter height for the Footrest 
Tromped.   
 
5.7.3. Compression Springs 
Four different Stainless Steel compression springs were procured (refer to Table 5.4).  
Six springs with the same physical characteristics were procured and one supplied to 
Lufthansa Technik for testing.  A Chatillion Digital Force Gauge recorded a force of 
94.31 N to deflect the spring by a height of 63.39 mm.  This differs from the spring used 
in D3 (Table 5.1), which required a force of 80.97N.  Two possible reasons for this 
difference in compression may exist.  Firstly, theoretical equations to determine the 
deflection height mathematically were conducted.  Secondly a certain degree of use or 
wear and tear may have affected the original spring compression value.  It is important to 
note that the original spring may have been used in an aircraft engine prior to use in the 
Tromped.  Provided it was previously used in its elastic range, this would have no 
bearing on performance. 
Compression Springs made from round wire are the easiest spring to design and produce.  
They are reliable, and have high fatigue properties.  As compression springs have an 
automatic stop, once they are fully compressed, this prevents over-deflection, limiting 
stress levels (Carlson, 1980).  Different spring materials are used in different 
environments such as high or low temperatures, vibration, shock loading, high endurance, 
nonmagnetic capabilities, low hysteresis and a variety of corrosive surroundings 
(Carlson, 1980). 
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5.8. Footrest Tromped prototype  
Although Tromped version 2, option II, was produced and favourably assessed 
replicating normal venous haemodynamics in the seated position (Sections 6.2 and 7.2), 
the design was considered too cumbersome for use on board aircraft.  Therefore this 
option was discounted on the basis of its size related to the bar running beneath the seats.  
The three seats joined together have a combined width of approximately 1447.8mm.  
However the bar, which runs underneath the three seats, is only 1219.2mm in length, 
ending midway of the inner seat, so that it is not long enough to reach the aircraft frame.  
This bar has two different dimensions varying in thickness, which seems to depend on 
which seat it is situated under and at which end of the aircraft it is placed. The slimmer 
bar has dimensions of 10 mm in width and 26mm in depth while the thicker bar has 
dimensions of 20mm wide, 30 mm deep.  
A disadvantage of this design option was the design features of the connecting bar from 
the Tromped to the seat cannot be standardised.  Also the floor width of the aisle seat is 
smaller in size compared to the middle and window seat and so the aircraft seat legs 
could also be a factor in determining the actual size of the exercise machine.   For these 
reasons, option II was not considered viable for use on board an aircraft and further 
thought was expanded into making the Tromped aircraft friendly.  
Upon acquisition, it was evident that the free length of the compression springs 
(101.6mm) used in the first two Tromped prototypes (Figure 5.7) would not be feasible 
for the third design (Figure 5.8).  Thus four springs of smaller dimensions, (Table 5.5) 
were chosen and sourced.  
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Table 5.5. Compression spring parameters used in the Footrest Haemodynamic 
Assessment.  
 
Wire 
diameter 
(mm) 
Outside 
diameter 
(mm) 
Free 
Length 
(mm) 
Minimum 
Working 
Length 
(mm) 
Approx. No. 
of working 
coils 
Load at 
minimum 
working length 
(N) 
Rate 
(N/mm) 
1.6 11.6 27.0 13.2 5.5 141.32 10.13 
1.6 14.1 36.0 14.1 5.5 112.73 5.19 
1.6 14.1 53.5 20.1 8.5 112.73 3.37 
2.0 22.0 41.0 13.6 3.5 132.34 4.85 
 Source, SpringMasters® Spring Directory. 
 
5.9. Material selected to manufacture the Tromped Footrest 
For the final Tromped prototype, various materials were investigated to determine which 
would be best suited for operation in an aircraft environment.  Therefore materials which 
are currently used in the manufacture of aircraft were investigated.  
Acrylonitrile Butadiene Styrene (ABS) material was chosen to produce the Tromped 
footrest prototypes.  Acrylonitrile imparts chemical resistance and rigidity, Butadiene 
ensures the product has impact strength, toughness and is resistant to abrasion, while 
Styrene contributes to easy processing.  Given this balance of properties, ABS 
copolymers are used increasingly for the manufacture and production of many industrial 
and domestic products. 
ABS is a ductile thermoplastic material, which has the advantage of high impact strength 
when compared to other thermoplastics, especially in low temperature conditions.  One of 
the material‟s unique properties is its ability to retain high levels of impact strength at sub 
zero temperatures.  The material exhibits, toughness, resilience, high impact strength, 
good chemical resistance, non toxicity and it is taint free.  
Thermal expansion of ABS is 10.1 × 10‾⁵ m/m °C.  All thermoplastics expand at a 
greater rate than metals.  So at the design stage allowance must be made for this.  The 
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working temperature range of ABS is -40°C to +70°C. So, with an increase in 
temperature, the rigidity of the material will decrease (ABS Material), 
http://www.eurapipe.com.au/cd/Eurapipe/Material_page1_files/image002.gif    
 
5.10. Manufacturing of the Tromped Footrest 
An aircraft footrest (Figure 6.12) was obtained prior to design of the Tromped footrest. 
Elements such as its size, shape and material type were noted and it was decided to use 
ABS material for the production of the Tromped footrest.   
 
 
Figure 5.12. The aircraft footrest. 
ABS was acquired in sheet form (material measurements 20mm × 610mm × 1220mm). 
This sheet of material was used to produce the Tromped footrest prototypes, generated 
from the AutoCAD diagram of the Tromped Footrest (Appendix D).  The underside of 
both the base and pedals were made separately and had a depth of six mm.  The 
dimensions of the upperside of the base were 290 × 110 × 20 mm.  The upperside base 
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was hollowed out to reduce the weight of the base and a centre web of thirteen mm width 
was incorporated into the design, for two reasons.  Firstly, the APG® assesses blood flow 
in one leg at a time, thus the need for one foot pedal.  Secondly, the centre web would 
help keep the centre bar in line with the screws, by cutting a hollow in it. Refer to Figure 
5.13. to view the hollowed out prototype.  So the Tromped footrest was cut in half, along 
the centre web, creating two prototype bases.  The dimensions of the footrest prototypes 
then became 145mm × 110 × 20 mm.  
 
 
Figure 5.13. The upperside of the hollowed out Footrest prototype.  
 
The design specifications of the Tromped footrest (295 ×115), automatically limited the 
size of the pedals (90mm × 90mm).  This meant that only the ball of the foot would 
actually compress the pedal (not the heel) unlike the previous two assessments where the 
foot as a whole was used.  As this was the case, the Tromped footrest pedal was not 
designed to replicate the shape of a foot.  Each of the four springs (of different 
dimensions) were wire locked onto four different aluminium plates of dimension 50 × 
50mm (Figure 5.14).  It then became apparent that two of these springs would have to be 
attached to the underside of the base.  As the free length of both these springs (53.5mm 
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and 41mm) were too long to be attached to the upperside of the base and remain in line 
with the footrest pedal.  
Thus the position of these two springs and their mats was determined.  The spring of free 
length 41mm, outside diameter 22 mm was placed on the underside of Prototype I.  The 
“would be” height of the pedal was then determined with the spring positioned at 
different points on the underside of the base.  It was decided that the front edge of this 
spring (free length 41mm) be positioned 20 mm from the outside front edge of the 
prototype.  To make this possible a square of dimension 50mm × 50mm was cut out of 
the upperside of the base.  Clearance of five mm completely around the spring was cut 
out of the upperbase so the spring would not foul it.  
   
 
Figure 5.14 Springs wirelocked onto their mats. 
 
The spring of free length 53.5 mm and outside diameter of 14.1 mm also had to be 
attached to the underside of the base.  As this spring had a smaller outside diameter to 
that previously discussed, the aluminium base plate was reduced in dimension from 
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50mm × 50mm × 1.5mm to 30mm × 50mm × 1.5mm.  Then the spring was positioned 
15mm from the outside front edge of the prototype II.  The remaining two springs had 
free lengths of 27 and 36mm respectively, which did not hamper the compression of the 
foot pedal, when attached to the upperside of prototypes III and IV.  
Two test rigs were designed and produced, to contain two of the footrest prototypes 
(Figure 5.15).  As the dimensions of the assessment room were unknown at the time, this 
seemed a practical option as a bed, aircraft seats and the APG® equipment were to be 
stored together with the Tromped Footrest rig, some room for manoeuvre would be 
required.  
 
 
Figure 5.15. Footrest Test Rig Dimensions. 
 
The aircraft footrest (Figure 5.12) had a solid bar running through its centre, which was 
attached at each end to supportive bars. This design permits the footrest to pivot and the 
actual device to be moved underneath the seat when not in use. It was decided for the 
purposes of the medical Footrest assessment (which replicated the seating arrangements 
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on board a commercial aircraft) it was sensible to achieve this pivot with the Footrest 
prototypes.  
Bars of two differing dimensions were required, to replicate the design of the footrest. 
Mild steel bars to the following specifications were used: 
i. [6mm × 200mm] ×4 
ii. [20mm × 4mm × 250mm]  × 8.  
The centre bar produced had the dimensions 6mm × 157mm. These were then threaded. 
The side bars of the Tromped footrest machined had dimensions of 20mm × 4mm × 
250mm.  The side bar, when inserted onto the centre bar of the rig, the footrest swung 
constantly on the test jig, hampering test results due to the sensitivity of the APG®. 
Smaller clearances eliminated this problem. 
It was decided that the Tromped footrest, be designed so that it would constantly be at an 
angle of 60° to the vertical, for ease of use.  This choice of inclination was reached after 
assessing the combined effect of spring free height with perceived passenger comfort and 
ease of operation.  So an angle bar was cut and then welded onto the side bar of the 
footrest and then screwed into the footrest base.  Spacers were attached to the spring 
plates to ensure that they would remain level once attached to the footrest base.  The 
upper and undersides of the Footrest bases were attached by two five mm countersunk 
nylock nuts. The base and pedal were attached at one end by a hinge and the other by 
wire locking the spring to the underside of the pedal, as shown in Figure 5.16.  An 
AutoCAD version of the Tromped Footrest is shown in Figure 5.17. 
Following the final assessment Footrest 1 and 2 were detached from the test rig to 
determine their individual weight. Both footrests were sent to Lufthansa Technik 
Aermotive Ireland and weighed using an Adventurer Ohaus Weighing Machine.  The 
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weight of Footrest 1 and Footrest 2 (when detached from their side bars) were determined 
as 0.459kg and 0.4428kg respectively.  
As previously determined (section 5.4) a Boeing 757 can have 41 rows of seats. Thus the 
additional weight of the spring and pedal to the aircraft is 36.97kgs.  
  
 
Figure 5.16. Tromped Footrest and Rig  
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Figure 5.17. The Tromped Footrest 
 
 
5.10.1. Reasons for integrating the Tromped into the aircraft footrest 
In conclusion, there were five reasons for integrating this device into a footrest: 
i. Not to hamper foot space as this could hinder evacuation time and safety 
of passengers (section 5.13).  
ii. Integration into a standard piece of equipment, previously approved by 
EASA CS-25 and CFR-25 (which are discussed in the following sections). 
iii. Two springs and two foot pedals of a light weight material, added to each 
footrest, should not significantly affect the aircraft gross take-off weight 
(AGTW). 
iv. The user would be required to place the ball of the foot on the pedals, with 
the arch of the foot resting on the bottom edge of the footrest.  The 
movement then produced by compressing the footrest pedal should 
increase the plantar flexing of the foot, which empties the proximal calf 
pump into the popliteal and femoral veins (Gardner and Fox, 1989) in 
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comparison to when the whole foot is placed flatly on either of the first 
two prototype designs.  Venous return can be increased by the flattening 
of the plantar arch, which results in the “lengthening of the venae 
commitantes of the lateral plantar arch” (Sochart and Hardinge, 1999, 
p.703). 
v. For smaller passengers whose legs are too short to reach the ground, it will 
alleviate the unwanted pressure which is exerted on the back of the knees 
(Quigley et al., 2001, p.20).  
 
5.11. Definition of a Medical Device  
Prior to assessment of the Tromped and Mediven Travel Stocking Experiment, an 
application to the Medical Ethics Committee in Beaumont Hospital (site of initial 
assessment of the Tromped DA) was made.  This highlighted the need for classification 
of the Tromped.  Recommendations by the committee (Appendix E) were made to 
contact the Irish Medicine Board (IMB).  The assessment protocol, specifications and 
photographs of the Tromped prototype TJA, were sent to a Doctor Niall MacAleenan, the 
medical assessor of the Medical Devices Department of the IMB.  He ruled that the 
Tromped would be classified as a medical device “as its intended use includes medical 
claims” (Appendix F) and that the Medical Devices Directive (93/42/EEC) and the 
Statutory Instrument SI 252 of 1994 (Annex I) of the European Communities (Medical 
Devices) Regulations 1994, be referred to and used as a template to conduct the research.  
A medical device is defined by the Council Directive (93/42/EEC) concerning medical 
devices as “…any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, including the software necessary for its proper application 
intended by the manufacturer to be used for human beings for the purpose of: 
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i. diagnosis, prevention, monitoring, treatment or alleviation of disease, 
ii.  diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap,  
iii.  Investigation, replacement or modification of the anatomy or of a physiological 
process, (93/42/EEC, Article 1, p.4.).  
As the Tromped is aimed at the prevention of a disease i.e. FRDVT by replacing a 
physiological process i.e. venous return it would appear to be a medical device by 
definition.   
Doctor MacAleenan‟s ruling concluded that as the development of the Tromped (in its 
current state) is for the purpose of a PhD thesis rather than commercialisation, this 
research be classified as non-commercial clinical research of a non-CE marked device 
and so therefore no further applications to the IMB would be required.  If patents are 
sought in the future, the European Communities (Medical Devices) Regulations 1994 will 
be consulted. 
The final prototype, the Tromped Footrest is designed so that it can be incorporated into 
an aircraft.  This too will be classed in the same manner as a medical device for the 
purpose of the Tromped Footrest experiment (Chapter 8).  
 
5.12. Medical Regulations and Aviation Requirements governing the “commercial” 
Tromped 
Article 2 of the Council Directive 93/42/EEC of 14 June 1993 concerning medical 
devices, refers to entering the medical device into the market for which it is intended (p5 
of 37).  It basically states that no member state of the EU should act to prevent this 
occurring, once use of the device will not affect the health of patients or their safety. The 
device must be properly installed, maintained and used in the manner for which it is 
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designed.  The Tromped footrest prototype was intended for use on board commercial 
passenger aircraft.  Therefore EASA‟s, Certification Specifications for Large Aeroplanes, 
CS-25, and the FAA‟s, Code of Federal Regulations (CFR) Part - 25, are all applicable in 
terms of installation and use of the Tromped, in compliance with large aircraft 
requirements.  
EASA, CS-25.625 and  CFR-25.625, Fitting factors (d), For each seat, berth, safety belt 
and harness the fitting factor in CS 25.785 (f)(3) apply plus AMC 25.561 (c) for the 
strength requirements of local attachments of each seat to the structure. 
CFR-25.785 is consistent with CS 25.785 (b), which states: “Each seat, berth, safety belt, 
harness, and adjacent part of the aeroplane at each station designated as occupiable 
during take-off and landing must be designed so that a person making proper use of these 
facilities will not suffer serious injury in an emergency landing as a result of the inertia 
forces specified in CS 25.561 and CS 25.562”.  
  
5.13. Application to the Tromped Design  
EASA CS-25.561 is concerned with emergency landing conditions of an aircraft.  If the 
aeroplane is damaged in emergency landing conditions on land or water, it is essential 
that the design protect each occupant under the following conditions. 
The structure must give each occupant every reasonable chance of escaping serious injury 
when proper use is made of seats, belts, and all other safety design provisions.  
Equipment, cargo in the passenger compartments and any other large masses, must be 
positioned so that if they break loose they will be unlikely to: 
i. Cause direct injury to occupants; 
ii. Penetrate fuel tanks or lines or cause fire or explosion hazard by  damage to 
adjacent systems; or 
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iii. Nullify any of the escape facilities provided for use after an emergency 
landing. 
             When such positioning is not practical (e.g. fuselage mounted engines or auxiliary power 
units) each such item of mass must be restrained under all loads up to those specified in 
subparagraph (b) (3) of this paragraph, which states that the local attachments for these 
items should be designed to withstand 1·33 times the specified loads if these items are 
subject to severe wear and tear through frequent removal (e.g. quick change interior 
items). 
Also seats and items of mass (and their supporting structure) must not deform in any 
manner that would impede subsequent rapid evacuation of occupants (See IAMC 
25.561(d). 
EASA CS-25.562 is concerned with dynamic conditions during emergency landing.  
Part (b) states: With the exception of flight deck crew seats, each seat type design 
approved for occupancy must successfully complete dynamic tests or be demonstrated by 
rational analysis based on dynamic tests of a similar type seat, in accordance with each of 
the following emergency landing conditions.  The tests must be conducted with an 
occupant simulated by a 77kg (170 lb) anthropomorphic, test dummy sitting in the 
normal upright position. 
 
5.14. Annex 1 the Council Directive 93/42/EEC 
 
5.14.1. General Requirements 1 of Annex I  
Essential requirements I. General Requirements I, of Annex I, of the Council Directive 
93/42/EEC of 14 June 1993 concerning medical devices, stipulates that a device “…when 
used under the conditions and for the purposes intended…” will not affect the safety of 
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its users, and if there are any risks these must be offset against the advantages of its use to 
the users (in this case airline passengers).  It is required, whether there are inherent risks 
involved, and that the device must have a “high level of protection of health and safety” 
(93/42/EEC, Annex 1, p.14). 
Section 2 states that manufacturers of the said device must ensure that they achieve the 
subsequent stipulations in the following order: 
i. Eliminate or reduce potential risks as much as possible by ensuring a   safe 
design and a safe production process); 
ii. Ensure sufficient protection measures are incorporated to raise an alarm or 
highlight the risks (if any) that cannot be eliminated during use; 
iii. Those users are notified of any outstanding risks due to any shortcomings 
of the protection methods incorporated into the design. 
 
Section 3 points out that the devices design, production and packaging, must be proven to 
live up to the standards and performance levels as set out by the manufacturers Medical 
Devices Directive (93/42/EEC).  Section 4 of Annex I is concerned with any stresses 
which can occur during the normal use of the device for which it is designed, inflicting 
injury or affecting the user or any person in its presence during its use.  Section 5 of 
Annex I relates to the transport and storage of the medical device.  It requires that devices 
“characteristics and performances” during its use will not be adversely affected.  This 
requirement would apply firstly to the transport of the Tromped from its place of 
production to the aircraft intending to provide this device.  Secondly, it would also apply 
to when the Footrest Tromped would be integrated into the aircraft seats, under which it 
is designed to be stored, when not in use by passengers. 
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Section 6 of Annex I is similar to general requirements section 1, where it states that any 
“undesirable” side-effect of the device during use be weighed against its purpose.  In the 
case of the Tromped, its purpose is to recreate the physiological process of ambulation in 
the seated position and the possibility of it causing harm is negligible during proper use. 
 
5.14.2. Part II, Requirements regarding Design and Construction   
This section is concerned with the chemical, physical and biological properties of the 
medical device. 
Section 7.1., Part II of Annex I, requires that specific attention be spent on: 
i. The type of materials chosen, especially if they have toxic or flammable 
properties.   
ii. Ensuring that the medical device‟s materials are compatible with 
biological tissues, cells and body fluids, if its intended use means the 
device will come in contact with any of the above mentioned.  As it was 
used external to the body, the Tromped Footrest is designed to be used by 
passengers while wearing footwear.  If a passenger were to remove his/her 
shoes and/or stockings, contact with the ABS material, would not provide 
any health problems.  
 
Section 7.2. of the Medical Devices Directive (93/42/EEC) requires that the risk of 
contaminants or residues being passed onto any person required to transport, store or use 
the device, be minimized through its design, manufacture and package procedures.  
With ABS there is no risk of any toxic metal substances and it is also taint free 
(http://www.eurapipe.com .   Section, 7.3., states “The devices must be designed and 
manufactured in such a way that they can be used safely with the materials, substances 
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and gases with which they enter into contact during their normal use or during routine 
procedures...” (93/42/EEC, Annex I, p. 15).  The Tromped footrest would be located in a 
pressurised aircraft cabin, replicating an altitude between 1,524m and 1829m (5-6000ft) 
during flight (Bagshaw, 1996). Hence ABS would not react negatively to oxygen, carbon 
dioxide or nitrogen.  Section 7.5 of Annex I stipulates a medical device must be designed 
and produced so that a risk of any substance leaking from the medical device is kept to a 
minimum.  It is a recommendation of section 7.6 that, if a risk is apparent that a substance 
could interfere negatively with the device once placed in its intended environment, this 
risk must be eliminated as much as possible.   A spring shield could be placed around the 
springs, so that nothing could become lodged in either the springs or under the pedals, 
hindering its efficiency and/or life span.  Section 8, is concerned with Infection and 
microbial contamination.  Part one of section 8, states that the design and production of 
the device must ensure that the risk of infection to the patient, user and/or third parties be 
eliminated or reduced as much as possible.  The medical device should allow ease of 
handling and minimise risk of contamination by the patient or vice versa.  The ABS 
Tromped Footrest would not have a higher chance of being contaminated than the other 
materials used on board an aircraft.  Also passengers wearing shoes during its use would 
reduce the risk of cross contamination. 
Section 9 is concerned with construction and environmental properties i.e. the operation 
of the device in the environment for which it is intended for use.  If the device is designed 
in such a way that the use of other devices or equipment in conjunction with the medical 
device is required then any connections between the devices must be safe and not impair 
the efficient operation of the combined devices.  If there are any restrictions these must 
be clearly visible on the label and in the instruction booklet. 
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The Tromped was integrated into a standard piece of aircraft furniture.  Its design is 
modelled on a Boeing 757 footrest, (Figure 5.12). 
Section 9.2 requires that: 
i. “the risk of injury, in connection with their physical features, including the 
volume/pressure ratio, dimensional and where appropriate ergonomic 
features” be reduced or minimised. 
ii. If a risk of a magnetic field, electrical fields, electrostatic discharge, 
temperature or any variations in pressure or acceleration exist, these must 
be reduced if possible. 
The Tromped was ergonomically designed to minimise risk of injury to aircraft 
passengers. The Anthropometric study (2001, p. 63) states “the design of any footrest 
device might usefully incorporate a capability for a rocking motion…This would allow 
the passenger to undertake optional and short periods of limited leg muscle „exercise‟, 
which might improve circulation and help to minimise factors causing DVT‟s.  The study 
also recommends that the footrest be moved under the seat not to hamper access or 
egress.  Section 9.3. relates to the design and manufacture of a device, which minimises 
the risk if any, of a fire or explosion occurring whilst in use.   
Section 10 of Annex 1, “requirements for devices with a measuring function” also applies 
to the Tromped footrest, as a counter device to record the number of pedal compressions 
would have been incorporated into its design, if proven to be efficient at creating 
substantial venous return.  Part one of this section, imposes a requirement that devices 
with a measuring function, or in the Tromped‟s case a measuring unit, will provide 
accuracy and any limits of accuracy must be stated by the producer of the medical device.  
Section 10.2 states that the “measurement, monitoring and display scale must be designed 
in line with ergonomic principles, taking account of the intended purpose of the device” 
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(93/42/EEC, Annex I, p. 16).  If the footrest prototypes were as effective as DA when 
used on a level examination couch then a recommendation of at least 10 compressions of 
the Tromped Footrest pedals, every half hour, to be recorded on the counter, so that adult 
passengers could calculate the preferred number of compressions, to prevent venous 
stasis could be made, as six plantar flexions is sufficient to ensure venous emptying 
(Needham, 2005).  Subsequent testing involving springs of differing resistance is 
required before this recommendation could be made.  
Any measurements made or recorded by a measuring device, must be expressed in legal 
SI units, according to section 10.3 of Requirements regarding design and construction, 
Annex II of Council Directive 93/42/EEC, which conform to the provisions of Council 
Directive 80/181/EEC.  
Section, 12, entitled “Requirements for medical devices connected to or equipped with an 
energy source” is not applicable.  The Footrest Tromped will not be powered by any 
electronic, internal or external source during use, solely by passenger feet.  Protection 
against mechanical and thermal risks, Section 12.7., is applicable to the Tromped Footrest 
medical device.  The device was designed and manufactured so that the user would be 
protected from resistance and in stability of the device, also taking into account any 
moving parts, which in the Trompeds case include the spring and foot pedal.  Section 
12.7.2. requires that both the design and manufacture of the medical device must ensure 
that a risk of vibration through product use, (unless vibrations are “part of the specified 
performance”) be minimised (Medical Devices Directive (93/42/EEC, p.18).  Use of the 
Tromped does not create vibrations of any kind.  Section 12.7.3. requires that the device 
emits low noise levels, the Tromped will not create noise during its use.  Section 12.9 
requires that any operating instructions provided on the device must be understandable to 
the user and/or patient.  All participants of the Tromped Medical assessments were given 
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guidelines on how to use the device prior to the experiments taking place.  As at this 
time, the device is not planned for commercialisation and so Section 13 information 
supplied by the manufacturer, is not applicable to this research.  
 
5.14.2.1. The Tromped Material 
If the commercial footrest Tromped was undergoing certification for approval under CS-
25 it would have to undergo dynamic testing or be demonstrated “by rational analysis” to 
be safe under emergency landing conditions.  
The Tromped footrest is manufactured from ABS material, has a spring which is wire 
locked to the pedal and so will not be the source of any fire while in use.  ABS material is 
not toxic and has good chemical resistance (www.eurapipe.com).  The Tromped Footrest 
was designed with ABS material to ensure minimum weight properties.  Also the 
material‟s safety and rigid thermoplastic properties were considered, with airline 
passengers in mind.  
 
5.14.2.2. The Tromped Spring  
When not in use, generally aircraft footrests are pushed back under the seats in front of 
the user, so they do not hamper ingress or egress of passengers.  Similar requirements 
would be necessary for the Tromped Footrest when not in use plus a bell like covering 
would be required to cover the spring to the underside of the pedal preventing access.  
The Tromped Footrest cannot through normal use affect the safety of airline passengers. 
As previously stated a shield could be used to prevent fingers or clothing becoming stuck 
within the spring.  
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5.14.2.3. Footrest Attachment  
Possibly through constant use the bolts and screws which maintain the Tromped footrest 
in one piece may exhibit loosening.  If the Tromped footrest had been proven successful 
at recreating normal venous haemodynamics in the seated position in all groups of 
participants, long-term testing on both the springs and the device would have been 
conducted.  
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CHAPTER 6  
HAEMODYNAMIC ASSESSMENT I 
 
6.0 Introduction 
This assessment was conducted to determine the haemodynamic efficiency of two 
prototype designs when used in the seated position.  Both of these prototypes were 
developed with the ultimate aim of preventing venous stasis during flight.  Hypothesis: to 
determine if Demonstrators A and B (of differing lengths) achieve adequate venous 
emptying.  
 
6.1. Air Plethysmography 
Once the volunteer stands up and maintains the limb in one position without any muscle 
contraction, “…arterial inflow to the limb will steadily fill the veins to maximal capacity 
at full venous pressure to form a continuous column of blood from the foot up to the level 
of the heart” (Tibbs, 1992, p.4). 
Air Plethysmography, as previously stated in section 4.5.1, is used to determine EVFs 
and RVFs, both of which are sensitive indicators of the venous pump function 
(Nicolaides and Sumner, 1991), with the RVF correlating closely with ambulatory 
venous pressure measurements (Christopoulos and Nicolaides, 1994).  In diseased limbs 
ambulatory venous pressure remains high as the calf muscle pump function inadequately 
functions in conjunction with the occurrence of reflux due to valveless deep veins (Tibbs, 
1992).  The ratios VFI, EVF and the RVF are all reproducible units irrespective of the 
fact that the venous volume (VV) may vary day to day as it is dependent on venous tone, 
which is itself variable.  Therefore, Air Plethysmography is an ideal test to determine the 
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effectiveness of the Tromped compression values, constantly producing both a sufficient 
EVF and RVF (Nicolaides & Sumner, 1991).  
Table 6.1. APG Assessments abbreviations key 
VV Venous Volume  
90%VV  Ninety percent of the venous volume + 
VFT Venous Filling Time + 
VFI Venous Filling Index - 
EV Ejection Volume + 
EVF Ejection Volume Fraction - 
RV Residual Volume  + 
RVF Residual Volume Fraction - 
TT Tiptoe  
DA, DB Demonstrator A, Demonstrator B  
W Walking  
+ Measured from APG tracing  
- Calculated derived values  
 
6.2. Haemodynamic Assessment I 
 
6.2.1. Patients 
Ten healthy volunteers recruited by advertisement posters displayed on DIT notice 
boards, in Bolton Street, February and March of 2005.  All healthy males and females 
between the age of 20 to 70 were eligible.  Exclusion criteria included varicose veins or 
previous surgery, previous DVT and/or recent immobilization including travel of greater 
than four hours, within previous six weeks. 
Five males and five females participated. Ages ranged from 20-68 years.  Mean age was 
38.7 +/-14.8.  The procedure was explained and written informed consent was obtained. 
 
6.2.2. Location 
The experiment was conducted in a temperature controlled room of 20º Centigrade in the 
Non-Invasive Vascular Unit, Beaumont Hospital.  This achieved equilibrium and 
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prevented vasoconstriction (Cole, 2001b).  The pressure of gas was seven mmHg within 
the air chamber. 
 
6.2.3. Researcher 
The author, CC, was the investigator and performed the assessments under direct medical 
supervision.  
 
6.2.4. Equipment 
The equipment used for the purpose of this assessment consisted of the Air 
Plethysmograph machine, an examination couch, DA and DB.  The couch was placed at a 
height of 468mm from the ground, in order to imitate the average height of a standard 
(economy class) aircraft seat, which varies from 457mm – 480mm (Quigley et al., 2001).   
 
6.2.5. Method 
i. The volunteers were placed in the supine position, on an examination 
couch with the appropriate sized calibrated air chamber of the APG 
surrounding the calf of their right leg (Figure 6.1.).  Venous volume was 
calculated in the seated position as the difference between the volume with 
the leg elevated in the supine position and the leg dependent in the seated 
position with the right foot placed on DA.  
ii. The standard APG assessment, tiptoe (section 4.5.2) was performed and 
acted as the control.  The EV and RV were measured in millilitres.  These 
values were used to calculate the EVFs and RVFs in the standing position 
(section 5.6).  
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Figure 6.1.  Participant wearing APG cuff with his right leg elevated. 
iii. At the end of the standard assessment, the two demonstrators, A and B 
were investigated.  In the supine position, once a steady baseline was 
recorded, the participants were then instructed to sit up on the examination 
couch and place their right foot on the pedal of DA (Figure 6.2).  The 
increase in venous volume achieved by this postural change was recorded 
as the sitting venous volume.   
iv. Again on achieving a steady baseline the participants were verbally 
instructed to fully compress the pedal and hold this position for five 
seconds and then release to the initial position with their foot resting on 
the uncompressed pedal.  This achieved activation of the calf muscle 
pump and results in a decrease in venous volume equivalent to the EV.  
This manoeuvre was repeated until two similar EVs were recorded.  
v. The volume remaining in the limb after compressing on the pedal of DA 
ten consecutive times is the RV and is measured as the difference between 
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the remaining volume and base line achieved when the participant returns 
to the supine position, with the leg elevated.  
vi. The procedures (iii – v) were repeated with DB. 
vii. All participants were then instructed to stand up from the examination 
couch and walk for two minutes in the assessment room, before returning 
to the supine position on the examination couch.  The average EV and RV 
walking values were then recorded.  
viii. The EVF and RVF achieved by DA and DB were then calculated as per 
standard assessment (section 6.6.).  
 
Figure 6.2. Volunteer with right leg resting on DA. 
 
A Diagrammatic representation of the APG tracing conducted is shown in Figure 6.3.  
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Figure 6.3.  Diagrammatic representation of the Air Plethysmograph tracing during 
Tromped Assessment of Demonstrators (blue) in the seated position. 
 
6.2.6. Statistical Analysis 
The statistical analysis was carried out using two formulae (Reilly, 2000); the mean of 
each result was determined by using equation 4.7, for example by dividing the sum of all 
ten patients standing venous volume by the number of values.  The standard deviation of 
each result was determined by using equation 4.8.  The paired Student‟s t-test was used to 
determine statistical significance.  Statistical significance was accepted at the 95% 
confidence level (p ≤ 0.05). With the number of degrees of freedom being 18, the critical 
value of t is ± 2.101.  
 
6.2.7. Results 
For absolute and derived values obtained from each manoeuvre, of this assessment for 
each of the ten participants (Appendix G).  Mean values are presented in Table 6.2. 
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Table 6.2. Results. 
n=10. Mean age 38.7 +/-14.83 
Standing Mean+/-Standard deviation 
VV (mls) 118.6 +/-31.05 
90%VV 106.74 +/-27.95 
VFT (sec) 178.75+ /-54.25 
VFI .679 +/-.144 
TT EV (mls) 72.9 +/-17.98 
TT EVF (%) 64.075 +/-16.918 
TT RV (mls) 21.1 +/-16.04 
TT RVF (%) 16.89 +/-12.7 
Ave Walking EV (mls) 46.8 +/-20.05 
Ave Walking RV (mls) 22.8+/-14.83 
Sitting VV (mls) 107.7+/-31.45 
SITTING 
Mean +/- SD DA DB 
EV (mls) 66.6+/-18.97 60.8+/-18.72 
EVF (%) 63.05+/-10.62 58.05+/-11.49 
RV (mls) 29.5+/-21.41 29.4+/-20.92 
RVF (%) 24.83+/-12.75 26.1+/-17.56 
 
 
The absolute results obtained from Part 1 of the study demonstrate that eight of the ten 
volunteers had normal VVs within the range of 80 to 170 mls (Bayes et al., 1994).  All 
ten participants had a normal VFI of less than 2ml/sec.  Standing VV ranged between 70 
and 166 mls, mean 118.6.  Sitting VV ranged between 55 and 150 mls, mean 107.7. 
 
6.2.7.1. EVF Results  
Standing EVF ranged between 38 and 93.3 mls, mean 64.07.  Volunteers two, nine and 
ten had abnormal EVs of 58 mls, 51mls and 57mls respectively.  These reduced EVs 
could have resulted from the volunteers being nervous and uncomfortable whilst standing 
and thus tensing the muscles in the cuff leg as a result.  DA EVF ranged between 42 and 
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78.2 mean 63.05.  Whereas DB EVF ranged between 44 and 80, mean 58.05.  In this 
procedure only an EV was achieved by walking as no full venous filling occurred 
between foot movements.  
Comparison of results obtained from  
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Figure 6.4. EVF obtained by tip-toe (control), DA and DB.  
 
 
Table 6.3. EVF obtained by tip-toe (control) DA and DB 
 Control DA DB 
EVFs% 64.075 66.6 58.05 
SD 16.918 18.97 11.49 
 
EVF achieved by control and exercise devices as measured by Air Plethysmograph 
represented as a fraction of the venous volume and expressed in percentage (%) and 
reported as Mean +/- SD.  
EVF within the range considered normal was achieved by control and DA.  It can be seen 
(Figure 6.4. and table 6.3.) that DA was the most efficient with an EVF of 66.6 percent.  
Tiptoe (control) was the second most efficient with an EVF of 64.08 percent.  DB was the 
least efficient producing an EVF, (58.05 percent) below the range considered normal, 
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greater than or equal to 60 percent as previously stated (Nicolaides and Sumner, 1991; 
Nicolaides, 1999), hence DB would be deemed inadequate despite the lack of statistical 
significance. No significant difference at the five percent level, existed between control 
and DA, control and DB or between DA and DB (Table 6.5).  
 
6.2.7.2. RVF Results 
Standing RVF ranged between 4.28 and 20.48 mls, mean 16.89.  DA RVF ranged 
between 6.6 and 46.6, mean 24.83.  DB RVF ranged between 6.6 and 67.5, mean 26.1.  
Only an RV was achieved by walking as no full venous filling occurred between 
movements. 
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Figure 6.5 RVF obtained by tip-toe (control), DA and DB.  
 
Table 6.4 RVF obtained by tip-toe (control), DA and DB. 
 Control DA DB 
RVFs% 16.89 24.83 26.1 
STD 12.7 12.75 17.56 
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RVF achieved by control and exercise devices as measured by Air Plethysmograph 
represented as a fraction of the venous volume and expressed in percentage (%) and 
reported as Mean +/- SD.  
 
RVF within the range considered normal was achieved by control, DA and DB.  It can be 
seen (Figure 6.5. and table 6.4.) that control was the most efficient with an RVF of 16.89 
percent.  DA was the second most efficient (RVF of 24.83) and DB the least efficient 
with an RVF of 26.1 percent.  A normal residual volume fraction is less than or equal to 
35 percent.  No significant difference at the five percent level existed between any of the 
RVF obtained (Table 6.5).  
 
Table 6.5 Comparison of EV and RV. 
Movement  t value 
EV 
t value 
RV 
Comparison of tiptoe control V‟s Ave walking value 3.06 S -0.246 NS 
Comparison of tiptoe control V‟s DA  0.762 NS -0.99 NS 
Comparison of tiptoe control V‟s DB  1.47 NS -0.995 NS 
Comparison of Ave walking value V‟s DA -2.26 S -0.813 NS 
Comparison of Ave walking value V‟s DB -1.61 NS -0.813 NS 
Comparison of DA V‟s DB 0.688 NS 0.01 NS 
Critical value at the five percent significance level = 2.101.  
 
6.3. Discussion 
Needham (2005) reported that as little as five or six “cycles” of dorsiflexion or plantar 
flexion movements will achieve maximum venous emptying.  So refilling time in a 
healthy limb will be quite slow as it is the arteries which will supply the blood rather than 
reflux in incompetent systems.  
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In an Air Plethysmography assessment conducted by Grey, (2001), no statistical 
difference was found when comparing a standing tiptoe movement to walking.  Therefore 
the standing tiptoe movement results produced from the Tromped assessment were used 
to compare with the sitting movements produced when using DA and DB. 
The average walking values were not used in comparison with the DA and DB as the 
ejection values recorded were produced from one singular movement, which was the foot 
pressing down on the pedal, holding that position for five seconds.  The average walking 
values were produced by the volunteers continuously taking steps.  There was a 
significant statistical difference in the comparison of the tiptoe standing movement and 
walking.  
 
6.4. Conclusion 
The hypothesis was to determine if DA and DB (of differing lengths) achieve adequate 
venous emptying.  The average tiptoe movement standing was compared with results 
achieved by both DA and DB.  No significant difference existed between tiptoe standing 
and DA or tiptoe standing and DB.  Both demonstrators achieved adequate venous 
emptying.  As previously stated DA achieved an EVF of 66.6 percent and an RVF of 
24.83 percent less than 35 percent.  DB achieved an EVF of 58.05 percent (less than the 
required 60 percent) and an RVF of 26.1 percent.  Thus if the force required to compress 
both pedals in DA and DB is responsible for satisfactory EVF and RVF values obtained, 
the position of the spring relative to the foot is immaterial.   
As DA produced more favourable results than DB, it was decided to use DA for further 
experiments.  
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CHAPTER 7  
THE TROMPED AND MEDIVEN® TRAVEL 
COMPRESSION STOCKING ASSESSMENT 
 
7.0. Introduction  
As travel compression stockings have become more popular with long haul passengers 
their haemodynamic effects were assessed along with DA and some of the inflight 
exercises airlines are promoting.  
Hypothesis: to determine the effectiveness of the Tromped in comparison to walking, 
wearing compression stockings and conducting the feet exercises advised by airlines.  
 
7.1. Haemodynamic Assessment II.  
 
7.1.1. Patients 
Ten healthy volunteers were recruited by advertising in DIT, Bolton Street (Appendix H, 
recruitment poster).  Healthy males or females between 20 to 35 years were invited to 
participate.  
Exclusion criteria were varicose veins or previous surgery, previous DVT and recent 
immobilisation including travel of greater than four hours, within previous 6 weeks to the 
study date. 
The ten healthy participants recruited to conduct this assessment comprised of eight 
males and two females.   An information letter was sent to each potential participant 
(Appendix I) and a questionnaire (Appendix J).  Ages ranged between 22 years and 34 
years, mean age 27 +/-3.57 years on the day of the study.  
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All procedures and protocol conformed with the Declaration of Helsinki. All gave written 
informed consent to participate in this study.   
Approval was obtained from the medical ethics committee of Beaumont Hospital. 
 
7.1.2. Location 
The study was performed in the Non-Invasive Vascular Unit, Beaumont Hospital.  The 
assessment room was maintained at a controlled temperature of 20º Centigrade, to obtain 
equilibrium and prevent vasoconstriction (Cole, 2001b)  
 
7.1.3. Researcher 
The author, CC, was the investigator and performed the assessments under direct medical 
supervision.  
 
7.1.4. Equipment 
The equipment used for the purpose of this assessment consisted of the Air 
Plethysmograph machine, an examination couch, a treadmill, DA and Mediven® travel 
compression stockings.   
The couch was placed at a height of 468mm from the ground, in order to mimic the 
average height of a standard (economy class) aircraft seat, which varies from 457mm – 
480mm (Quigley et al., 2001).   
 
7.1.5. Method 
i. The volunteers were placed in the supine position, for validation, on an 
examination couch with a calibrated air chamber surrounding the calf of their 
right leg.  The standard APG assessment, (Control) was performed (section 
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4.5.2) to measure venous volume (VV), ejection volume (EV), residual 
volume (RV) in millilitres and used to calculate ejection volume fraction 
(EVF) and residual volume fraction (RVF) see Figure 7.1.  
ii. When a steady baseline was recorded, the participant was asked to walk on to 
the treadmill at a speed of 2.5km/hr for two minutes duration (Figure 7.2).  On 
completion of the two minutes the participants were then asked to return to the 
supine position with the leg elevated once again to determine the RV post 
walking. 
iii. When the participant‟s veins were empty and a steady baseline recorded then 
she/he was asked to sit up on the examination couch and place his/her right 
foot on the uncompressed DA.  Two similar EVs and the RV were obtained in 
the same manner as in the first assessment (Section  6.2.5). 
iv. Once a steady baseline was again recorded the participant was asked to sit on 
the edge of the bed, and gently place both feet on the ground however without 
the right foot bearing any weight.  The sitting venous volume was recorded 
before the participant was asked to conduct the plantar flexion movement 
(Figure 7.3) (raise his/her right heel off the ground while pressing the ball of 
the foot against the ground) and hold this position for five seconds.  This 
procedure was repeated until two similar EV values were recorded.  The 
resultant reduction in volume was measured as the EV.  
v. When a steady baseline was recorded the participant was instructed to conduct 
the plantar flexion manoeuvre ten consecutive times before returning to the 
supine position with the right leg elevated at 45º once again so the RV could 
be calculated. 
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vi. When a steady baseline was once again recorded the participant was asked to 
sit on the edge of the bed, without bearing any weight on the right foot.  The 
sitting VV was recorded before the participant was instructed to conduct the 
dorsiflexion movement (raise the toes of the right foot off the ground and hold 
for five seconds) see Figure 7.4.  This procedure was repeated until two 
similar EV values were recorded.   
 
Figure 7.1.  Tip-toe manoeuvre in the standing position, with the Mediven® Travel 
Stocking (black) on the Right limb, underneath the APG Cuff 
 
vii. When a steady baseline was recorded the participant was instructed to conduct 
the dorsiflexion manoeuvre with the right foot ten consecutive times before 
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returning to the supine position with the right leg elevated at 45º once again so 
the RV could be calculated.   
 
Figure 7.2. Participant walking on the treadmill, while wearing the Mediven® 
Travel Stocking (black) underneath the APG Cuff.  
 
viii. When a steady baseline is recorded the participant was asked to sit on the edge 
of the bed again, without the right foot bearing any weight.  Once the sitting 
VV and a steady baseline were recorded again, he/she was instructed to raise 
the right foot slightly off the ground and move the right foot clockwise in a 
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circular position, 360º once before returning the foot gently to the ground 
without bearing any weight.  This procedure was repeated until two similar 
EVs were recorded.  Then the RV can be calculated once a steady baseline is 
recorded, by the participant repeating this circular movement ten consecutive 
times, before returning to the supine position, with the leg elevated, until a 
steady base line was recorded once again. 
 
Figure 7.3. Heel up (plantar flexion) of the right foot, in the seated position, without 
the Mediven® knee length stockings.  
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ix. The APG machine was then switched off and the cuff removed from the 
participant‟s right leg.  Participants rested for 15 minutes before his/her right 
leg was measured to accurately determine the knee length mediven® travel 
stocking size.  The instructions accompanying the stockings state “Measure 
the circumference above the ankle at its narrowest part”.  All ankle 
measurements were taken using a spring loaded measuring tape.  
 
 
Figure 7.4. Toes up (dorsiflexion) of the right foot, in the seated position, whilst 
wearing the Mediven® Travel stocking (black).    
x. Once the correct stocking size (refer to Section 4.8) was determined for the 
participant being tested, he/she was asked to place the stocking on the right 
leg and then return to the supine position on the same examination couch as in 
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Part 1, remaining in this position for ten minutes in the temperature controlled 
room.  
xi. The APG can be applied over compression stockings (Christopoulos and 
Nicolaides, 1994).  To prevent the APG cuff slipping over the stocking during 
the various manoeuvres and walking, self adhesive Velcro pads were used to 
attach the APG cuff and the stocking (Figure 7.5) (Ibegbuna et al., 2003).  
xii. The air chamber was then placed around each participant‟s right calf again 
and connected to the APG machine and inflated to 7mmHg.  The right leg was 
elevated and the machine calibrated in the same manner as in Part 1 of the 
experiment.  
 
Figure 7.5. Double sided Velcro attached to the underside of the APG Cuff.  
 
xiii. All the procedures from procedure (i) to (viii) of Part 1 of the experiment were 
repeated and recorded in the same order while the participant wore the 
mediven® travel stocking underneath the APG cuff.  
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7.2. Statistical Analysis 
The mean of each result was determined by using equation 4.7, for example by dividing 
the sum of all ten patients standing venous volume by the number of values.  
The standard deviation of each result was determined by using the equation 4.8.   
The paired Student‟s t-test (equation 4.9) was used to determine the statistical 
significance between any of the movements mean values when compared both with and 
without wearing stockings.  Statistical significance was accepted at the 95% confidence 
level (p ≤ 0.05).  With the number of degrees of freedom being 18, the critical value of t 
is ± 2.101.  
 
7.3. Results 
This assessment involved two parts; the first conducting all manoeuvres without wearing 
the travel stockings (Table 7.1); the second conducting all manoeuvres whilst wearing the 
travel stockings (7.2).  Absolute and derived values were obtained from Part I and Part II 
of this assessment, from each manoeuvre for each of the ten participants (Appendix K).  
Mean values are presented in Tables 7.3 and 7.4.  
The absolute results obtained from Part 1 of the study, show that all ten participants had a 
normal standing VV which ranges between 80 and 170mls (Bays et al., 1994) and normal 
VFIs of less than two ml/sec.   
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Table 7.1 Mean and Standard deviation results for part I of the assessment, without 
stockings.  
 
n = 10, mean age 27 +/-3.57 
Standing Mean+/-Standard deviation 
VV (mls) 123.3+/-28.85 
90%VV 111.96+/-24.95  
VFT (sec) 178.65+/-31.56 
VFI 0.709+/-0.179 
TT EV (mls) 73+/-15.93 
TT EVF (%) 51.73+/-14.42 
TT RV (mls) 21.6+/-11.72 
TT RVF (%) 16.73+/-8.91 
Ave Walking EV (mls) 34.4+/-12.18 
Ave Walking RV (mls) 21.05+/-13.62 
Sitting VV (mls) 98.5+/-20.45 
SITTING 
Mean +/- SD DA Plantar flexion Dorsiflexion Circle 
EV 61.9+/-17.4 45.2+/-18.47 45.3+/-15.01 27.35+/-11.12 
EVF 62.36+/-8.13 45.81+/-13.78 47+/-14.419 27.4+/-7.78 
RV 28.1+/-12.17 33.6+/-15.71 24.9+/-17.18 33.7+/-22.2 
RVF 30.11/-14.58 34.77+/-16.25 26.08+/-16.02 34.98+/-19.64 
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Table 7.2 Mean and Standard deviation results for part II of experiment with 
Mediven® stockings.  
 
n=10, mean age 27 +/-3.57 
Standing Mean+/-Standard deviation 
VV (mls) 87.4+/-27.64 
90%VV 78.66+/-24.88 
VFT (sec) 166.85+/-50.65 
VFI 0.561+/-0.25 
TT EV (mls) 54.4+/-17.03 
TT EVF (%) 65.354+/-16.27 
TT RV (mls) 25.8+/-14.94 
TT RVF (%) 29.62+/-14.53 
AV Walking EV (mls) 24.8+/-10.72 
AV Walking RV (mls) 24.4+/-15.08 
Sitting VV (mls) 71.4+/-24.15 
SITTING 
Mean +/- SD DA Plantar flexion Dorsiflexion Circle 
EV 46.6+/-18.72 40+/-13.28 27.4+/-13.45 24+/-11.21 
EVF 64.797+/-13.7 61.64+/-22.71 40.699+/-19.03 35.483+/-16.01 
RV 21.7+/-14.53 20.8+/-12.03 17.5+/-15.45 21.15+/-12.94 
RVF 33.68+/-21.93 27.79+/-13.16 21.98+/-11.6 29.35+/-16.51 
 
 
7.3.1. EVF Results, Part I – WITHOUT STOCKINGS 
Standing VV ranged between 86 and 160 mls, mean 123.3 mls. Standing EVF ranged 
between 47.5 and 87.2 mls, mean 51.73 mls (Appendix K).  Participants numbered five 
and seven had abnormal EVs of 54mls and 52mls respectively.  All other eight 
participants had normal tiptoe EVs. 
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Sitting VV ranged between 62 and 123 mls, mean 98.5 mls.  Only an EV was achieved 
by walking as no full venous filling occurred between steps.  DAs EVF ranged between 
48.59 and 81.9, mean 62.36.  Plantar flexion EVF ranged between 21.1 and 77.58, mean 
45.81.  Dorsiflexion EVF ranged between 11.92 and 69.44, mean 47 and Circle EVF 
ranged between 16.05 and 44.9, mean 27.4.  
Figure 7.6 and Table 7.3 display EVF results for all manoeuvres conducted without 
stockings. 
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Figure 7.6.  EVF obtained by tip-toe (control), use of DA and the three forms of 
exercise as advised by airlines without stockings.  
Table 7.3. EVF obtained by tip-toe (control), use of DA and the three forms of 
exercise as advised by airlines without stockings.  
 
 Control DA Plantar flexion Dorsiflexion Circle 
EVFs % 51.73 62.36 45.81 47 27.4 
SD 14.42 8.13 13.78 14.42 7.78 
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EVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
as measured by Air Plethysmograph represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD. 
 
Each of the values obtained in Figure 7.6 and in Table 7.3 were derived from participants 
not wearing Mediven® stockings.  EVF within the range considered normal was 
achieved by only DA (62.36 percent).  The standing tiptoe EVF was below 60 percent at 
51.73 percent.  Both the plantar flexion and dorsiflexion (advised by airlines) produced 
similar mean EVFs of 45.81 and 47 percent respectively.  The final movement required 
each participant to raise their right foot off the ground and rotate their ankle through 360º 
in a circle.  This produced the lowest EVF, of 27.4 percent.  All three exercises, 
advertised by airlines are not efficient in creating sufficient venous return to the heart to 
prevent stasis.  
A significant difference exists between tiptoe standing EV when compared to each of the 
following manoeuvres: 
i. Plantar flexion; 
ii. Toes up (dorsiflexion), 
iii. Circle 360º, 
No significant statistical difference exists between control and DA.  Even though the 
plantar flexion movement (EVF of 47.83±13.6) did not achieve the required EVF of 
greater than 60 percent, no significant difference existed when it was compared to DA.  A 
significant difference exists between DA EV when compared to the circle manoeuvre.  
When Plantar flexions was compared to dorsiflexion, no significant difference was 
evident. A significant difference existed between Dorsiflexion and circle. 
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7.3.2. EVF Results Part II – WITH STOCKINGS 
The second part of the study involved all ten participants repeating part one‟s 
manoeuvres, while wearing Mediven® compression stockings. Standing VV ranged 
between 42 and 125 mls, mean 87.4 mls (Appendix K).  Standing EVF ranged between 
31.66 and 102.82 mls, mean 65.35 mls (Table 7.2). Participants numbered three, four, 
seven, eight and nine produced EVs less than the normal range of 60-150ml (Bays et al., 
1994) which again could be as a result of the reduction in VV of the limb due to the 
compression stockings.  
Sitting VV ranged between 35 and 115 mls, mean 71.4 mls.  Only an EV was achieved 
by walking as no full venous filling occurred between steps.  DA EVF ranged between 
42.87 and 92.59 mls, mean 64.79 mls. Plantar flexion EVF ranged between 13.91 and 
100 mls, mean 61.64 mls.  Dorsiflexion EVF ranged between 9.25 and 65.62 mls, mean 
40.69 mls and circle EVF ranged between 13.63 and 67.56 mls, mean 35.48 mls.  Figure 
7.7 and Table 7.4 display EVF results achieved with stockings. 
EVF within the range considered normal was achieved by all manoeuvres except 
Dorsiflexion (40.69 percent) and the circle manoeuvre (35.48 percent).  
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Figure 7.7.  EVF obtained by tip-toe, use of DA and the three forms of exercise as 
advised by airlines whilst wearing the Mediven® stockings.  
 
Table 7.4. EVF obtained by tip-toe, use of DA and the three forms of exercise as 
advised by airlines whilst wearing the Mediven® stockings.  
 Control DA Plantar flexion Dorsiflexion Circle 
EVFs % 65.354 64.79 61 40.69 35.48 
SD 16.27 13.7 22.71 19.03 16.01 
 
 
EVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
as measured by Air Plethysmograph represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
No statistical difference exists between control and DA.  A significant difference at the 
five percent level exists between tiptoe standing, when compared to each of the above 
three manoeuvres; dorsiflexion, plantar flexion and circle.  No significant difference 
exists between plantar flexion compared to DA.  There is also a significant difference 
between DA EV and the circle manoeuvres EV.  The circle manoeuvre produced the least 
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EVF values of 26.75±11.39 with stockings and 24±11.21 with stockings.  No significant 
difference existed between dorsiflexion EV and circle EV.  
Table 7.8 and Figure 7.5 display the EVFs achieved when conducting all manoeuvres 
both with and without the Mediven® Travel compression stockings.  
 
The Tromped and Mediven Travel 
Compression Stocking Experiment
 
Sock
 
Sock
 
Sock
 
Sock
 
Sock
0
10
20
30
40
50
60
70
80
90
Tiptoe DA   Plantar
flexion
   Dorsi   
flexion
Circle 360
E
V
F
 %
  
  
. 
 
No Sock
Sock
 
Figure 7.8. EVF values obtained by tip-toe, use of the Tromped and the three forms 
of exercise as advised by airlines with and without Mediven® Stockings.  
 
Table 7.5. EVF values obtained by tip-toe, use of the Tromped and the three forms 
of exercise as advised by airlines with and without Mediven® Stockings. 
Without Stockings With Stockings 
 Control DA Plantar 
flexion  
Dorsi 
flexion 
Circle Control DA Plantar 
flexion  
Dorsi 
flexion 
Circle 
EVF 
(%) 
51.73 62.36 45.81 47 27.4 65.354 64.79 61 40.69 35.48 
SD 14.42 8.13 13.78 14.419 7.78 16.27 13.7 22.71 19.03 16.01 
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EVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
comparing values obtained with and without Mediven® Compression Stockings. Values 
measured by Air Plethysmograph are represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
 
Only the Tromped (seated position) produced a mean EVF of greater than 60 percent, in 
both parts of the study, i.e. with and without wearing the Mediven® graduated 
compression stockings.  All manoeuvres, excepting dorsiflexion, produced a greater EVF 
when participants wore the stockings than when compared to them conducting 
manoeuvres without the stockings.  A significant statistical difference exists when the 
tiptoe movement, (without stockings) was compared to tiptoe movement (with stockings).  
Table 7.4 displays the t-values for all compared manoeuvres ejection volumes.   
 
Table 7.6 Comparison of EV values 
Manoeuvre                       T values  
 Without stockings With stockings 
Comparison of tiptoe control versus DA 1.29 NS -1.22 NS 
Comparison of tiptoe control versus Plantar flexion 3.36 S -1.93 NS 
Comparison of tiptoe control versus dorsiflexion 3.9 S -0.5 NS 
Comparison of tiptoe control versus Circle 7.26 S -1.52 NS 
Critical value at 5% significance level =2.101.  
 
No significant statistical difference exists between Tiptoe (without stocking) versus DA 
(with stocking).  DA is as efficient if used with or without Mediven® stockings, as no 
significant difference exists between the EV values obtained when participants did and 
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did not wear Mediven stockings while compressing the Tromped pedal.  No significant 
difference existed between plantar flexion (without stockings) compared with plantar 
flexion (with stockings) and the Circle manoeuvre (without stockings) compared to the 
circle manoeuvre (with stockings).  
 
7.3.3. RVF Results Part I – WITHOUT STOCKINGS 
Tiptoe (control) RVF ranged between 7.54 and 40, mean 16.73.  DA RVF ranged 
between 9.3 and 53.9, mean 30.11.  Plantar flexion RVF ranged between 16.6 and 63.3, 
mean 34.77.  Dorsiflexion RVF ranged between 11.2 and 67.88, mean 26.08 and Circle 
RVF ranged between 5.17 and 62.38, mean 34.98.  Figure 7.9 and Table 7.7 display the 
RVFs obtained when conducted without stockings. 
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Figure 7.9.  RVF obtained by tip-toe (control), use of DA and the three forms of 
exercise as advised by airlines, without stockings.  
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Table 7.7. RVF obtained by tip-toe (control), use of the DA and the three forms of 
exercise as advised by airlines, without stockings.  
 Control DA Plantar flexion Dorsiflexion Circle 
RVFs % 16.73 30.11 34.77 26.08 34.98 
SD 8.91 14.58 16.25 16.02 19.64 
 
RVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
as measured by Air Plethysmograph represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
RVF within the range considered normal was achieved by all manoeuvres.  The tiptoe 
movement (control) produced the most efficient RVF of 16.73+/-8.91.  The dorsiflexion 
manoeuvre was second to control.  It produced a RVF of 26.08±16.02.  DA produced an 
RVF of 30.11±14.58, plantar flexion 34.77±16.25 and circle RVF of 34.98±19.64.  No 
significant difference was detected between control and any of the manoeuvres.   
 
7.3.4. RVF Results Part II of the study 
The standing tiptoe RVF (with stockings) ranged between 12.12 and 55.17, mean 29.62.  
TJA (in the seated position) RVF ranged between 10.71 and 84, mean 33.68.  Plantar 
flexion RVF ranged between 8.1 and 51.85, mean 27.79.  Dorsiflexion RVF ranged 
between 10.6 and 52.17, mean 21.98 and Circle RVF ranged between 9.52 and 71.87, 
mean 29.35.  Figure 7.10 and Table 7.8 display RVFs obtained when conducted with 
stockings.  
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 Figure 7.10.  RVF obtained by tip-toe, use of DA and the three forms of 
exercise as advised by airlines whilst wearing the Mediven® stockings.  
 
Table 7.8. RVF obtained by tip-toe, use of TJA and the three forms of exercise as 
advised by airlines whilst wearing the Mediven® stockings.  
 Control DA Plantar flexion Dorsiflexion Circle  
RVFs % 29.62 33.68 27.79 21.98 29.35 
SD 14.53 21.93 13.16 11.6 16.51 
RVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
as measured by Air Plethysmograph represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
 
RVF within the range considered normal was achieved by all manoeuvres assessed.  
Dorsiflexion produced an RVF of 21.98±11.6.  Plantar flexion produced a RVF of 
27.79±13.16.  The circles manoeuvre whilst seated (29.35±16.51) and the tiptoe control 
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movement, standing (29.62±14.53).  The Tromped produced the least RVF value of 
33.86±21.93.  Even though the Tromped ranked fifth off all manoeuvres conducted, it 
still produced an efficient RVF, less than the required 35 percent (Nicolaides and 
Sumner, 1991), which means it is effective at preventing venous stasis in the lower limbs, 
even when users wear the Mediven® Compression Stockings.  No statistical difference 
existed between any of the manoeuvres conducted.  
Figure 7.11 and Table 7.9 display the RVF achieved when conducting all manoeuvres 
both with and without the Mediven® Travel compression stockings.  
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Figure 7.11. RVF values obtained by control, DA and the three forms of exercise as 
advised by airlines with and without Mediven® Stockings.  
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Table 7.9. RVF values obtained by control, DA and the three forms of exercise as 
advised by airlines with and without Mediven® Stockings.  
Without Stockings With Stockings 
 Control DA Plantar 
flexion  
Dorsi 
flexion 
Circle Control DA Plantar 
flexion  
Dorsi 
flexion 
Circle 
RVF 
(%) 
16.73 30.11 34.77 26.08 34.98 29.62 33.68 27.79 21.98 29.35 
SD 8.91 14.58 16.25 16.02 19.64 14.53 21.93 13.16 11.6 16.51 
 
RVF achieved by control, the Tromped and exercise manoeuvres as advised by airlines, 
comparing values obtained with and without Mediven® Compression Stockings. Values 
measured by Air Plethysmograph represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
Results obtained with stockings differed from those of Part 1 of the study which was 
conducted without participants wearing Mediven® stockings.  The circle manoeuvre 
produced the highest RVF (34.98±19.64), without stockings, however this was still 
considered within the normal range of less than 35 percent. 
Table 7.10 displays the t-values for all compared manoeuvres residual volumes.   
 
Table 7.10 Comparison of RV values 
Manoeuvre  t values 
 Without stockings With stockings 
Comparison of tiptoe control versus DA  -1.216     NS 0.62 NS 
Comparison of tiptoe control versus Plantar flexion  -1.936 NS 0.83 NS 
Comparison of tiptoe control versus dorsiflexion -0.5 NS 1.22 NS 
Comparison of tiptoe control versus Circle -1.52 NS 0.74 NS 
Critical value at 5% significance level =2.101.  
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Figure 7.12. Comparison of walking values obtained, with and without wearing 
stockings. 
 
Table 7.11. Average EV‟s and RV‟s achieved by walking.  
 Average EV 
No stockings 
Average RV 
No stockings 
Average EV 
with stockings 
Average RV 
with stockings 
Values % 36.4 19.75 24.8 24.4 
SD 15.71 14.71 10.72 15.08 
 
Average EV‟s and RV‟s achieved by walking, comparing values obtained with and 
without Mediven® Compression Stockings. Values measured by Air Plethysmograph 
represented as a fraction of the venous volume and expressed in percentage (%) and 
reported as Mean +/- SD.  
Walking without stockings produced an average EV of 36.4±15.71 while walking with 
stockings produced an average EV of 24.8±10.72.  An average RV of 19.75±14.71 was 
recorded without stockings and an average RV value of 24.4±15.08 was produced when 
participants wore the Mediven Stockings.  
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A significant difference (Table 7.12) at the five percent level exists between the tiptoe 
control EV and the average walking EV. However no significant difference was recorded 
between tiptoe control RV and the average walking RV value.  
 
Table 7.12 Comparison of EV and RV values 
Manoeuvre                       t values  
 Without stockings With stockings 
Comparison of control EV versus Walking EV 5.97 S 4.65 S 
Comparison of control RV versus Walking RV 0.09 NS 0.2 NS 
Critical value at 5% significance level =2.101.  
 
7.4. Discussion  
The participants results obtained from Part II of the study demonstrate that while wearing 
the Mediven® Travel Compression Stockings, reduced standing VVs were recorded for 
four of the participants.  This could be due to the fact that compression stockings reduce 
the cross-sectional area of the limb (Agu et al., 1999; Partsch, 1999; Morris and 
Woodcock, 2004) so therefore naturally the venous volume of blood should be reduced.  
All ten participants had a normal VFI.  
Each individual has an inherent venous volume, which makes it differ from that of the 
next individual. Each participant acted as their own control. Once a normal venous 
system was established for each participant, results derived from the tiptoe manoeuvre 
were recorded as the control values.  As each participant‟s venous volume varied, so did 
their ejection volumes and residual volumes for each resulting manoeuvre.  There is a 
wide range of acceptable normal results however once you reach over a certain threshold 
then it is termed incompetent.  Large errors may be due to the fact that some participants 
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had a more active venous pump, whereas others may have been nervous during the 
assessment and thus failed to relax the calf muscles of the right leg sufficiently during 
venous filling thus resulting in varied values.  
The medial gastrocnemius is the muscle which does the most work to create the plantar 
flexion manoeuvre (Quaresima et al., 2001).  Thus this muscle is predominantly used 
during walking and compression of the Tromped pedals. 
The average walking values were produced by the volunteers continuously taking steps. 
Taking 95 percentile p>0.05 there was a significant difference in the comparison of the 
tiptoe standing movement (without stockings) and walking (without stockings) because 
an average walking value was used.  This also applied when the tiptoe standing value 
with stockings was compared with the walking value while wearing stocking.  
The EVF produced as a result of compressing DA‟s pedal remained the same when 
conducted with stockings; however the stockings produced greater EVFs for every other 
manoeuvre conducted, in comparison to manoeuvres conducted without wearing 
stockings.  This was in keeping with the findings of Christopolous et al., (1987).  
Therefore DA is efficient at activating the venous pump regardless.  When the student t-
test was used to compare EV values obtained by DA with volunteers wearing and not 
wearing stockings, no statistical difference between the two was calculated.  So DA is as 
efficient when used with or without stockings. 
Dorsiflexion and the Circle manoeuvres (advocated by airlines) did not produce EVF 
within the range considered normal with stockings. This suggests that using Mediven® 
compression stockings alone, as a form of prophylaxis, is not sufficient to prevent venous 
stasis and the possibility of preventing FRDVT.  This finding is corroborated in several 
studies, where compression stockings failed to prevent against FRDVT and FRSVT 
(Belcaro et al., 2001a; Scurr et al., 2001; Hughes et al., 2003). 
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Only DA achieved the acquired EVF of greater than 60 percent and an RVF of less than 
35 percent in the seated position.   
Walking with stockings produced EVs smaller than those achieved when walking without 
wearing stockings. This is because the cross sectional area of the limb and the diameter of 
the veins would be reduced by the stockings, thus reducing the volume of blood.  The RV 
was greater with stockings than without. This was expected as the purpose of wearing 
compression stockings is to create venous return.  
 
7.5. Conclusion 
The objective of the research for which results are presented in this chapter was to 
determine the effectiveness of the Tromped in comparison to walking, wearing 
compression stockings and conducting feet exercises advised by airlines.   
The haemodynamic assessments established that DA was more efficient than some of the 
exercises that the airlines advise their passengers to conduct during flight.   
Thus further testing of a new prototype (Tromped footrest) with improved ergonomics 
designed for use on board an aircraft was planned to prevent stasis and thus the possible 
onset of FRDVT.  This new prototype design would be incorporated into an aircraft 
footrest so long haul passengers could exercise and promote venous return in the seated 
position.  With this design concept in mind a proposed in-flight assessment was 
developed which would require the use of an aircraft for four hours or more.  The Irish 
Air Corps and the RFA were contacted to determine if they could facilitate a 
haemodynamic assessment on board one of their aircraft.  However both parties after 
consideration stated that such an assessment would be impossible.  Contact with Purdue 
University West Lafayette Indiana, America was then made.  The college was very 
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interested in research collaboration however they could not facilitate the assessment 
requirements either. 
Thus after futile attempts to arrange an in-flight assessment it was decided the next 
natural progression was to conduct the footrest heamodynamic assessment in an aircraft 
seat without the pressurised chamber of an aircraft cabin.    
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CHAPTER 8  
THE TROMPED FOOTREST ASSESSMENT 
 
8.0. Introduction  
The objective of this assessment was to determine if any of the four Tromped footrests, 
when seated in an aircraft seat, (section 5.10) are as effective as DA and tiptoe control 
manoeuvre and to determine which gives the greatest venous emptying.  
 
8.1. The Tromped Footrest Assessment  
 
8.1.1. Patients 
Eighteen volunteers were recruited by advertising in DIT Bolton Street (Appendix L).  
Healthy males or females between the ages of 25 to 50 years were invited to participate.  
Selection criteria included six healthy individuals, six women taking the oral 
contraceptive pill and six individuals with a BMI of greater than 30.  Exclusion criteria 
were varicose veins or previous surgery, previous DVT and recent immobilization 
including travel of greater than four hours, within previous six weeks to the study date.  
Eight males and ten females ranging in ages from 25 to 50 participated.  Mean age 
35.61±9.58 years on the day of the study.  Each volunteer completed a questionnaire 
(Appendix M) and signed an informed consent form (Appendix N), before 
commencement of the study.  Their height in metres and weight in kilograms were then 
recorded (Table 8.1).  
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8.1.2. Location 
The assessment was conducted in a temperature controlled room of 20º (as shown in 
Figures 8.1 and 8.2). 
  
8.1.3. Researcher 
The assessment was conducted by one investigator, the author, Carolyn Collins. 
 
Table 8.1. Body Mass Index of each volunteer. 
Patient  Date of Birth Weight (kgs) Height (m) BMI (kg/m
2
) 
1 1/08/58 70 1.64 26.02 
2 18/08/81 60 1.53 25.63 
3 04/02/71 91 1.6 35.54 
4 14/06/67 141 1.83 42.1 
5 02/10/60 95 1.79 29.65 
6 01/09/63 62 1.74 20.47 
7 10/06/79 72 1.8 22.22 
8 05/12/56 84 1.8 25.92 
9 27/07/63 104 1.83 31.05 
10 08/11/79 52 1.6 20.31 
11 1/06/73 85 1.8 26.23 
12 28/07/80 58 1.57 23.53 
13 08/10/56 100 1.87 28.59 
14 08/09/56 94 1.77 30.00 
15 25/01/82 74 1.7 25.6 
16 17/10/81 57 1.64 21.19 
17 12/10/78 65 1.71 22.22 
18 12/02/77 161 1.82 48.6 
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8.1.4. Equipment 
The APG® machine, a bed, aircraft seat, weighing scales, measuring tape, Footrest 
prototypes I – IV and DA were the equipment used to conduct this haemodynamic 
assessment.  
 
Figure 8.1. Layout of the Tromped Footrest Assessment room. 
 
Figure 8.2. APG Equipment in relation to the aircraft seats and bed.  
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8.1.5. Method 
The assessment protocol and procedures were approved by the DIT ethics committee and 
conformed to the Declaration of Helsinki.  
The footrest prototypes were labelled (I-IV). Footrest I and II were attached to one test 
rig and footrest III and IV attached to a second test rig.  The aircraft seats were positioned 
beside the examination couch (distance mm to be determined for ease of access to the 
seat).  Taking a seat pitch of 762mm (30 inches), it was determined where the two test 
rigs should be positioned on the wooden mat (in relation to the aircraft seats) and this was 
then marked.  Using a butterfly screw both test rigs were firmly attached to the wooden 
mat while in use, to ensure consistency with each test conducted.  The APG equipment 
was placed on a trolley with wheels for manoeuvrability. 
i. The standard APG assessment, (Control) was performed to measure venous 
volume (VV), ejection volume (EV), residual volume (RV) in millilitres and 
used to calculate ejection volume fraction (EVF) and residual volume fraction 
(RVF) as explained in detail in section 4.5.2.  
ii. When a steady baseline was recorded, the participant was instructed to sit on 
the aircraft seat, with her or his foot resting on the uncompressed pedal of 
Footrest I (Figure 8.3).  The sitting venous volume was then recorded.  
iii. When a steady baseline was recorded, the participant was instructed to depress 
the pedal with their right foot (a clicking sound donated when the pedal was 
fully depressed) and maintain this position for five seconds before returning 
their foot to the initial position of resting it on the uncompressed pedal.  
iv. This procedure was then repeated until two similar EV values were recorded.  
v. When a steady baseline was again recorded the participant was instructed to 
compress the pedal ten consecutive times.  Upon completion the participant 
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was asked to return to the supine position on the examination couch with the 
right leg elevated. 
vi. When a steady baseline was again recorded in the supine position, the 
participant was instructed to sit again in the aircraft seat and place his/her 
right foot on Prototype II.  Procedures (ii-xi) were repeated in that order, for 
Prototypes II, III and IV, respectively. 
vii. The participant was then instructed to return to the supine position, with the 
right foot resting on the support.  Once a steady baseline was recorded, he/she 
was asked to return to the aircraft seat and place his/her foot on DA, (used in 
the previous two experiments).  Procedures ii to xi were repeated. 
viii. The participant was then instructed to return to the supine position, with the 
right foot resting on the support so that the RV could be recorded. 
 
8.2. Statistical Analysis 
The mean of each result (for all 18, obese, normal and contraceptive group) was 
determined by using equation 4.7, for example by dividing the sum of all 18 patients 
standing venous volume by the number of values.  The standard deviation of each result 
(for all four groups) was determined by using equation 5.8.  
The paired Student‟s t-test (equation 5.9) was used to determine the statistical 
significance of any comparison between any of the movements mean values. Statistical 
significance was accepted at the 95% confidence level (p ≤ 0.05).  With the number of 
degrees of freedom being 34, (for all 18 participants) the critical value of t is ± 2.032.  
For the individual groups of six, with a 95% confidence level (p ≤ 0.05), the number of 
degrees of freedom being ten, (for all six participants) the critical value of t is ± 2.228.  
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Figure 8.3. Participant resting her foot on Footrest one, whilst sitting on the 
aircraft seat. 
 
8.3. Results  
 
8.3.1. Absolute and derived results of all 18 participants 
The absolute and derived values for each of the 18 participants were calculated 
(Appendix O).  Mean values are presented in Table 8.2.  
The standing VV ranged between 40 and 193 mls, mean 116.16 mls. All 18 participants 
had a normal VFI of less than two ml/sec.   
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Table 8.2. Results of all 18 volunteers. 
n = 18, Mean age 35.61+/-9.58 
Standing Mean+/-Standard deviation 
VV (mls) 116.16+/-43.76 
90%VV 104.27+/-38.18 
VFT (sec) 138.83+/-33.08 
VFI 0.89+/-0.39 
TT EV (mls) 67.22+/-37.39 
TT EVF (%) 67.22+/-17.2 
TT RV (mls) 31.11+/-20.12 
TT RVF (%) 27.94+/-18.96 
Sitting VV (mls) 94.55+/-27.07 
SITTING 
Mean +/- SD Footrest 1 Footrest 2 Footrest 3 Footrest 4 DA 
EV 49.61+/-30.24 44.5+/-25.5 18+/-34.54 18+/-38.69 54.27+/-26.63 
EVF 49.63+/-22.09 45.81+/-18.16 42+/-19.59 44.01+/-21.3 55.65+/-19.5 
RV 18+/-33.81 45.05+/-17.49 40.66+/-17.03 35.16+/-19.12 42.77+/-19.14 
RVF 53.81+/-20.12 50.27+/-20.9 42.49+/-18.31 38.83+/-24.15 47.64+/-24.29 
 
 
8.3.2. EVF Results of all 18 participants. 
Standing EVF ranged between 37.27 and 97.95 mls, mean 67.22.  Seven of the 18 
participants had reduced standing EVs (less than 60mls).  These were participants one, 
two, six, seven, 15, 16 and 17.  They had EVs of 53mls, 41mls, 45mls, 53mls, 48mls, 
50mls and 20mls respectively.   
Sitting VV ranged between 50 and 140 mls, mean 94.55 mls.  Footrest I EVF ranged 
between 16 and 93.93 mls, mean 49.63.  Footrest II EVF ranged between 17.5 and 71.64 
mls, mean 45.81 mls.  Footrest III EVF ranged between 12 and 70.9 mls, mean 42 mls.  
Footrest IV EVF ranged between 4.21 and 89.09 mls, 44.01 mls.  TJA EVF ranged 
between 26.59 and 94.54 mls, mean 55.65 mls 
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Figure 8.4. EVF obtained by tip-toe, Footrest I – IV and DA of all 18 volunteers.  
 
Table 8.3. EVF obtained by tip-toe, Footrest I – IV and DA of all 18 volunteers.  
 Control Footrest 
 I 
Footrest 
 II 
Footrest  
III 
Footrest 
 IV 
DA 
EVFs % 67.22 49.63 45.81 42 44.01 55.65 
SD 17.2 22.09 18.16 19.59 21.3 19.5 
 
EVF achieved by control, Footrest I – IV and DA in all 18 volunteers. Values measured 
by Air Plethysmograph represented as a fraction of the venous volume and expressed in 
percentage (%) and reported as Mean +/- SD.  
 
EVF within the range considered normal was only achieved by the control (tiptoe) 
manoeuvre which produced an EVF of 67.22±17.2.  DA produced an EVF of 55.65±19.5 
however this and all other devices for this study group produced results less than the 
range considered normal.  Therefore a statistical difference was observed when control 
was compared to all four footrests and DA.  No statistical difference exists between 
Footrest I and DA.  However a significant difference was not observed between Footrest 
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I when compared to both Footrest III and Footrest IV.  A significant difference was 
observed when Footrest II was compared to both Footrest III and Footrest IV, however 
no statistical difference existed when it was compared to DA.  No significant difference 
was observed between Footrest III and Footrest IV however a significant difference 
existed between Footrest III and DA, also Footrest IV and DA.  
 
8.3.3. RVF Results of all 18 participants 
Standing RVF ranged between 4.44 and 87.36 mls, mean 27.94 mls.  Footrest I RVF 
ranged between 31.81 and 90.76 mls, mean 53.81 mls.  Footrest II RVF ranged between 
13.2 and 93.75 mls, mean 50.27 mls.  Footrest III ranged between 4.716 and 78.94 mls, 
mean 42.49 mls.  Footrest IV ranged between 4.716 and 90.52 mls, mean 38.83 and TJA 
RVF ranged between 14.15 and 88.88 mls, mean 47.64 mls.   
RVF within the range considered normal was only achieved by control (tiptoe) with a 
value of 27.94±18.96.  A significant difference exists between control and Footrest I. 
Even though Footrest II, III and IV and DA produced RVFs which are not considered 
within the normal range, no significant difference exists between them and control.  
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Figure 8.5. RVF obtained by tip-toe, Footrest I – IV and DA of all 18 volunteers.  
 
Table 8.4. RVF obtained by tip-toe, Footrest I – IV and DA of all 18 volunteers.  
 Control  Footrest  
I 
Footrest  
II 
Footrest 
III 
Footrest 
 IV 
DA 
RVFs % 27.94 53.81 50.27 42.49 38.83 47.64 
SD 18.96 20.12 20.9 18.31 24.15 24.29 
 
RVF achieved by control, Footrest I – IV and DA in all 18 volunteers.  Values measured 
by Air Plethysmograph are represented as a fraction of the venous volume and expressed 
in percentage (%) and reported as Mean +/- SD.  
 
A significant difference at the five percent level exists between Footrest I when compared 
to Footrest II, III, IV and DA.  No significant difference was observed between all other 
device results when compared (Table 8.5). 
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Table 8.5. Comparison of EV and RV for all 18 participants.  
Maneouvre t  value 
EV  
t  value 
RV 
Comparison of tiptoe standing V‟s Footrest I   2.597 S 1.413 NS 
Comparison of tiptoe standing V‟s Footrest II 3.238 S -2.218 S 
Comparison of tiptoe standing V‟s Footrest III 5.088 S -1.537 NS 
Comparison of tiptoe standing V‟s Footrest IV   4.813 S -0.619 NS 
Comparison of tiptoe standing V‟s Test Jig A 2.29 S -1.78 NS 
Critical value at 5 percent significance level = 2.032 
 
8.3.4. Results of the Normal Group 
The absolute and derived values for the Normal study group can be found in Appendix P.  
Mean values are presented in Table 8.6. 
Table 8.6. Results of the Normal study group 
n=6, Mean age 41.83+/-8.85 
Standing Mean+/-Standard deviation 
VV (mls) 135.66+/-42.11 
90%VV 121.26+/-38.9 
VFT (sec) 129.16+/-24.61 
VFI 1.041+/-0.293 
TT EV (mls) 94.66+/-49.72 
TT EVF (%) 65.74+/-16 
TT RV (mls) 31.5+/-8.13 
TT RVF (%) 26.3+/-12.91 
Sitting VV (mls) 95.33+/-28.56 
SITTING 
Mean 
 +/- SD 
Footrest 1 Footrest II Footrest III Footrest IV DA 
EV 56.5+/-32.96 45+/-24.7 44.33+/-20.97 45+/-18.01 51.83+/-25.55 
EVF 59.27+/-23.06 46.57+/-17.98 47.97+/-18.26 48.79+/-15.5 53.89+/-19.5 
RV 48.33+/-13.73 45.66+/-13.09 44.5+/-10.22 30.33+/-12.14 45.5+/-14.77 
RVF 54.24+/-16.89 51.99+/-21.71 39.66+/-16.52 35.84+/-18.93 52.48+/-22.43 
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Standing VV ranged between 87 and 193 mls, mean 135.66 mls.  All participants had 
normal VFIs.  
 
8.3.4.1. EVF Results of the Normal Group 
Standing EVF ranged between 48.62 and 93.26 mls, mean 65.74 mls.  Participants one, 
six, seven and 13 had abnormal EVs of 53 mls, 45 mls, 53 mls and 180 mls respectively.  
Sitting VV ranged between 54 and 132 mls, mean 95.33 mls.  Footrest I EVF ranged 
between 27.65 and 93.93 mls, mean 59.27 mls.  Footrest II EVF ranged between 23.4 and 
70.45 mls, mean 46.57 mls.  Footrest III EVF ranged between 17.02 and 70.31 mls, mean 
47.97 mls.  Footrest IV EVF ranged between 24.46 and 67.18 mls, mean 48.79 mls and 
DA EVF ranged between 26.59 and 90.56 mls, mean 53.89 mls.  
EVF within the range considered normal was only achieved by the control (tiptoe) 
manoeuvre.  Footrest I produced an EVF of 59.27±23.06, however this is slightly less 
than the range considered normal which is greater or equal to 60 percent.  DA produced 
an EVF of 53.89± 19.5, which is less than the normal range.  A statistical difference at 
the 5 percent level was observed between control and Footrest III and control and 
Footrest IV. 
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Figure 8.6. EVF obtained by tip-toe, Footrest I – IV and DA in the Normal group. 
 
Table 8.7. EVF obtained by tip-toe, Footrest I – IV and DA in the Normal group.  
 Control Footrest  
I 
Footrest 
II 
Footrest 
III 
Footrest  
IV 
TJA 
EVFs % 65.74 59.27 46.57 47.97 48.79 53.89 
SD 16 23.06 17.98 18.26 15.5 19.5 
 
EVF achieved by control, Footrest I – IV and the Demonstrator A in the Normal study 
group. Values measured by Air Plethysmograph are represented as a fraction of the 
venous volume and expressed in percentage (%) and reported as Mean +/- SD.  
 
8.3.4.2. RVF Results of the Normal Group  
Standing RVF ranged between 12.95 and 52.87 mls, mean 26.3 mls.  Footrest I RVF 
ranged between 27.27 and 78.72 mls, mean 54.24 mls.  Footrest II RVF ranged between 
27.27 and 93.75 mls, mean 51.99 mls.  Footrest III RVF ranged between 34.09 and 67.02 
mls.  Footrest IV RVF ranged between 9.52 and 66.66 mls, mean 35.84 and DA RVF 
ranged between 20.32 and 88.88 mls, mean 52.48 mls. 
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Figure 8.7. RVF obtained by tip-toe, Footrest I – IV and DA in the Normal group.  
 
Table 8.8. RVF obtained by tip-toe, Footrest I – IV and DA in the Normal group.  
 Control Footrest  
I 
Footrest 
II 
Footrest 
III 
Footrest  
IV 
DA 
RVFs % 26.3 54.24 51.99 39.66 35.84 52.48 
SD 12.91 16.89 21.71 16.52 18.93 22.43 
 
RVF achieved by control, Footrest I – IV and DA in the Normal study group. Values 
measured by Air Plethysmograph are represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
 
RVF within the range considered normal was only achieved by the control (tiptoe) 
manoeuver.  Footrest IV produced a RVF of 35.84±18.93 however this is slightly greater 
than the range considered normal which is less than 35 percent.  A statistical difference at 
the five percent level was observed between control and Footrest I, control and Footrest 
II, control and Footrest III and between Footrest I and Footrest IV (Table 8.9).    
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Table 8.9. Comparison of EV and RV for the Normal group.  
Maneouvre t  value 
EV 
t  value 
RV 
Comparison of tiptoe standing V‟s Footrest I   1.56 NS -2.58 S 
Comparison of tiptoe standing V‟s Footrest II 2.19 NS -2.25 S 
Comparison of tiptoe standing V‟s Footrest III 2.28 S -2.44 S 
Comparison of tiptoe standing V‟s Footrest IV   2.3 S 0.196 NS 
Comparison of tiptoe standing V‟s DA 1.876 NS -2.03 NS 
Critical value at 5 percent significance level = 2.228 
 
8.3.5. Results of the Obese Group 
The absolute and derived values for the obese group can be found in Appendix Q.  Mean 
values are presented in Table 8.10.  Standing VV ranged between 81 and 175 mls, mean 
116.16 mls.  All six of the obese study group had a normal VFI.   
 
8.3.5.1. EVF Results of the Obese Group 
Standing EVF ranged between 54.28 and 97.5 mls, mean 67.22 mls.  All six of this study 
group had normal standing EVs ranging between 60 and 96 mls, mean 85.83 mls.   The 
sitting VV ranged between 80 and 146 mls, mean 107.83 mls.  Footrest I EVF ranged 
between 37.89 and 76.36 mls, mean 58.53 mls.  Footrest II EVF ranged between 21.05 
and 69.09 mls, mean 49.44 mls.  Footrest III EVF ranged between 14.75 and 70.9 mls, 
mean 47.72 mls.  Footrest IV EVF ranged between 4.21 and 89.09 mls, mean 46.68 mls 
and DA EVF ranged between 38.75 and 94.54 mls, mean 62.71 mls (Figure 8.8 and Table 
8.11). 
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Table 8.10. Results of the Obese Study Group 
n = 6, Mean age 39+/-7.02, Mean BMI of 36.15+/-7.03 
Standing Mean+/-Standard deviation 
VV (mls) 117.33+/-36.25 
90%VV 105.6+/-32.63 
VFT (sec) 151.66+/-43.46 
VFI 0.8946+/-0.498 
TT EV (mls) 85.83+/-13.92 
TT EVF (%) 77.148+/-16.46 
TT RV (mls) 22.16+/-21.59 
TT RVF (%) 19.328+/-12.29 
Sitting VV (mls) 107.83+/-20.03 
SITTING 
Mean +/- 
SD 
Footrest 1 Footrest 2 Footrest 3 Footrest 4 DA 
EV 63.16+/-16.98 55.16+/-25.8 51.66+/-22.87 52.66+/-32.98 68.33+/-24.53 
EVF 58.53+/-12.61 49.44+/-17.07 47.22+/-18.76 46.68+/-26.01 62.71+/-19.54 
RV 43.66+/-16.74 45.66+/-23.66 38.16+/-24.34 42.33+/-28.08 37.33+/-23.52 
RVF 40.75+/-14.94 42.05+/-22.44 35.31+/-23.19 39+/-27.59 33.51+/-17.25 
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Figure 8.8. EVF obtained by tip-toe, Footrest I – IV and DA in the obese group.  
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Table 8.11. EVF obtained by tip-toe, Footrest I – IV and DA in the obese group.  
 Control Footrest 
I 
Footrest 
II 
Footrest 
III 
Footrest 
IV 
DA 
EVFs % 77.148 58.53 49.44 47.22 46.68 62.71 
SD 16.46 12.61 17.07 18.76 26.01 19.54 
 
EVF achieved by control, Footrest I – IV and Demonstrator A in the Obese group. Values 
measured by Air Plethysmograph are represented as a fraction of the venous volume and 
expressed in percentage (%) and reported as Mean +/- SD.  
 
EVF within the range considered normal was achieved by the control (tiptoe) manoeuver 
and DA.  DA produced an EVF of 62.71±19.54.  Footrest I produced an EVF of 58.53 ± 
12.61, which is less than the range considered normal.  Therefore a significant difference 
at the five percent level between control and each of the four Footrests was observed.  
However no statistical difference between control and DA was observed.  A statistical 
difference at the five percent level was observed between Footrest I and Footrest III and 
Footrest III and DA (Table 8.13).  
 
8.3.5.2. RVF Results of the Obese Group 
Standing RVF ranged between 4.44 and 31.42 mls, mean 19.328 mls.  Footrest I RVF 
ranged between 18.86 and 68.42 mls, mean 40.75 mls.  Footrest II RVF ranged between 
13.2 and 83.15 mls, mean 42.05 mls.  Footrest III RVF ranged between 4.716 and 78.94 
mls, mean 35.31 mls.  Footrest IV RVF ranged between 4.716 and 90.52 mls, mean 39 
and DA RVF ranged between 14.15 and 56.84 mls, mean 33.51 mls.  
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Figure 8.9. RVF obtained by tip-toe, Footrest I – IV and DA in the obese group. 
 
Table 8.12. RVF obtained by tip-toe, Footrest I – IV and DA in the obese group.  
 Control Footrest  I Footrest 
II 
Footrest 
III 
Footrest  
IV 
DA 
RVFs % 19.328 40.75 42.05 35.31 39 33.51 
SD 12.29 14.94 22.44 23.19 27.59 17.25 
 
RVF achieved by control, Footrest I – IV and D A in the Obese group. Values measured 
by Air Plethysmograph are represented as a fraction of the venous volume and expressed 
in percentage (%) and reported as Mean +/- SD.  
 
RVF within the range considered normal was achieved by the control (tiptoe) maneouver 
and DA.  The most efficient maneouver to control was DA with an RVF of 33.51±17.25.  
Footrest III produced an RVF of 35.31 ± 23.19, which is slightly greater than the normal 
range of less than 35 percent.  No significant difference at the five percent level between 
any of the devices was observed (Table 8.13). 
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Table 8.13. Comparison of EV and RV for the Obese group.  
 t value 
EV values 
t  value 
RV values 
Comparison of tiptoe standing V‟s Footrest I   2.529 S -0.191 NS 
Comparison of tiptoe standing V‟s Footrest II 2.56 S -1.797 NS 
Comparison of tiptoe standing V‟s Footrest III 4.6 S -1.204 NS 
Comparison of tiptoe standing V‟s Footrest IV   2.269 S -1.394 NS 
Comparison of tiptoe standing V‟s DA 1.519 NS -1.163 NS 
 Critical value at 5 percent significance level = 2.228 
 
8.3.6. Results of the Oral contraceptive group 
The absolute and derived values for the oral contraceptive group can be found in 
Appendix AIII.  Mean values are presented in Table 8.11.  Standing VV ranged between 
40 and 165 mls, mean 95.5 mls.  All participants had normal VFIs.   
 
8.3.6.1. EVF Results of the Oral contraceptive group 
Participants ten and 17 had abnormal EVs of 165 and 40 mls respectively.  This is not 
surprising as oestrogens (contraceptive pill) induce hypercoagulation (Tibbs, 1992).  
Participant ten‟s abnormality may be attributed to the pill.  Participant 17 appears to have 
been nervous or had balance which resulted in her tensing her muscles impairing venous 
flow.  
Standing EVF ranged between 37.27 and 80 mls, mean 58.78 mls.  Sitting VV ranged 
between 50 and 130 mls, mean 80.83 mls.  Footrest I EVF ranged between 16 and 67.69 
mls, mean 31.14 mls.  Footrest II EVF ranged between 17.5 and 66 mls, mean 41.14 mls.  
Footrest III EVF ranged between twelve and 65.38 mls, mean 30.91 mls.  Footrest IV 
EVF ranged between 22.38 and 76.92 mls, mean 36.55 mls and TJA EVF ranged 
between 27.69 and 81.25 mls, mean 50.36 mls.  
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Table 8.14 Results of the Oral Contraceptive study group.  
n = 6, Mean age 26+/-1.35. 
Standing Mean+/-Standard deviation 
VV (mls) 95.5+/-46.02 
90%VV 85.95+/-34.18 
VFT (sec) 135.66+/-53.82 
VFI 0.734+/-0.327 
TT EV (mls) 56.66+/-27.13 
TT EVF (%) 58.78+/-13.76 
TT RV (mls) 39.66+/-22.99 
TT RVF (%) 41.92+/-20.75 
Sitting VV (mls) 80.83+/-25.68 
SITTING 
Mean +/- SD Footrest 1 Footrest 2 Footrest 3 Footrest 4 Test Jig A 
EV 29.16+/-26.81 33.33+/-20.87 28.66+/-25.99 33.33+/-30.21 42.66+/-23.11 
EVF 31.14+/-16.75 41.14+/-17.64 30.91+/-17.5 36.55+/-18.93 50.36+/-17.25 
RV 51.5+/-16.13 43.83+/-13.56 39.33+/-12.28 32.83+/-19.58 45.5+/-16.83 
RVF 66.27+/-19.4 56.5+/-14.77 49.38+/-11.66 41.65+/-24.75 56.87+/-14.11 
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Figure 8.10. EVF obtained by tip-toe, Footrest I – IV and DA in the Oral 
Contraceptive group. 
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Table 8.15. EVF obtained by tip-toe, Footrest I – IV and DA in the Oral 
Contraceptive group. 
 Control Footrest  
I 
Footrest 
II 
Footrest 
III 
Footrest  
IV 
DA 
EVFs % 58.78 31.14 41.14 30.91 36.55 50.36 
SD 13.76 16.75 17.64 17.5 18.93 17.25 
 
EVF achieved by control, Footrest I – IV and the Tromped Demonstrator  A by the Oral 
contraceptive group. Values measured by Air Plethysmograph are represented as a 
fraction of the venous volume and expressed in percentage (%) and reported as Mean +/- 
SD.  
EVF within the range considered normal was not achieved by any of the manoeuvers, 
including control.  Control did achieve an EVF of 58.78±13.76, which is less than the 
range considered normal (greater than 60 percent).  No significant difference at the five 
percent level between control and the five devices was observed (Table 8.17). 
 
8.3.6.2. RVF Results of the Oral contraceptive group 
Standing RVF ranged between 27.27 and 87.36 mls, mean 41.92 mls.  Footrest I RVF 
ranged between 38.8 and 90.76 mls, mean 66.27 mls.  Footrest II RVF ranged between 
33.07 and 74.19 mls, mean 56.5 mls.  Footrest III RVF ranged between 34.61 and 62.68 
mls, mean 49.38 mls.  Footrest IV RVF ranged between 7.69 and 70 mls, mean 41.65 mls 
and DA RVF ranged between 40.76 and 80.64 mls, mean 56.87 mls. 
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The Tromped Footrest Assessment -  Oral 
Contraceptive group
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Figure 8.11. RVF obtained by tip-toe, Footrest I – IV and DA in the Oral 
Contraceptive group.  
 
Table 8.16 RVF obtained by tip-toe, Footrest I – IV and DA in the Oral 
Contraceptive group.  
 
 Control Footrest 
 I 
Footrest 
II 
Footrest 
III 
Footrest 
 IV 
TJA 
RVFs 
% 
41.92 66.27 56.5 49.38 41.65 56.87 
SD 20.75 19.4 14.77 11.66 24.75 14.11 
 
RVF achieved by control, Footrest I – IV and the Tromped Test Jig A in the Oral 
contraceptive group. Values measured by Air Plethysmograph are represented as a 
fraction of the venous volume and expressed in percentage (%) and reported as Mean +/- 
SD.  
RVF within the range considered normal was not achieved by any of the manoeuvers, 
including control.  No statistical difference between control and the five devices was 
observed (Table 8.17).  
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Table 8.17 Comparison of EV and RV for the Oral Contraceptive group.  
 t value 
EV values 
t  value 
RV values 
Comparison of tiptoe standing V‟s Footrest I   1.76 NS -1.032 NS 
Comparison of tiptoe standing V‟s Footrest II 1.66 NS -0.3826 NS 
Comparison of tiptoe standing V‟s Footrest III 1.82 NS 0.031 NS 
Comparison of tiptoe standing V‟s Footrest IV   1.4 NS 0.554 NS 
Comparison of tiptoe standing V‟s DA 0.962 NS -0.502 NS 
 Critical value at 5 percent significance level = 2.228 
 
8.3.7. Results of all four study groups 
 
8.3.7.1 EVF Results comparing all four study groups 
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 Figure 8.12. Comparison of the four groups EVFs for control,  
Footrest I – IV and DA. 
 
The control (tiptoe) movement produced a mean EVF of 67.22±17.2 in all eighteen 
volunteers. As can be seen from all the results (except in the case of the obese group) 
neither of the four Tromped footrests, or DA produced an EVF greater than 60 percent.  
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8.3.7.2. RVF Results of all four study groups 
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 Figure 8.13. Comparison of the four groups RVFs for control,  
Footrest I – IV and DA. 
 
The control (tiptoe) movement produced a mean RVF of 27.94±18.96in all eighteen 
volunteers.  As can be seen from all the results (except in the case of the obese group) 
neither of the four Tromped footrests, or DA produced a RVF less than 35 percent.  
 
8.4. Discussion 
The standing tiptoe movement acted as control, as they did in the previous experiments, 
and were used to compare the results obtained from all four footrests and DA, to 
determine if any of the footrest prototypes were as efficient as tiptoe and the Tromped. 
As previously stated, both the calf muscle pump (refer to section 2.6.3) in conjunction 
with respiratory muscle pump (section 2.3.2) facilitate the return of blood to the heart 
Miller et al., (2005).  Sitting in an aircraft seat can affect the blood flow in the lower 
extremites in a negative way, due to the incline in the aircraft seat.   
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The previous two assessments conducted with DA produced adequate results, all ten 
participants were required to sit on the examination couch which had a level surface 
while using DA.  The only difference with this experiment was that the examination 
couch was replaced with aircraft seats.  These aircraft seats had a width of 560mm, the 
distance from the front edge of the seat to the back cushion was 550mm.  Owing to the 
design of the seat incline (Figure 8.14), the participants knees were 40mm higher than the 
underneath of their buttocks.  It is hypothesised that this incline of 40mm prevented 
normal return of blood to the heart, therefore, affecting normal respiration while 
restricting the gastrointestinal transit and normal blood circulation of all the 18 
participants who took part in this assessment (Hinninghofen & Enck, 2006).  
 
 
 
Figure 8.14. Incline of the Aircraft Seat.  
 
 
Further research conducted to compare venous return in various seat designs both with 
and without using the Footrest Test Jigs in the seated position is recommended.   
The obese group produced a control mean EVF of 77.148±16.46 and a mean RVF of 
19.328±12.29. Footrest Pedal I produced a mean EVF of 58.33±12.61 which was 
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promising however the mean RVF of 40.75±14.94 was not satisfactory as it was above 
the required value of 35 percent. Tromped footrests II to IV were not efficient at creating 
sufficient venous return. DA was efficient for this group alone when used in-situ in an 
aircraft seat, at promoting sufficient venous return.  It produced a mean EVF of 
62.71±19.54 and an adequate mean RVF of 33.51±17.25. 
The aircraft seat may not have interfered in venous return of obese people, as they would 
have larger buttocks and larger thighs than the other participants, thus reducing the angle 
of decline in the seat and the affect of poor circulation the other participants experienced.   
 
8.5. Conclusion 
The objective of the assessment was to determine if any of the four Tromped footrests 
(section 4.10) are as effective as DA and tiptoe control manoeuver and to determine 
which gives the greatest venous emptying.  
Activation of the CMPF did achieve venous return from the calf area, however only as far 
as the thigh area, which could predispose a passenger to proximal DVT.   
 
 
 
 
 
 
 
 
 
 
 251 
CHAPTER 9 
CONCLUSIONS & RECOMMENDATIONS 
 
9.0. Conclusions 
Death resulting from long haul flight has been established.  This dissertation describes 
research to produce and evaluate an in-flight exercise device to alleviate FRDVT.  
Airlines recommend in-flight exercises during flight.  These consist of plantar flexion 
(pressing the balls of ones feet against the ground) and dorsiflexion (raising the toes off 
the ground).  Thus a spring loaded novel prototype device “The Tromped” was envisaged 
which would allow the user to replicate both of these manoeuvres when used on board 
commercial aircraft but gain greater benefit from being required to do more work.  This 
research hypothesised that compression of a spring loaded pedal, while seated, would 
activate the calf muscle pump initiating venous return.   
An attempt to conduct an in-flight assessment was unsuccessful.  Airlines, the Irish Air 
Corps, the Royal Air Force and an American University were all lobbied towards this 
aim.  Unfortunately none of the airlines were interested as they will not accept liability 
for this life threatening syndrome.  The Irish Air Corp, the RAF and Perdue University 
exhausted all measures in an attempt to collaborate with this research.  However flight 
duration and access to a hospital with ultrasound machinery and specialised medical 
requirements posed a problem.  
It is important to realise that DVT may be symptomatic and asymptomatic. It is as a 
result of the latter, that it is impossible to determine a specific incidence of FRDVT. 
Travellers may have a DVT for up to two to three weeks after a flight before they become 
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aware of their condition. Other travellers may develop an embolus, which can then kill if 
it becomes lodged in an artery of the lung.  
This body of research could be used to increase FRDVT awareness as set out in the 
Research objectives, section 1.1.2. and has led to these conclusions: 
i. FRDVT is a real problem, one which is killing air passengers and will 
continue to do so if some form of prophylaxis is not developed for 
commercial use on commercial aircraft; 
ii. Plantar flexion against a predetermined resistance of 94.31 N to deflect the 
spring by a height of 63.39mm, when seated on a level seat can effectively 
replicate normal venous ambulation in healthy individuals. However when 
used in an aircraft seat, it only appears efficient at promoting sufficient venous 
return in the obese.  Therefore this research has established that FRDVT has a 
third causative factor, in the configuration of the aircraft seat.  
iii. If a form of in-flight prophylaxis is one day available on board commercial 
aircraft, its design will be influenced by aircraft design requirements, 
legislation, medical evidence and both airline and consumer acceptance.  
Ruling out commercial and social factors to alleviate this problem is 
impossible. 
iv. Compression of the Tromped footrest pedal with springs of Force ranging 
from 112.73N to 141.32N and free lengths of 27-53.5mm in an aircraft seat, 
cannot replicate normal venous ambulation and so recommendations for 
further research in this area is necessary. 
 
FRDVT is a real problem and knowledge of its true incidence is required.   
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In the context of FRDVT prophylaxis, mechanical methods would seem most attractive, 
however no ideal device has of yet been described.  Air volume systems, Lym Gym, 
Airogym and Veinguard were all investigated.  However as each of these devices aim to 
increase flow in the seated position by movement of air in a partially inflated system, 
they are unsuitable for use in flight.  The changes in air pressure which occur with 
different altitudes result in inconsistent work achieved by movements.  This increases the 
difficulty quantifying the amount of work required to effectively achieve the CMPF, thus 
reducing venous stasis adequately.   
The Skywalker‟s pedals are not securely attached to the base. The semi-circular pivot is 
detachable which means the design does not conform to aviation standards.  A device 
such as the Novamedix A V impulse system, in its present form is unsuitable for use 
during flight due to the air compressor.    Hence the need for a more suitable in-flight 
device along mechanical lines that will adequately activate the calf muscle pump function 
and result in sufficient venous return. 
Proprietors, executives of airlines and every court in the world, need to be informed that 
an episode of DVT may lead to death by PE, and that every survivor of a DVT is at risk 
of life long health problems. If an airline passenger suffers from a first event of DVT they 
may suffer the consequences of this for the rest of their lives in the form of chronic 
venous disease. This will not only inhibit the distance that they can walk due to pain and 
swelling (Neglén, 2003, Padberg et al., 2003,) and IC (Tibbs, 1992), but could lead to 
complications such as ulceration possibly (Ramaswamai and Nicolaides, 1994; Meissner, 
2002), and the increased chance of developing recurrent thrombi, which could kill 
eventually.  
 
 
 254 
9.1. Recommendations 
Further research should be conducted. It is proposed that it concentrates on the following 
four areas: 
i. Various seat types, (to be used on board commercial aircraft) especially ones 
with no dip in the seat cushion, or possibly with dips of only ten or 20mm, 
should be assessed with the APG and volunteers of varying weight, height, 
age and medical status should be used to determine which is optimal for 
normal venous return; 
ii. Re-conduct the Tromped Footrest assessment, with springs of stronger 
stiffness to determine if this design could be effective for use on board 
commercial aircraft; 
iii. Investigate the efficiency of the Tromped in new study groups; such as those 
with genetic defects associated with thrombi development, obese women, 
obese women on the pill, groups of various height such as under 1.5m and 
over 1.9m; 
iv. Conduct an in-flight assessment with an optimised Tromped footrest.  
 
This body of research has led to the following general recommendations: 
i. Some form of prophylaxis should be made available to the general flying 
public by the airlines to prevent against FRDVT. 
ii. It is necessary that a system of logging incidences of medical DVT and PE 
and FRDVT and PE into a database becomes compulsory.  This must be 
conducted at national and international level, as the full extent of the 
seriousness of DVT and PE will never be realised until this recommendation 
is put into effect. Factors such as number of flights flown, dates of travel, 
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duration of flights taken and hours spent in airports as well as if economy or 
business class flown should be documented.  
iii. It should be mandatory world wide that all medical episodes or instances 
which occur on board an aircraft be documented in full. Where a death may 
occur on an aircraft or in the airport grounds, a post mortem should be 
mandatory, with the results of the post mortem then logged into the system.  
iv. In-depth research should be conducted to redesign aircraft seats so that they 
can be both comfortable and conducive to facilitating venous return to the 
heart. 
v. An international minimum standard size passenger space of at least 760mm 
(30 inches) should be made obligatory, out of a duty of care to passengers for 
both safety reasons and comfort levels. 
vi. Government spending both at a national and international level is 
recommended in conjunction with airline spending to tackle the medical 
problems associated with flying both short haul and long haul flights. 
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1 Beaumont Hospital 
Ethics (Medical Research) Committee  
 
Chairperson:  Professor Gerry McElvaney                Administrator:  Gillian Vale 
Convenor:   Professor Kieran Murphy 
6th July 2006 
2 Our reference: 06/56 
 
Dr. Patricia Fitzgerald 
Director of Non-Invasive Vascular Unit 
Department of Surgery 
Beaumont Hospital 
 
 
Dear Dr. Fitzgerald  
 
06/56 – Dr. Patricia Fitzgerald – The Tromped and Mediven ® Travel Compression Stocking 
Experiment 
 
The above protocol was reviewed at a recent meeting of the Ethics (Medical Research) Committee, held on 
the 1st September 2006.  The following points need to be addressed: 
 
1. The Committee asks if the „Tromped and Mediven ® Travel Compression Stocking‟ is classed as 
a „medical device‟ and requests that the Principal Investigator confirm this with Dr. Niall 
MacAleenan, Medical Devices Section of the Irish Medicines Board.   If this proves to be the case 
and if this study proves to be a „clinical trial of a medical device‟, it may be necessary to complete 
Box B on page 3 of the application form.   
 
2. The Committee states that the sections entitled „Part 1 of the study‟ and „Part 2 of the study‟ in 
the Patient Information Leaflet are too long and detailed.  The description of the exercises is 
long and confusing, and would be better explained verbally to the patients during the assessment.  
Of note, the description of the exercises in the Patient Information Leaflet also differs from the 
description in the application form and in the protocol. 
 
3. The Committee ask if it is possible to reach a statistically-significant conclusion (Question 8) with 
only 10 participants. 
 
4. The Committee requests that the reply to Question 14 be amended to state there is no direct 
benefit to participants in taking part in this study. 
 
5. The Committee states that the reply to Question 10 be amended to state there is a risk to 
participants and to outline what this risk is.  (If there was no risk, the exclusion criteria in this 
study would not be so detailed.)  The committee seeks clarification on what the risk of 
participation is for a participant who unknowingly fulfils one of the exclusion criteria (e.g. an 
undiagnosed bleeding disorder), and proceeds to participate in this study.   
 
6. The Committee states that the Recruitment Poster does not need to include all the exclusion 
criteria.  Participants will not understand the term „exclusion criteria‟ and one needs medical 
knowledge to understand some of the exclusion criteria as currently listed in the poster.  It is also 
possible for the participants to fulfill some of the exclusion criteria and to be unaware of this.   
 
 
 
7. The Committee states that Question 7 (a), page 1 of the Questionnaire refers to “a journey of 
greater than four hours in length.”    However other parts of the application refer to 8 hours.  
Please clarify. 
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8. The Committee seeds confirmation that none of the ten participants will be in a supervisory or 
dependent relationship with any of the investigators. 
 
9. The Committee states that it is not appropriate to send the „research experiment protocol‟ to 
participants.  Please amend the „Letter to Participants‟ accordingly. 
 
10. Given the exclusion criteria, the Committee requests that written informed consent is obtained 
from all ten participants by Dr. Patricia Fitzgerald.  (Question 26).  It is not appropriate for Ms. 
Collins to obtain consent. 
 
11. The committee requests that the sentence:  “You are obliged to COMPLY with the instructions and 
give honest true information,” be deleted from page 5 of the Patient Information Leaflet.    
 
12. The committee requests that all reference to contraception be removed from the Patient 
Information Leaflet, as this does not appear to be relevant to the study.  Please amend and 
comment. 
 
13. The committee requests that the paragraph entitled “Confidentiality Issues” on page 6 of the 
Patient Information Leaflet be amended.  It is inaccurate to inform patients that only anonymous 
(rather than coded) data will be collected.  (See Question 38, Application Form). 
 
14. The committee requests that the Patient Information Leaflet inform participants that their data will 
be stored for 10 years and then shredded, as per Question 37 of the Application Form. 
 
15. Please respond with a cover letter addressing each of these points, cover letter to be signed by 
Principal Investigator.   This cover letter should address each of the above numbered points.  (One 
copy of the cover letter is sufficient) 
 
16. Please note that all revised documents must be clearly marked VERSION 2 and dated.  In 
addition all changes made to version 2 documents as compared to originally submitted 
documents should be clearly underlined or highlighted.  (One copy of all revised documents, 
VERSION 2, is sufficient) 
 
With best regards 
 
Yours sincerely 
 
 
 
Professor Kieran Murphy 
Convenor 
Ethics (Medical Research) Committee  
 
 
 
c.c. Ms. Carolyn Collins, 26 Croydon Green, Marino, Dublin 3 
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LETTER OF RECOMMENDATION FROM 
DR. MacALEENAN 
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APPENDIX G 
ASSESSMENT I ABSOLUTE AND DERIVED 
VALUES 
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Patient 1 2 3 4 5 6 7 8 9 10 
Age 4 
/01 
/39 
6 
/02 
/77 
5 
/12 
/56 
1 
/08 
/64 
6 
/02 
/81 
22 
/09/ 
72 
7 
/12 
/48 
14 
/12 
/84 
25 
/04 
/58 
04 
/01 
/79 
Control           
VV (mls) 110 100 150 100 75 130 135 166 70 150 
90%VV 99 90 135 90 67.5 117 121.5 149.4 63 135 
VFT 
(sec) 
140 137 151 143 163 255 181 290 112.5 215 
VFI 
(ml/sec) 
0.78
5 
0.729 0.99 0.699 0.46 0.5 0.745 0.572 0.622 0.697 
EV mls) 100 58 101 60 70 80 60 92 51 57 
EVF (%) 90.9 58 67.3 60 93.3 61.5 44.4 55.4 72.85 38 
RV(mls) 10 47 26 10 7 15 10 34 3 49 
RVF (%) 9.09 47 17.33 10 9.3 11.5 7.4 20.48 4.28 32.6 
Av W EV 25 45 70 30 15 70 75 43 30 65 
Av W 
RV 
10 40 40 21 30 45 22 0 5 15 
Sitting           
VV mls) 55 150 125 100 75 150 95 80 105 142 
DA, EV 
(mls) 
43 77 90 42 45 90 60 62 64 93 
DA, EVF 
(%) 
78.2 51.3 72 42 60 60 63.15 77.5 60.95 65.49 
DA, RV 
(mls) 
7 65 36 32 5 70 20 14 30 16 
DA, RVF 
(%) 
12.7 43.3 28.8 32 6.6 46.6 21.05 17.5 28.57 11.26 
DB, EV 
(mls) 
35 50 92 44 60 80 45 48 68 86 
DB, EVF 
(%) 
63.6
3 
33.33 73.6 44 80 53.33 47.36 60 64.76 60.56 
DB, RV 
(mls) 
7 60 20 22 5 65 20 54 14 27 
DB, RVF 
(%) 
12.7
2 
40 16 22 6.6 43.33 21.05 67.5 13.33 19.01 
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STOP THE CLOTS! 
ARE  YOU  AWARE  OF  THE  DANGERS  OF  FLYIING  LONG  
HAUL  FLIIGHTS?  
   
 WOULD YOU BE WILLING TO AID 
TESTING OF AN IN-FLIGHT 
EXERCISE DEVICE? 
(ARE YOU BETWEEN 20 AND 35?) 
10 HEALTHY VOLUNTEERS ARE REQUIRED.  
 
THIS RESEARCH IS NON-INVASIVE. 
An  Aii rr   Chaa mbee rr   wii ll ll   bee   pll aa cc ee d  on  tt hee   paa rr tt ii cc ii paa ntt ss   rr ii ghtt   cc aa ll ff   (( ff rr om  knee ee   tt o  aa nkll ee )) ..     
You  wii ll ll   bee   rr ee quii rr ee d  tt o  cc onducc tt   ff oott   movee mee ntt ss   ii n  aa   ss tt aa ndii ng  aa nd  ss ee aa tt ee d  poss ii tt ii on  whii ll ee   
wee aa rr ii ng  aa   Mee dii vee n®,,   knee ee   ll ee ngtt h,,   cc omprr ee ss ss ii on  ss tt occ kii ng  ff orr   tt hee   ss ee cc ond  haa ll ff   off   tt hee   
ee xpee rr ii mee ntt ..     
  
  
NO  DIISCOMFORT  OR  PAIIN  WIILL  BE  FELT!! !!   
  
  
  
YOU  MAY  BE  SUIITABLE  IIF  YOU  HAVE  NOT  HAD::   
1) VARICOSE VEINS OR PREVIOUS SURGERY FOR VARICOSE VEINS. 
2) PREVIOUS EPISODE OF VENOUS THROMBOEMBOLISM (DVT). 
3) TRAVELLED BY AIR FOR GREATER THAN 4 HOURS DURATION, DURING THE LAST 6 
WEEKS 
4) HAVE NOT HAD SURGERY IN THE LAST 12 WEEKS. 
 
  
II F  II NTERESTED  PLEASE  CONTACT::   CAROLYN  
PHONE::     01-- 402  3605                                                                          
EMAII L::   Carolyn.Collins@dit.ie  
 
Poster, Version 2, September 2006 
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DUBLIN INSTITUTE OF TECHNOLOGY 
 
February 16
th
 2008. 
 
Dear Sir or Madam,  
 
 
      Firstly many thanks for considering volunteering in this research study. As you may 
know the dangers of flight related deep vein thrombosis are real, so you will be aiding the 
attempt to provide a solution for long haul passengers, possibly yourself and family 
members. 
 
     This research is non-invasive. A chamber filled with air will be placed around your 
lower right limb (from ankle to knee). It is not as tight as a blood pressure cuff and you 
will experience no discomfort or pain. 
 
 
You will be instructed when and how to conduct different exercise manoeuvres in the 
standing and seated position, with the air chamber surrounding your calf for the duration 
of the assessment.  
 
 
I look forward to meeting with you in the near future. If you have any questions or 
queries, please do not hesitate to contact me, either by telephone or email.  
 
 
Sincerely,  
 
 
 
 
________________________ 
Carolyn Collins 
 
Postgraduate research student,  
Department of Transport Engineering,  
Faculty of Engineering,  
Bolton Street,  
Dublin 1. 
 
Email: Carolyn.collins@dit.ie 
Telephone: xxx xxxxxxx 
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The Mediven® Travel Compression 
Stocking Experiment  
 
 
 
 
 
 
 
(January, 2007)   
 
 
 
 
 
 
 
 
Questionnaire for participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
Principal Investigator: Doctor Patricia Fitzgerald.  
Please fill in the following questions, by ticking the appropriate boxes and filling in 
any relative additional information required. 
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Surname: 
 
  
Forename: 
 
Date of Birth:  
 
 
1. Have you ever been diagnosed with a thrombus (clot)?   Yes                  No   
 
 
2. Do you have varicose veins?                                             Yes                 No  
 
 
3. Do you have arterial disease?                                            Yes                 No 
 
 
4. Have you had any surgery within the last 12 weeks?       Yes                  No 
 
 
5. Have you ever been diagnosed with cancer?                   Yes                    No 
 
 
6. Are you taking the oral contraceptive at the moment?      Yes                No 
 
 
7 (a) Are you pregnant or have you been pregnant within the last six months?  
                                        
                              Yes                       No    
 
7 (a). Have you travelled a journey of greater than four hours in length, in the seated 
position, within the last six weeks?      
 
                                        Yes                           No 
 
 
7 (b). If so what was the duration of travel  
 
7 ( c ) Which form(s) of transport did you travel by? 
 
Car                  Bus                    Train               Airplane                   Boat 
 
If you answered yes to ONE of questions numbered 1- 7, we regret that you will be 
unable to participate in this research experiment.  
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8 (a). Are you taking any medication at the moment?          Yes                  No 
 
 
8 (b). If so, what is the purpose of the medication?  
 
 
 
8 ( c ). What is the name of your medication?  
 
 
 
 
 
11. Are you on Hormone Replacement Therapy at the moment?   Yes                 No 
 
 
 
 
 
 
Signed (Participant) 
 
 
Date:  
 
 
 
I agree that the identity of this participant will remain anonymous. 
 
 
Signed (Investigator) 
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ASSESSMENT II (PART I & II) ABSOLUTE 
AND DERIVED VALUES  
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Mediven assessment Results, (Without Stocking) 
 
Patient 1 2 3 4 5 6 7 8 9 10 
Date of 
Birth 
12 
/01 
/80 
13 
/12 
/76 
18 
/8/ 
83 
07 
/02 
/84 
22 
/09 
/72 
14 
/12 
/84 
04 
/01/ 
79 
13 
/12 
/81 
11 
/09 
/77 
08 
/04 
/77 
Control           
VV (mls) 154 160 89 104 106 139 106 160 140 86 
90%VV 
(ml) 
138.
6 
144 80.1 93.6 95.4 125.1 95.4 144 126 77.4 
VFT 
 (sec) 
226 158 126 200 206.
5 
201 144 152 206 167 
VFI 
(ml/sec) 
0.68 1.01 0.71 0.52 0.51 0.69 0.74 1.05 0.67 0.51
4 
EV (mls) 94 76 65 65 54 66 52 106 77 75 
EVF (%) 61.0
3 
47.5 73.0
3 
62.5 50.9
4 
55.93 49.0
5 
66.25 55 87.2 
RV (mls) 18 13 13 40 18 27 8 44 25 10 
RVF (%) 11.7 8.125 14.6 40 16.9 22.88 7.54 27.5 17.9 11.6
2 
Av (W) EV 30 72 25 25 35 25 20 22 55 35 
Av (W) RV 40 35 5 30 0.5 15 40 18 17 10 
Sitting           
VV (mls) 123 118 72 76 62 107 110 109 116 92 
Demonstrator A 
EV (mls) 74 81 45 43 38 52 70 65 95 56 
 EVF (%) 60.2 68.64 62.5 56.5 61.3 48.59 63.6 59.6 81.9 60.8
6 
RV (mls) 24 11 16 41 30 38 22 53 28 18 
RVF (%) 19.51 9.3 22.2 53.9 48.38 35.5 20 48.62 24.13 19.5
6 
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Patient 1 2 3 4 5 6 7 8 9 10 
Date of 
Birth 
12 
/01 
/80 
13 
/12 
/76 
18 
/8/ 
83 
07 
/02 
/84 
22 
/09 
/72 
14 
/12 
/84 
04 
/01/ 
79 
13 
/12 
/81 
11 
/09 
/77 
08 
/04 
/77 
PLANTARFLEXION 
EV (mls) 45 63 34 35 28 38 49 23 90 51.08 
EVF (%) 36.58 53.3 47.22 46.05 45.16 35.51 44.54 21.1 77.58 51.08 
RV (mls) 29 33 12 46 28 45 22 69 35 17 
RVF (%) 23.57 27.96 16.6 60.5 45.16 42 20 63.3 30.17 18.47 
DORSIFLEXION 
EV (mls) 47 65 50 35 30 43 55 13 63 52 
EVF (%) 38.2 55.08 69.44 46.05 48.38 40.18 50 11.92 54.31 56.52 
RV (mls) 15 16 19 20 19 23 17 74 13 33 
RVF (%) 12.1 13.5 26.38 26.3 30.64 21.49 15.45 67.88 11.2 35.86 
CIRCLE 
EV (mls) 34 53 24 21 14 25 32 17.5 36 17 
EVF 
(mls) 
 
27.6 
 
44.9 
 
33.33 
 
27.63 
 
22.58 
 
23.36 
 
29.09 
 
160.5 
 
31.03 
 
18.47 
RV (mls) 11 75 26 37 21 47 15 68 6 31 
RVF 
(mls) 
 
8.94 
 
63.5 
 
36.11 
 
48.68 
 
33.87 
 
43.92 
 
13.63 
 
62.38 
 
5.17 
 
33.69 
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Mediven® Assessment II Results, (With stockings) 
Patient 1 2 3 4 5 6 7 8 9 10 
Date of 
Birth 
12 
/01 
/80 
13 
/12 
/76 
18 
/8/ 
83 
07 
/02 
/84 
22 
/09 
/72 
14 
/12 
/84 
04 
/01/ 
79 
13 
/12 
/81 
11 
/09 
/77 
08 
/04 
/77 
Control           
VV 
(mls) 
125 105 42 76 99 87 44 106 106 70 
90%VV 112.5 94.5 37.8 68.4 89.1 78.3 39.6 108 95.4 63 
VFT 
(sec) 
190 106 145 178 302 161 164.5 130 134 158 
VFI 0.657 0.99 0.28 0.42 0.32 0.54 0.26 0.92 0.79 0.44 
EV(mls) 80 67 25 52 67 60 30 38 50 72 
EVF (%) 64 63.8 66.66 68.42 67.67 68.96 68.18 31.66 47.16 102.82 
RV mls) 36 14 14 35 12 48 7 38 44 10 
RVF(%) 28.8 13.3 33.33 46.05 12.12 55.17 15.9 35.84 41.5 14.28 
Average 
(W) EV 
30 35 15 20 25 50 12 16 20 25 
Average 
(W) RV 
45 40 16 35 10 7 14 45 27 5 
Sitting           
VV(mls) 95 89 37 66 64 75 35 115 84 54 
Demonstrator A 
EV (mls) 42 55 24 42 41 54 15 88 55 50 
EVF (%) 44.2 61.79 64.86 63.63 64.06 72 42.85 76.52 65.47 92.59 
RV mls 14 18 23 17 25 63 12 21 9 15 
RVF(%) 14.7 20.2 62.16 25.75 39.06 84 34.28 18.26 10.71 27.7 
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Patient 1 2 3 4 5 6 7 8 9 10 
Date of 
Birth 
12 
/01 
/80 
13 
/12 
/76 
18 
/8/ 
83 
07 
/02 
/84 
22 
/09 
/72 
14 
/12 
/84 
04 
/01/ 
79 
13 
/12 
/81 
11 
/09 
/77 
08 
/04 
/77 
Heel up, 
EV (mls) 
43 50 21 34 44 57 31 16 50 54 
Heel up, 
EVF (%) 
45.26 56.17 56.75 51.51 68.75 76 88.57 13.91 59.52 100 
Heel up, 
RV (mls) 
29 33 3 19 25 11 6 42 12 28 
Heel up, 
RVF %) 
30.5 37.07 8.1 28.78 39.06 14.66 17.14 36.52 14.28 51.85 
Toes up, 
EV (mls) 
38 48 24 32 42 15 16 16 38 5 
Toes up, 
EVF (%) 
40 53.93 64.86 48.48 65.62 20 45.71 13.91 45.23 9.25 
Toes up, 
RV (mls) 
25 16 4 7 16 20 7 60 10 10 
Toes up, 
RVF (%) 
26.3 17.9 10.8 10.6 25 26.66 20 52.17 11.9 18.5 
Circle, 
EV (mls) 
34 24 25 9 15 17 18 39 45 14 
Circle, 
EVF 
(mls) 
35.78 26.96 67.56 13.63 23.43 22.66 51.42 33.9 53.57 25.92 
Circle, 
RV (mls) 
22.5 30 11 22 46 14 4 39 8 15 
Circle, 
RVF 
(mls) 
23.68 33.7 29.72 33.33 71.87 18.66 11.4 33.9 9.52 27.77 
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STOP THE CLOTS! 
ARE YOU AWARE OF THE DANGERS OF 
FLYING LONG HAUL FLIGHTS? 
 
 WOULD YOU BE WILLING 
TO AID TESTING OF AN IN-
FLIGHT EXERCISE DEVICE? 
(ARE YOU BETWEEN 25 AND 50?) 
6 healthy, 6 obese (male/female) and 6 
women taking the oral contraceptive 
pill are required.  
 
THIS RESEARCH IS NON-INVASIVE. 
Volluntt eerr s  wii ll ll   wearr   an  aii rr   chamberr   on  ttheii rr   call ff     
(( ff rrom  knee  tt o  anklle)) ,,     
  &  conductt   ffoott   movementt s  ii n  a  stt andii ng  and  sii tt tt iing  posii tt ii on..   
  
NO DISCOMFORT OR PAIN WILL BE FELT!! 
 
IIF  IINTERESTED  PLEASE  CONTACT  CAROLYN::   
PHONE::  402  3605  
EMAIL::   Carolyn.collins@dit.ie  
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 QUESTIONAIRE 
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The Tromped Footrest Experiment 
 
 
 
 
 
 
 
(March, 2007)   
 
 
 
 
 
 
 
 
Questionnaire for participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
Principal Investigator: Carolyn Collins  
 
 
 
 
 68 
Please fill in the following questions, by ticking the appropriate boxes and filling in 
any relative additional information required. 
 
 
Surname: 
 
  
Forename: 
 
Date of Birth:  
 
 
1. Have you ever been diagnosed with a thrombus (clot)?   Yes                  No   
 
 
2. Do you have varicose veins?                                             Yes                 No  
 
 
3. Do you have arterial disease?                                            Yes                 No 
 
 
4. Have you had any surgery within the last 12 weeks?       Yes                  No 
 
 
5. Have you ever been diagnosed with cancer?                   Yes                    No 
 
 
6 (a) Are you pregnant or have you been pregnant within the last six months?  
                                        
                              Yes                       No    
 
7 (a). Have you travelled a journey of greater than four hours in length, in the seated 
position, within the last six weeks?      
 
                                        Yes                           No 
 
 
7 (b). If so what was the duration of travel  
 
7 ( c ) Which form(s) of transport did you travel by? 
 
Car                  Bus                    Train               Airplane                   Boat 
 
 
 
 
If you answered yes to ONE of questions numbered 1- 7, we regret that you will be 
unable to participate in this research experiment.  
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8 (a). Are you taking any medication at the moment?          Yes                  No 
 
 
8 (b). If so, what is the purpose of the medication?  
 
 
 
8 ( c ). What is the name of your medication?  
 
 
 
 
 
11. Are you on Hormone Replacement Therapy at the moment?   Yes              No 
 
 
 
12. Are you taking the oral contraceptive at the moment?      Yes                      No 
 
12 (b)  If yes, what is the name of this oral contraceptive pill?  
 
________________________________________________________________  
 
 
Signed (Participant) 
 
 
Date:  
 
 
 
I agree that the identity of this participant will remain anonymous. 
 
 
Signed (Investigator) 
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CONSENT FORM  
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Section 3 CONSENT FORM 
 
Researcher‟s Name:  CAROLYN COLLINS 
(use block capitals) 
Title:   
Faculty/School/Department:   
FACULTY OF ENGINEERING, DEPARTMENT OF TRANPSORT ENGINEERING 
Title of Study:   
THE DEVELOPMENT OF AN IN-FLIGHT MEDICAL DEVICE THE TROMPED TO PREVENT 
FLIGHT RELATED DEEP VEIN THROMBOSIS. 
 
To be completed by the: 
subject/patient/volunteer/informant/interviewee/parent/guardian (delete as necessary) 
 
3.1  Have you been fully informed/read the information sheet about this study?                YES/NO 
 
3.2   Have you had an opportunity to ask questions and discuss this study?                        YES/NO 
 
3.3.  Have you received satisfactory answers to all your questions?                                    YES/NO 
 
3.4 Have you received enough information about this study and any associated health and 
        safety implications if applicable?                                                                                   YES/NO 
 
3.5 Do you understand that you are free to withdraw from this study? 
 
 at any time 
 without giving a reason for withdrawing 
 without affecting your future relationship with the Institute                                         YES/NO 
 
3.6 Do you agree to take part in this study the results of which are likely to be published? 
                                                                                                                                                YES/NO 
 
3.7 Have you been informed that this consent form shall be kept in the confidence  
        of the researcher?                                                                                                            YES/NO 
                                                                                              
 
Signed_____________________________________                        Date __________________ 
 
Name in Block Letters __________________________________________________________ 
 
Signature of Researcher  ________________________________     Date __________________ 
 
 
Please note: 
 For persons under 18 years of age the consent of the parents or guardians must be obtained or an 
explanation given to the Research Ethics Committee and the assent of the child/young person should 
be obtained to the degree possible dependent on the age of the child/young person.  Please complete 
the Consent Form (section 4) for Research Involving „Less Powerful‟ Subjects or Those Under 18 Yrs. 
 
 In some studies, witnessed consent may be appropriate. 
 
 The researcher concerned must sign the consent form after having explained the project to the subject 
and after having answered his/her questions about the project. 
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ASSESSMENT III ABSOLUTE & DERIVED 
VALUES FOR ALL 18 PARTICIPANTS 
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Assessement III Results obtained when volunteers were standing 
Patient VV 
(mls) 
90% VV VFT 
(secs) 
VFI 
(ml/s) 
TT 
EV (mls) 
TT 
EVF (%) 
TT 
RV (mls) 
TT  
RVF (%) 
1 109 98.1 129 0.844 53 48.62 28 25.68 
2 110 99 97 1.134 41 37.27 30 27.27 
3 98 88.2 172 0.569 96 97.95 5 5.10 
4 90 81 194 0.463 74 82.22 4 4.44 
5 160 144 177 0.903 95 59.37 50 31.25 
6 87 73.3 110 0.74 45 51.72 46 52.87 
7 89 80.1 106 0.839 53 59.55 24 26.96 
8 170 153 115 1.478 103 60.58 27 15.88 
9 81 72.9 185 0.437 60 74.07 10 12.34 
10 165 148.5 151 1.09 105 63.63 55 33.33 
11 166 149.4 179 0.927 134 80.72 39 23.49 
12 95 85.5 149 0.637 76 80 83 87.36 
13 193 173.7 136 1.419 180 93.26 25 12.95 
14 175 157.5 94 1.86 95 54.28 55 31.42 
15 90 81 111 0.81 48 53.33 27 30 
16 73 65.7 154 0.474 50 68.49 30 41.09 
17 40 36 152 0.263 20 50 13 32.5 
18 100 90 88 1.136 95 95 9 31.42 
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Assessement III Results (Volunteers 1-9) obtained when seated  
Patient 1 2 3 4 5 6 7 8 9 
Sitting          
VV (mls) 54 65 95 110 110 94 64 123 80 
Footrest I, EV 
(mls) 
35 17 36 67 84 26 46 39 45 
Footrest I, EVF 
(%) 
64.81 26.15 37.89 60.9 76.36 27.65 71.87 31.7 56.25 
Footrest I, RV 
(mls) 
32 59 65 35 45 74 44 54 32 
Footrest I, RVF 
(%) 
59.25 90.76 68.42 31.81 40.9 78.72 68.75 43.9 40 
Footrest II, EV 
(mls) 
19 22 20 40 76 22 43 38 36 
Footrest II, EVF 
(%) 
35.18 33.84 21.05 36.36 69.09 23.4 67.18 30.89 45 
Footrest II, RV 
(mls) 
24 33 79 55 45 61 60 50 17 
Footrest II, RVF 
(%) 
44.44 50.76 83.15 50 40.9 64.89 93.75 40.65 21.25 
Footrest III EV 
(mls) 
31 26 14 78 74 16 45 43 38 
Footrest III EVF 
(%) 
57.4 40 14.73 70.9 67.27 17.02 70.31 34.95 47.5 
Footrest III RV 
(mls) 
32 27 75 46 23 63 39 51 20 
Footrest III RVF 
(%) 
59.25 41.53 78.94 41.81 20.9 67.02 60.93 41.46 25 
Footrest IV EV 
(mls) 
30 15 4 56 98 23 43 38 33 
Footrest IV EVF 
(%) 
55.55 23.07 4.21 50.9 89.09 24.46 67.18 30.89 41.25 
Footrest IV RV 
(mls) 
36 5 86 55 36 47 25 24 12 
Footrest IV RVF 
(%) 
66.66 7.69 90.52 50 32.72 50 39.06 19.51 15 
DA EV (mls) 33 18 56 104 91 25 28 66 31 
DA EVF (%) 61.11 27.69 58.94 94.54 82.72 26.59 43.75 53.65 38.75 
DA RV (mls) 48 28 54 16 38 69 30 25 21 
DA RVF (%) 88.88 43.07 56.84 14.54 34.54 73.4 46.87 20.32 26.25 
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Experiment III Results (Volunteers 10-18) obtained when seated in aircraft seats. 
Patient 10 11 12 13 14 15 16 17 18 
Sitting          
VV (mls) 140 132 67 105 134 93 80 50 106 
Footrest I, EV (mls) 88 124 16 69 73 25 21 8 74 
Footrest I, EVF (%) 62.85 93.93 23.88 65.71 54.47 26.88 26.25 16 50 
Footrest I, RV (mls) 56 36 26 50 65 77 53 38 20 
Footrest I, RVF (%) 40 27.27 38.8 47.6 48.5 82.79 66.25 76 40.75 
Footrest II, EV (mls) 78 93 30 55 96 23 14 33 63 
Footrest II, EVF (%) 55.71 70.45 44.77 52.38 71.64 24.73 17.5 66 59.43 
Footrest II, RV (mls) 43 36 30 43 64 69 53 35 14 
Footrest II, RVF (%) 30.7 27.27 44.77 40.95 47.76 74.19 66.25 70 13.2 
Footrest III EV (mls) 85 85 14 46 66 23 18 6 40 
Footrest III EVF (%) 60.71 64.39 20.89 43.8 49.25 24.73 22.5 12 37.73 
Footrest III RV (mls) 45 45 42 37 60 53 50 19 5 
Footrest III RVF (%) 32.14 34.09 62.68 35.23 44.77 56.98 62.5 38 4.716 
Footrest IV EV (mls) 100 76 15 60 90 23 29 18 35 
Footrest IV EVF (%) 71.42 57.57 22.38 57.14 67.16 24.73 36.25 36 33.01 
Footrest IV RV (mls) 36 40 12 10 60 62 48 34 5 
Footrest IV RVF (%) 25.71 30.3 17.9 9.52 44.77 66.66 60 70 4.716 
DA EV (mls) 80 63 25 96 75 45 65 23 53 
DA EVF (%) 57.14 47.72 37.31 90.56 55.97 48.38 81.25 46 50 
DA RV (mls) 53 55 33 46 80 75 54 30 15 
DA RVF (%) 37.85 41.66 49.25 43.8 59.7 80.64 67.5 60 14.15 
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APPENDIX P 
ASSESSMENT III 
ABSOLUTE & DERIVED VALUES FOR 
NORMAL GROUP 
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Participant 1 6 7 8 11 13 
STANDING 
VV (mls) 109 87 89 170 166 193 
90VV 98.1 73.3 80.1 153 149 173.7 
VFT 129 110 106 115 179 136 
VFI 0.844 0.74 0.839 1.478 0.927 1.419 
TT EV 53 45 53 103 134 180 
TT EVF 48.62 51.72 59.55 60.58 80.72 93.26 
TT RV 28 46 24 27 39 25 
TT RVF 25.68 52.87 26.96 15.88 23.49 12.95 
SITTING 
Sitting VV 54 94 64 123 132 105 
Footrest I EV 35 26 46 39 124 69 
Footrest I EVF 64.81 27.65 71.87 31.7 93.93 65.71 
Footrest I RV 32 74 44 54 36 50 
Footrest I RVF 59.25 78.72 68.75 43.9 27.27 47.6 
Footrest II EV 19 22 43 38 93 55 
Footrest II EVF 35.18 23.4 67.18 30.89 70.45 52.38 
Footrest II RV 24 61 60 50 36 43 
Footrest II RVF 44.44 64.89 93.75 40.65 27.27 40.95 
Footrest III EV 31 16 45 43 85 46 
Footrest III EVF 57.4 17.02 70.31 34.95 64.39 43.8 
Footrest III RV 32 63 39 51 45 37 
Footrest III RVF 59.25 67.02 60.93 41.46 34.09 35.23 
Footrest IV EV 30 23 43 38 76 60 
Footrest IV EVF 55.55 24.46 67.18 30.89 57.57 57.14 
Footrest IV RV 36 47 25 24 40 10 
Footrest IV RVF 66.66 50 39.06 19.51 30.3 9.52 
DA EV 33 25 28 66 63 96 
DA EVF 61.11 26.59 43.75 53.65 47.72 90.56 
DA RV 48 69 30 25 55 46 
DA RVF 88.88 73.4 46.87 20.32 41.66 43.8 
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APPENDIX Q 
ASSESSMENT III ABSOLUTE & DERIVED 
VALUES FOR OBESE GROUP 
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Participant 3 4 5 9 14 18 
STANDING 
VV (mls) 98 90 160 81 175 100 
90VV 88.2 81 144 72.9 157.5 90 
VFT 172 194 177 185 94 88 
VFI 0.569 0.463 0.903 0.437 1.86 1.136 
TT EV 96 74 95 60 95 95 
TT EVF 97.95 82.22 59.37 74.07 54.28 95 
TT RV 5 4 50 10 55 9 
TT RVF 5.1 4.44 31.25 12.34 31.42 31.42 
SITTING 
Sitting VV 95 110 110 80 134 106 
Footrest I EV 36 67 84 45 73 74 
Footrest I EVF 37.89 60.9 76.36 56.25 54.47 50 
Footrest I RV 65 35 45 32 65 20 
Footrest I RVF 68.42 31.81 40.9 40 48.5 40.75 
Footrest II EV 20 40 76 36 96 63 
Footrest II EVF 21.05 36.36 69.09 45 71.64 59.43 
Footrest II RV 79 55 45 17 64 14 
Footrest II RVF 83.15 50 40.9 21.25 47.76 13.2 
Footrest III EV 14 78 74 38 66 40 
Footrest III EVF 14.73 70.9 67.27 47.5 49.25 37.73 
Footrest III RV 75 46 23 20 60 5 
Footrest III RVF 78.94 41.81 20.9 25 44.77 4.716 
Footrest IV EV 4 56 98 33 90 35 
Footrest IV EVF 4.21 50.9 89.09 41.25 67.16 33.01 
Footrest IV RV 86 55 36 12 60 5 
Footrest IV RVF 90.52 50 32.72 15 44.77 4.716 
DA EV 56 104 91 31 75 53 
DA EVF 58.94 94.54 82.72 38.75 55.97 50 
DA RV 54 16 38 21 80 15 
DA RVF 56.84 14.54 34.54 26.25 59.7 14.15 
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APPENDIX R 
ASSESSMENT III ABSOLUTE & DERIVED 
VALUES FOR ORAL CONTRACEPTIVE 
GROUP 
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Participant 2 10 12 15 16 17 
STANDING 
VV (mls) 110 165 95 90 73 40 
90VV 99 148.5 85.5 81 65.7 36 
VFT 97 151 149 111 154 152 
VFI 1.134 1.09 0.637 0.81 0.474 0.263 
TT EV 41 105 76 48 50 20 
TT EVF 37.27 63.63 80 53.33 68.49 50 
TT RV 30 55 83 27 30 13 
TT RVF 27.27 33.33 87.36 30 41.09 32.5 
SITTING 
Sitting VV 65 140 67 93 80 50 
Footrest I EV 17 88 16 25 21 8 
Footrest I EVF 26.15 62.85 23.88 26.88 26.25 16 
Footrest I RV 59 56 26 77 53 38 
Footrest I RVF 90.76 40 38.8 82.79 66.25 76 
Footrest II EV 22 78 30 23 14 33 
Footrest II EVF 33.84 55.71 44.77 24.73 17.5 66 
Footrest II RV 33 43 30 69 53 35 
Footrest II RVF 50.76 30.7 44.77 74.19 66.25 70 
Footrest III EV 26 85 14 23 18 6 
Footrest III EVF 40 60.71 20.89 24.73 22.5 12 
Footrest III RV 27 45 42 53 50 19 
Footrest III RVF 41.53 32.14 62.68 56.98 62.5 38 
Footrest IV EV 15 100 15 23 29 18 
Footrest IV EVF 23.07 71.42 22.38 24.73 36.25 36 
Footrest IV RV 5 36 12 62 48 34 
Footrest IV RVF 7.69 25.71 17.9 66.66 60 70 
DA EV 18 80 25 45 65 23 
DA EVF 27.69 57.14 37.31 48.38 81.25 46 
DA RV 28 53 33 75 54 30 
DA RVF 43.07 37.85 49.25 80.64 67.5 60 
 
 
